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ABSTRACT 
Identification of novel tumour-specific genes and pathways is a key strategy to gain 
additional prognostic markers and to identify molecular targets for chemical and/or 
immunological therapy. Combination of subtractive cDNA libraries and cDNA 
microarrays lead us to identify the human calcium-activated chloride channel 2 
(CLCA2) as one gene being highly expressed in lung squamous cell carcinoma (lung 
SCC) [1]. The presence of T cell epitopes of CLCA2 and its immunological properties 
have also been described by our group [2]. CLCA2 is a member of the family of 
calcium-activated cytoplasmic trans-membrane chloride channel proteins [3]. Four 
human members have been identified, three of them are proteolytically processed 
into two subunits, whereas CLCA3 represents a truncated and secreted protein [4]. In 
contrast to other family members, CLCA2 displays a very restricted expression profile 
in normal tissues (larynx, esophagus, skin).  
In the course of this PhD-Thesis a preferential overexpression of CLCA2 in human 
squamous cell carcinomas (SCC) of different origins, including their lymph node 
metastases, could be demonstrated. In addition, overexpression was also detected in 
mycosis fungoides, a cutaneous T cell lymphoma, and in a subset of infiltrating ductal 
breast cancers. Preliminary IHC analyses confirmed expression of CLCA2 in human 
SCC samples. In silico expression analyses of xenografted SCC cell lines into nude 
mice revealed a dramatic increase in CLCA2 expression, suggesting a role of CLCA2 
in late stage tumourigenesis. 
Loss-of-function studies in SCC cell lines by siRNA-mediated knock-down of CLCA2 
lead to inhibition of proliferation, reduction in viability, subsequently to induction of 
apoptotic processes, and to an arrest in G2-phase of the cell cycle. In contrast, 
breast cancer cell lines stayed unaffected at least in 2D-tissue culture. Inducible 
expression of CLCA2 in tumour cells in combination with a detailed mutational 
analysis demonstrated a proteolytic (most likely autocatalytic) processing (hydrolase) 
activity of CLCA2 and proposed a structural metal site for Zn2+ coordination. 
Altogether, these data strongly support the presence of a zincin-like hydrolase 
domain in the N-terminal region of CLCA2. As predicted by bioinformatic analyses 
and in analogy to CLCA1 a monobasic cleavage site could be confirmed by “Alanine-
walking” mutagenesis, with the predicted cleavage recognition site: P3(Tyr/Phe) – 
P2(X) – P1(Arg/Lys) – P1’(Tyr/Phe) – P2’(Phe/Ala).  
ABSTRACT 
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Inhibition of glycosylation revealed that both, the stability and the proteolytic 
processing are impaired when glycosylation is inhibited.  
For a better simulation of the situation in a tumour, CLCA2-expressing clones were 
also grown in multicellular tumour spheroids. In contrast to growth in 2D-cultures a    
> 2.5-fold increase in the relative proliferation rate in the three-dimensional culture 
could be identified upon induction of CLCA2 expression.  
For a better understanding of the involvement of CLCA2 in signal transduction a 
comprehensive expression profiling study on Affymetrix GeneChips was performed 
followed by RT-qPCR and phospho-proteom studies with selected genes. In total      
~ 150 genes were shown to be differentially regulated upon induction of CLCA2 
expression. Among those genes are CDIPT, MLL2, and SFI1 which play an important 
role in cell cycle regulation. Utilising Ingenuity Pathways Analysis – a text- and data-
mining program – several interaction-networks were identified. All of them could be 
linked with important canonical signal transduction cascades or interaction networks 
such as the TNF–IL2–IL10 interaction network or the ERK–MAPK signaling cascade. 
Phospho-proteom studies confirmed these findings and additionally identified a 
strong impact of CLCA2 on translational modulation.  
Although these expression profiling data can only be regarded as preliminary they, 
however, offer the basis for further focused studies for the characterisation of CLCA2 
as a promising target in SCC tumourigenesis. 
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ZUSAMMENFASSUNG 
Die Identifikation von neuen tumorspezifischen Genen und Signalwegen ist eine 
Schlüsselstrategie, um neue zusätzliche prognostische Marker und molekulare 
Targets für chemische und/oder immunologische Therapien zu finden. 
Eigene Arbeiten führten mittels Kombination von subtraktiven cDNA Banken und 
cDNA Gen-Chips zur Identifikation des humanen Kalzium-aktivierten Chloridkanals 2 
(CLCA2), als ein Gen, das im Plattenepithelkarzinom der Lunge überexprimiert wird  
[1]. Die Anwesenheit von T-Zell Epitopen und dessen immunologische Eigenschaften 
wurden ebenfalls von uns beschrieben [2]. 
CLCA2 ist ein Familienmitglied der Kalzium-aktivierten cytoplasmatischen 
transmembranen Chloridkanal Proteine [3]. Vier humane Mitglieder wurden bislang 
identifiziert, drei davon werden proteolytisch in zwei Untereinheiten gespalten, wobei 
CLCA3 ein trunkiertes segregiertes Protein ist [4]. Im Unterschied zu anderen 
Familienmitgliedern zeigt CLCA2 ein sehr restriktives Expressionsprofil in 
Normalgeweben (Larynx, Ösophagus, Haut). 
Im Zuge der vorliegenden Dissertation konnte eine präferenzielle Überexpression 
vom CLCA2 in humanen Plattenepithelkarzinomen verschiedenen Ursprungs, wie 
auch deren korrespondierender Lymphknoten-Metastasen nachgewiesen werden. 
Zusätzlich konnte eine Überexpression auch in Mycosis fungoides (einem T-Zell 
Lymphom, das vorwiegend die Haut betrifft) und in einer Untergruppe von 
infiltrierenden duktalen Brustkarzinomen gezeigt werden. 
Präliminäre immunohistochemische Analysen bestätigten die Expression von CLCA2 
in Proben von humanen Plattenepithelkarzinomen. In silico Transkriptionsanalysen 
weisen auf einen dramatischen Anstieg der CLCA2 Expression hin, wenn 
Plattenepithelkarzinom-Zelllinien in einem Xenograft-Nacktmaus-Modell implantiert 
werden, was Rückschlüsse auf eine mögliche Rolle von CLCA2 in der späten Phase 
der Tumorgenese zulässt. 
Das Ausschalten der Funktion von CLCA2 in Plattenepithelkarzinomen mittels siRNA 
führte zur Inhibition der Proliferation, zur Reduktion der Viabilität, zur Induktion von 
apoptotischen Prozessen und zu einem Arrest in der G2-Phase des Zellzykluses. Im 
Vergleich dazu, blieben Brustkarzinom-Zelllinien - zumindest in 2D-Zellkulturen - 
davon unbeeinflusst. Induzierte Expression von CLCA2 in Tumorzellen in 
Kombination mit Mutationsanalyse wiesen eine proteolytische (höchstwahrscheinlich 
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autokatalytische) Prozessierungsaktivität (Hydrolaseaktivität) von CLCA2 nach und 
lassen die Präsenz einer strukturellen Metallallionen-Stelle für die Koordination von 
Zn2+ vermuten. 
Zusammengefasst weisen diese Daten auf eine Zincin-ähnliche Hydrolasedomäne in 
der N-terminalen Region von CLCA2 hin. 
Wie in bioinformatischen Analysen vorhergesagt und in Analogie zu CLCA1, konnte 
eine „monobasische Spaltstelle“ durch „Alanin-walking“ bestätigt werden, wobei die 
vorhergesagte Spaltstelle sich wie folgt präsentiert: P3(Tyr/Phe) – P2(X) – 
P1(Arg/Lys) – P1’(Tyr/Phe) – P2’(Phe/Ala). 
Inhibition der Glykkosylierung zeigte, dass dadurch sowohl die Stabilität als auch die 
proteolytische Prozessierung beeinträchtigt werden. 
Für eine bessere Simulation der Situation in einem Tumor wurden CLCA2-
exprimiernde Klone in multizellulären  Tumor-Sphäroiden kultiviert. Im Vergleich zu 
2D-Kulturen konnte ein über 2,5-facher Anstieg der relativen Proliferationsrate in der 
dreidimensionalen Kultur aufgrund von CLCA2 Expression nachgewiesen werden. 
Für ein besseres Verständnis der Beteiligung von CLCA2 in der Signaktransduktion, 
wurde eine umfassende Transkriptionsprofilierungs-Studie mit Affymetrix Gen-Chips 
durchgeführt. Im Anschluss daran folgten weitere Untersuchungen durch quantitative 
Real-Time PCR und Phospho-Protein Studien mit ausgewählten Genen. Insgesamt 
konnte gezeigt werden, dass aufgrund von CLCA2-Induktion ~ 150 Gene differentiell 
reguliert sind. Unter anderem sind das CDIPT, MLL2 und SFI1, welche eine wichtige 
Rolle in der Zellzyklus-Regulation spielen. Durch die Verwendung von „Ingenuity 
Pathways Analysis“ – einem „text- and data-mining“ – Analysenprogramm konnten 
Interaktionsnetzwerke identifiziert werden, die allesamt in Verbindung mit wichtigen 
kanonischen Signaltransduktionskaskaden oder Interaktionsnetzwerken gebracht 
werden können, wie etwa das TNF–IL2–IL10 Interaktionsnetzwerk, oder die ERK–
MAPK Signalkaskade. Phosphoproteom Studien bestätigten in der Folge diese 
Ergebnisse und konnten zusätzlich den Zusammenhang dieser 
Interaktionsnetzwerke mit translationaler Modulation aufzeigen. 
Obwohl die Daten der Transkriptionsprofilierung nur ein vorläufiges 
Zwischenergebnis darstellen, dienen sie als gute Ausgangsbasis für die Planung 
weiterer Studien zur Charakterisierung von CLCA2 als ein vielversprechendes Target 
in der Plattenepithel-Tumorgenese. 
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INTRODUCTION 
Cancer 
In all industrialised countries, cancer is the second most common cause of death, 
exceeded only by cardiovascular diseases. To imagine, a total of 1,437,180 new 
cancer cases and 565,650 deaths from cancer are projected to occur in the United 
States in 2008 – but these cases do not even include basal cell and squamous cell 
cancers of the skin [5]. 
 “Cancer” refers to over 150 diseases which have in common the characteristics of 
uncontrolled growth of cells and the ability to invade and damage normal tissues – 
locally or at distant sites in the body. 
Dependent on the tissue of origin, tumours can be classified into the three major 
groups of carcinomas, sarcomas and leukaemias. Carcinomas are derived from 
epithelial cells and account for 90 % of human cancers. Sarcomas are developing 
from mesodermal cells; they are tumours of the connective or supportive tissue such 
as bone, cartilage, muscle, blood vessels, fat and of soft tissue. Leukaemias or 
lymphomas are originating from blood or the lymphatic system, respectively. 
Furthermore, there is the group of melanomas, which are malignant tumours of 
melanocytes, which are found predominantly in skin and gliomas, which are tumours 
with its origin in brain or spine (nerve tissue). 
Cancer is predominately a genetic disease arising from the accumulation of 
mutations [6], either inherited (germline) or acquired (somatic), in critical proto-
oncogenes or tumour suppressor genes. Also epigenetic changes can cause cancer 
[7], such as loss of imprinting [8] or hyper- or hypomethylation of 5-methylcytosine 
[9], as well as chromosomal instability [10] and microsatellite instability [11].  
The transformation of a normal cell into a highly malignant tumour cell – the process 
of tumourigenesis – is a multistep process [12-14] in terms of stepwise genetic 
variation. The originally proposed model of Nowell [12], suggests the evolution of 
tumour cell populations in terms of stepwise genetic variation by an induced change 
in a single previously normal cell which makes it neoplastic and provides it with a 
selective growth advantage over adjacent normal cells. As a result of genetic 
instability in the expanding population, mutant cells are produced, which are nearly 
all eliminated due to metabolic disadvantages or immunologic destruction, but 
INTRODUCTION 
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occasionally one has an additional selective advantage and this mutation becomes 
the precursor of a new predominant subpopulation. Over time there is a sequential 
selection by an evolutionary process of sublines which are genetically and 
biologically increasingly abnormal. Different tumours acquire certain similarities, but 
divergences occur as well, as local conditions in each neoplasm differently affect the 
emergence of variant sublines. 
Frequently, a single cancer cell contains mutations in a lot of genes, gross 
chromosomal abnormalities and widespread changes in its gene expression profile 
[15]. Hanahan and Weinberg suggest a succession of six independent steps of 
essential alteration in the genotype of a cell, whereby each step represents a 
physiological barrier that must be overcome in order for a cell to progress further 
toward the end point of malignancy [13;16]. These steps are: 
- “Self-sufficiency in growth signals”, which will be a first step towards loss of 
growth regulation in a normal cell. The tumour cell becomes independent of 
exogenous growth stimuli, as e.g. the tumour cell produces their own growth 
factors in an autokrine mechanism. As an example, PDGF (platelet-derived 
growth factor) and TNFα (tumour necrosis factor α) is produced by 
glioblastomas and sarcomas [17]. 
- “Insensitivity to antigrowth-signals”: Mutations in tumour suppressor genes may 
induce the proliferative potential of a tumour cell, when the tumour suppressor 
gene normally protects cells of uncontrolled proliferation by regulation of the 
transition of G1- to S-phase in the cell cycle and normally force cells into the 
quiescent (G0) state. These signals are mainly transduced by soluble growth 
inhibitors or inhibitors embedded in the extracellular matrix (ECM) or located on 
the surface of neighbouring cells. Tumour cells often interfere with the Rb 
(retinoblastoma) tumour suppressor, which controls most of the antiproliferative 
signals in the cell, by mutation or hypophosphorylation [18;19]. Alternatively, 
cells may be induced to permanently relinquish their proliferative potential by 
being induced to enter into postmitotic states, usually associated with 
acquisition of specific differentiation-associated traits. Another way to avoid the 
antiproliferating state is the downregulation of integrins which mediate various 
intracellular signals. By this, integrins not only define cellular shape and mobility 
but also regulate the cell cycle. Integrins essentially contribute to cell division, 
cell survival, cellular differentiation and apoptosis.  
INTRODUCTION 
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- “Evasion of apoptosis” which means that cancer cells acquires resistance 
towards apoptosis and do not undergo apoptosis, if the cells have been 
damaged. Therefore, tumour cells disrupt sensors for apoptosis by e.g. 
mutations in the tumour suppressor gene p53, which affords unlimited 
replication. On the other hand downregulation of Fas receptors and killing of 
activated T-lymphocytes through the constitutive expression of Fas-ligand by 
tumour cells has been suggested as a mechanism for pathologic suppression of 
immune surveillance [19], and has been demonstrated in melanomas and colon 
cancers as an important antiapoptotic mechanism [20;21]. 
- “Limitness of replicative lifespan” can be obtained in a tumour cell by 
upregulation of e.g. the enzyme telomerase, which maintains the lengh of 
telomeres [22] and therefore contributes to the capability of unlimited replication. 
- “Sustained angiogenesis” is achieved by changing the balance of angiogenic 
inducers and inhibitors to induce and sustain angiogenesis [23] e.g. by 
increased expression of proangiogenic factors such as vascular endothelial 
growth factor (VEGF) and/or fibroblast growth factor (FGF). 
- “Tissue invasion and metastasis”: To transform a primary tumour into an 
invasive and metastasising tumour, which is able to invade local tissues and 
blood as well as lymphatic vessels, changes in the expression pattern of 
adhesion molecules like cell-cell adhesion molecules (CAM’s) and integrines are 
necessary to make the tumour less adhesive [24]. Furthermore, upregulation of 
extracellular matrix-degrading proteases supports the evasion of tumour cells 
through the basal cell membrane across blood vessel walls and into connective 
tissues. Such a cell-to-cell interaction molecule is e.g. E-cadherine, which is 
also involved in β-catenin signalling [25]. Recently, it was shown that expression 
of E-cadherin correlates with the presence of nodal metastases at the time of 
diagnosis in SCC of the head and neck [26;27]. 
This very general overview on cancer demonstrates that the cause of cancer is not 
linked to a single molecular event but in contrast, tumourigenesis encompasses 
complex molecular interactions and deregulation of signaling cascades in which 
single proteins are involved. Some of these altered proteins may play an essential 
role, others may only be regarded as passenger alterations (mutations).  
"Oncogene addiction" describes the acquired dependence of tumour cells on an 
activated oncogene for their survival and/or proliferation. This phenomenon has 
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important implications for the success of targeted cancer therapies [28;29]. It was 
first discussed for mutations in the EGFR gene of human NSCLCs [30;31]. 
Epithelial and Squamous Cell Carcinoma (SCC) 
An epithelium is defined as a layer of cells that is located at the boundary of body 
cavities and the connective tissues. Epithelial cells are arranged along the basement 
membrane, which mainly consists of collagens. As shown in Figure 1, different types 
of epithelial structures are classified by shape, stratification and specialisation. 
Squamous epithelium can be distinguished by two types of “simple squamous 
epithelia”, which is single-layered, and the type of stratified squamous epithelia, 
which is multilayered (Figure 1). Squamous epithelial exhibits a typically flat and 
scale-like shape. Several molecular biomarkers for squamous epithelium were 
identified, which are human desmocollin 3 (DSC3) [32], keratin 5 (KRT5) [33], 
desmoglein 3 (DSG3) [34], plakophilin 1 (PKP1) [35], plakophilin 3 (PKP3) [36], 
PERP [37], and syndecan [38]. 
Squamous cell carcinoma (SCC) specifically derives from squamous epithelial cells 
and may occur in many different organs, including skin, lung, cervix, prostate, 
esophagus, urinary bladder, and the head and neck region.  
Accounting for approximately 20 % of cutaneous malignancies, SCC is the second 
leading cause of skin cancer in Caucasians [39] (after basal cell carcinoma, but more 
common than melanoma) with over 250,000 new cases per year estimated in the 
United States, whereby incidence appears to be in the rise [40]. Most cases of head 
and neck cancer are due to SCC. About 30 % of all lung cancers are SCCs.  Two 
thirds of all SCCs are located in the central lung, the remaining one third is 
peripheral. 
In the carcinoma in situ (the earliest form), the squamous epithelium is replaced by 
malignant squamous cells and with ongoing growth, tumour cells invade the sub-
epithelial basement membrane. Carcinomas in situ do not necessarily progress to 
invasive carcinomas, but they can spontaneously regress to normal mucosa. The 
histological pattern of SCC appears as intracellular bridging, horn pearl formation and 
individual cell keratinisation; these features become more and more characteristic, 
the higher such a tumour is differentiated. About 5 % of SCCs are invasive and 
metastasise to different sites in the body [41]. For most of the SCCs there exists a 
high medical need for novel targeted therapies. Especially in recurrent and/or 
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metastatic SCC of the head and neck, there have been no improvements in survival 
in last decade [42]. Therefore, the identification of SCC-specific proteins is a key 
element to gain additional prognostic markers and a prerequisite to develop novel 
chemical and immunological therapeutic strategies for treatment of SCCs. 
 
Figure 1. Different types of epithelia 
(Taken from http://training.seer.cancer.gov/module_anatomy/unit2_2_body_tissues1_epithelial.html) 
 
Identification of the Novel Tumour-Specific Gene CLCA2 
Combination of subtractive hybridisation using a pool of lung squamous cell 
carcinoma (lung-SCC) as tester and a pool of 11 critical normal tissues as driver on 
cDNA microarrays lead to the identification of the human calcium-activated chloride 
channel 2 (CLCA2) as one gene being highly expressed in lung-SCC [1]. In addition, 
selected HLA-A2-restricted peptides from CLCA2 have been selected and by using in 
vitro priming, T cell lines against the CLCA2-derived KLLGNCLPTV, LLGNCLPTV, 
and SLQALKVTV peptides have been generated. These primed T cells also 
recognised allogeneic tumour cells in an antigen-specific and HLA-restricted fashion. 
Moreover, peptide LLGNCLPTV was also independently recognised by CD8(+) T 
cells expanded from pancreatic carcinoma/T cell cocultures whereas CLCA2-specific 
CD8(+) T cells were absent from the peripheral blood of healthy donors. These data 
indicate that an immune response can be induced against CLCA2, which thus may 
become an important antigen for anti-tumour vaccination approaches [2]. However, 
the contribution of CLCA2 in tumour growth and/or survival and its biological role in 
tumourigenesis is still unknown.  
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The CLCA (CaCC) Family of Putative Calcium-Activated 
Chloride Channels 
The CLCA gene family is a growing family of trans-membrane proteins with a 
putative role in chloride conductivity across the outer cell membrane, that is regulated 
by the intracellular concentration of calcium [3]. CLCA proteins are of high interest for 
respiratory disorders with chronic mucus overproduction, including asthma, chronic 
obstructive pulmonary disease (COPD), and cystic fibrosis. 
To date, 17 homologous genes have been identified so far in mammalians. The 
family consists of the two bovine founder molecules: bCLCA1 (alias CaCC) [43;44] 
and bCLCA2 (alias Lu-ECAM-1) [45;46]; six murine homologues: mCLCA1 [47;48], 
mCLCA2 [49], mCLCA3 (alias gob-5) [50], mCLCA4 [51], mCLCA5 [52] and 
mCLCA6 [52]; four human homologues: hCLCA1 [53;54], hCLCA2 [55;56], hCLCA3 
[4], hCLCA4 (CaCC2) [54]; one porcine homologue: pCLCA1 [57]; a rat homologue: 
rCLCA1 [58] and two rat-brain homologues: rbCLCA1 [59] and rbCLCA2 [60]; one 
equine homologue: eCLCA1 [61]; and one canine homologue: cCLCA1 [62]. 
All members of this gene family map to the same site on chromosome 1p31-p22 [63] 
and share high degrees of homology in size, sequence, and predicted structure; but 
they differ significantly in their tissue distribution and in cellular expression pattern. 
With the exception of the truncated secreted member human CLCA3 [64], all are 
synthesised as an 902-943 amino acid precursor trans-membrane glycoprotein of 
approximately 125 kDa weight, which is rapidly cleaved into 90 and 35 kDa subunits 
[4]. Another common feature is a symmetrical multiple Cysteine motif in the amino-
terminal tail. For human CLCA1 a novel conserved metallo-hydrolase structural 
domain was shown [65]. 
Despite the well characterised biophysical property as chloride channels, 
demonstrated by cell transfection and patch clamp studies, other functions and their 
physiological significance are poorly understood. Independently of their alleged role 
in ion conductance, the field of functionalities seems to be quite broad. Certain CLCA 
family members may serve as cell-adhesion molecules and may play a role in tumour 
metastasis. Aberrant morphology of cells overexpressing murine CLCA2 has been 
interpreted as evidence for modulation of the cell cycle by CLCA proteins [66]. A 
mechanism of tumour suppressive effects of CLCA proteins has been reported, but is 
not understood in detail yet.  
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Human CLCA2: Present Status and Rationale  
The human CLCA2 protein is highly homologous to murine CLCA5 [52]. It is 
expressed as a 943 amino acid precursor whose N-terminal signal sequence is 
removed, followed by internal cleavage near amino acid position 670. Biochemical 
analysis of human CLCA2 suggested five trans-membrane domains [64], three of 
which were predicted to be located in the larger amino-terminal part and two in the 
smaller ~ 38 kD carboxy-terminal cleavage product. More recent investigations of 
trans-membrane geometry predict that a C-terminal 22-amino-acid hydrophobic 
segment comprises the only trans-membrane pass [67]. However, the native 
structure remains unclear. 
A tumour suppressive effect of human CLCA2 has been suggested through pro-
apoptotic action: Stable transfection of CLCA2 into a human breast carcinoma cell 
line reduced its invasive growth in vitro and slowed their tumourigenicity in vivo  
[66;68]. The von Willebrand factor type A (vWA) domain has been discovered in 
CLCA2 [69], and was shown to play a role in adhesion by being involved in the 
binding of Integrin β4 to human CLCA2.  
In contrast to other family members, human CLCA2 displays a very restricted tissue 
expression profile. It is selectively expressed in human lung, trachea and mammary 
gland [55]. Expression in uterus, prostate, testis was also reported [54], as well as in 
corneal epithelium [56]. Since this protein is expressed predominantly in trachea and 
lung, it is suggested that CLCA2 might play a role in the complex pathogenesis of 
cystic fibrosis. It may also serve as adhesion molecule for lung metastatic cancer 
cells, mediating vascular arrest, and colonisation. 
In a tumour attachment model the expression of human CLCA2 on lung endothelial 
cells was demonstrated to mediate the attachment of breast cancer cells, by binding 
to Integrin β4 [70]. The additional function of this family of proteins as adhesion 
molecules is supported by the prediction of a von Willebrand factor type A adhesion 
domain [71]. This domain was first described as the adhesion element in blood-
clotting proteins. Binding between murine CLCA1 and Integrin β4 was demonstrated 
to induce the activation of the focal adhesion kinase in cancer cells [72]. The 
adhesion function of this class of proteins was further demonstrated by the fact that 
the lung epithelial bovine CLCA2 was shown to mediate lung metastasis of 
melanoma cells in mice [73].  
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Multiple tissue Northern blot analysis revealed a very restricted expression profile in 
normal tissues as it was only detected in larynx and esophagus. In addition, a weak 
expression was detected in skin and testis (PhD-Thesis of Ulrich König 2001, 
Boehringer Ingelheim Austria). These findings are supported by the work from Pauli 
and Gruber [54;55]. In situ hybridisations and a large set of comparative 
hybridisations on cDNA arrays followed by real time PCR studies supported this 
result; 100 % of lung SCC patient samples exhibit high upregulation of human 
CLCA2, whereas residual normal lung was negative for human CLCA2.  
Suggesting CLCA2 as a novel marker for SCC, these data served as the basis for 
the present PhD-Thesis, with the aim of the functional characterisation of CLCA2 in 
human tumour cells. Recent data of gene expression profiling of primary and 
metastatic melanoma reported differential gene expression of human CLCA2 
between metastatic melanoma and non-metastatic cutaneous tumours [74], and 
confirmed data which have been obtained during this PhD-Thesis.  
 
Based on previous studies of our group and others (see above), there is profound 
evidence that CLCA2 is a tumour-associated protein which might play an important 
role in sqamous cell carcinogenesis. However, very little is known about the function 
of CLCA2 and its essential contribution to tumour cell growth and/or survival.  
Therefore, the aims of this PhD-Thesis can be summarised as follows:  
- performing a detailed in silico expression profile analysis utilising mainly the in-
house expression database BioExpress (GeneLogic Inc.), 
- functional characterisation of CLCA2 by gain- and loss-of-function studies in 
selected SCC cell lines, 
- identification of functionally essential amino acids of CLCA2 by mutational 
analyses (putative metallo-hydrolase domain), 
- analysing the effect of wild type and mutant CLCA2 in 3D culture, 
- expression profiling on Affymetrix GeneChips of cell lines upon induction with 
wild type and mutated CLCA2, selecting differentially induced genes and 
analysing those genes by RT-qPCR and Western blot analysis, and finally 
- utilising data mining algorithms to bring CLCA2 and the differentially induced 
genes into a biological context. 
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RESULTS 
This PhD-Thesis is based on data of previous projects in the Sommergruber lab at 
Boehringer Ingelheim Austria, which aimed at the identification of novel putative 
targets for anti-cancer therapy. In these studies, Stefan Amatschek compared during 
his diploma thesis tumourous and non-tumourous patient samples by analysing 20 
breast carcinomas, 11 lung squamous cell carcinomas (SCC), 11 lung 
adenocarcinomas (AC), 8 renal cell arcinomas (RCC), and 16 corresponding normal 
tissues utilising PCR-based cDNA subtraction analyses combined with subsequent 
cDNA microarray analyses. The obtained data allowed the discrimination between 
mRNA transcripts, which are exclusively expressed in lung SCC and/or lung ACs [1]. 
One of these transcripts was identified as the human calcium-activated chloride 
channel, family member 2 (CLCA2). 
During his PhD-Thesis, Ulrich König could confirm the lung SCC-specific mRNA 
expression of CLCA2 by different methods such as Northern blot, RT-qPCR, in situ 
hybridisation and others. Additionally, he could identify an overexpression of CLCA2 
mRNA transcript in esophageal SCCs in comparison to normal esophageal tissue. In 
addition, he could show that selected HLA-A2-restricted peptides from CLCA2 can be 
used for in vitro priming T cell lines [2]. 
In Silico Analysis of Expression Data 
The expression levels of CLCA2 mRNA were investigated in available normal tissue 
samples, tumourous tissue samples and tumour cell lines utilising Boehringer 
Ingelheims proprietary BioExpress database (GeneLogic Inc.), which includes 
expression data from ~ 14.000 human tissue samples, analysed on Affymetrix 
GeneChips. 
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Expression Profiling of CLCA2 in Normal Tissue Samples 
By comparison of 31 different normal tissues using BioExpress database (GeneLogic 
Inc.), CLCA2 expression could only be found in normal skin, larynx and esophagus 
(Figure 2).  
The expression of CLCA2 mRNA seems to be tightly regulated, as its mRNA is only 
found in a small number of normal tissues and is not ubiquitously expressed.  
 
 
 
Figure 2. CLCA2 mRNA expression in normal tissue samples 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised [75]. 
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Expression Profiling of CLCA2 in Tumourous Tissue Samples 
The expression levels of CLCA2 were examined in those available tumourous and 
corresponding normal tissue samples, where the disease annotation was confirmed 
by the revision of the clinical history by an experienced pathologist. The verified 
diagnostic sample annotation was taken as the primary quality criteria for sample 
selection.  
Varying portions of tumour cells on the individual tissue sections could distort some 
of the relative expression values. In-depth statistical analyses of those samples, of 
which the percentage of tumour cells per section was available and accordingly 
correlated (data not shown), resulted in negligible corrections of the relative 
expression values.  
Data for cervix carcinomas could only be linked to squamous cell carcinomas (SCC). 
For those two indications no further tumour type sub-classification could be found in 
BioExpress database (GeneLogic Inc.). Tumours from the lung were subdivided into 
small cell lung cancers (SCLC), adenocarcinomas (AC), adenosquamous 
carcinomas (AdSqCa), large cell carcinomas (LCC), and squamous cell carcinomas 
(SCC). For a fraction of SCCs from the head and neck region it was possible to 
classify those samples into two sub-categories (esophageal and laryngeal tumours), 
since data of the corresponding normal tissue were also available. For tumours of the 
urinary bladder mainly data on transitional cell carcinomas (TCC), the most common 
type of bladder carcinomas, were available. Lymph node metastases were 
subcategorised, corresponding to the tumour subtype of the primary tumour they 
descend from, namely melanoma (Mel), adenocarcinomas (AC), and squamous cell 
carcinomas (SCC).  
As previously mentioned, CLCA2 expression was already detected in esophageal 
and lung SCCs by Northern blotting and RT-qPCR. As shown in Figure 4, analyses 
of the expression pattern in the BioExpress database (GeneLogic Inc.) confirmed 
these data and indicated a preferential overexpression of CLCA2 for lymph node 
metastases of SCCs (LNSCCMet) as well as for SCCs of the larynx, the cervix, the 
head and neck region, and of a subpopulation of the infiltrating ductal breast 
carcinoma and mycosis fungoides.  
There is a clear preference of elevated levels of CLCA2 mRNA transcript in SCCs 
such as larynx SCC, head and neck SCC or cervix SCC (Figure 4).  
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After in-depth analyses of the available clinical history of the normal skin samples a 
discrimination between skin samples derived from healthy individuals and skin 
samples from cancer patients was possible. As the expression levels for CLCA2 are 
significantly higher in most of the skin samples, which were taken from cancer 
patients distant from the primary tumour site (Figure 3), it is very likely that the 
expression levels of CLCA2 in tumour-associated normal samples of larynx and 
esophagus are similarly altered by distant primary tumours. However, for these 
tissues samples no reliable clinical history was available.  
 
                
Figure 3. CLCA2 mRNA expression in skin samples of different origins 
PV: Verified by pathologist; green: Skin-derived from non-tumour (normal) samples; blue: Normal skin tumour-
associated samples; yellow: Normal skin samples w/o assignment. CLCA2 mRNA expression was analysed using 
Affymetrix GeneChip technology. The Affymetrix identification code for CLCA2 is 206165_s_at. The expression 
levels of CLCA2 mRNA are shown in box-plots. The vertical centre line in the box indicates the median. The box 
itself represents the interquartile range (IQR) between the first and third quartiles. Whiskers extend to 1.5 times 
the IQR; the position of extreme values, if above the upper whisker limits, are marked by open circles. The human 
sample collection has been described by the originator of the BioExpress database (GeneLogic Inc.). Numbers in 
brackets indicate the sample numbers. All samples have been MAS5-normalised. 
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In contrast to SCCs, overexpression of CLCA2 is neither detected in ACs and their 
corresponding lymph node metastasis, nor in tumours of the hematopoietic or 
lymphatic system indicating again its highly SCC-specific expression (Figure 4).  
 
 
 
Figure 4. CLCA2 mRNA expression in various tumours 
All: Acute lymphocytic leukaemia, Ca: Carcinoma, Met: Metastases, Tiss: Tissue, Squam: Sqamous, InfDuc: 
Infiltrating ductal, InfLob: Infiltrating lobular, PapillFollic: Papillary and follicular, Malig: Malignant, TransCellCa: 
Trans cell carcinoma, ColonMucinCa: Mucinous colon carcinoma, GlioblastMultiform: Glioblastoma multiforme. 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. 
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Figure 5 comprises a comparison of the major therapeutically relevant tumour types 
versus their corresponding normal tissues. Elevated levels of CLCA2 mRNA 
transcript were detected only in lung SCC and could not be found in lung AC or the 
corresponding normal tissues. In prostate and colon carcinomas no CLCA2 
expression was found (Figure 5). 
In breast cancer, a subpopulation of the infiltrating ductal carcinomas shows 
overexpression of CLCA2, which is represented by the high amount of outliers in 
Figure 5. However, it remains unclear whether distinct chromosomal aberrations or 
different differentiation stages lead to the induction of and/or dependence on CLCA2 
in this subset of breast cancer samples. In this context it has to be mentioned that 
Her2 amplification is also found only in a subset (outlier) of breast cancer samples.  
 
          
 
Figure 5. CLCA2 mRNA expression in tumourous tissues: Major therapeutically important tumour types 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. Abbreviations see Figure 4. 
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In Figure 6 lymph node metastases are compared with a set of “minor indications” 
and their corresponding normal tissues. Again, CLCA2 overexpression could only be 
detected in lymph node metastases derived from SCC but not AC-driven metastases.  
 
 
 
Figure 6.  CLCA2 mRNA expression in lymphnode metastases 
SoftTissMaligFibrousHistocyt: Soft tissue malignant fibrous histiocytoma; other abbreviations see Figure 4. 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. 
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In the view of elevated CLCA2 transcript levels in tumour-associated skin biopsies 
(see Figure 3) it is of interest that a dramatic increase of CLCA2 mRNA was 
identified in mycosis fungoides (Figure 7).  Mycosis fungoides is the most common 
type of cutaneous T cell lymphoma (CTCL). It is a Non-Hodgkin lymphoma, which is 
predominantly related to skin. It generally affects the skin, but may progress internally 
over time. As shown in Figure 3, mRNA expression of CLCA2 seems to be induced 
in tumour-associated skin rather than in normal skin. Similarly, mycosis fungoides 
might make use of CLCA2 for its colonisation of the skin during its course of 
progression. In contrast, no CLCA2 expression is found in Hodgkin lymphomas. 
In summary, it seems that formation of SCC-derived metastases are somehow linked 
with CLCA2 expression (Figure 6) supporting the idea that CLCA2 might play a 
crucial role in the formation of SCC-derived metastases and for the progression of 
mycosis fungoides (Figure 7).  
 
  
Figure 7. CLCA2 mRNA expression in lymphomas and mycosis fungoides 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. Abbreviations see Figure 4. 
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In contrast to mycosis fungoides no (elevated) expression of CLCA2 was detectable 
in B cell and T cell lymphomas and their corresponding normal tissues/cells (Figure 
8, Figure 9 and Figure 10).  
      
Figure 8. CLCA2 mRNA expression in a panel of lymphomas and B cell leukaemias and their 
corresponding normal tissues 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. DLBL: Diffuse large B cell lymphoma; other abbreviations see Figure 4. 
 
 
            
Figure 9. CLCA2 mRNA expression in T cell and B cell lymphomas and their corresponding normal 
tissues 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. Abbreviations see Figure 4. 
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Figure 10. CLCA2 mRNA expression in acute leukaemias such as acute myeloid, acute promyelocytic, 
and acute monocytic leukeaemia 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. CML: Chronic myelogenous leukemia; other abbreviations see Figure 4. 
 
 
As different generations of Affymetrix GeneChips have been used, an in silico 
comparison was performed to test for the robustness and reproducibility of the 
expression profile of CLCA2. As clearly seen in Figure 11, the expression profile of 
CLCA2 is independent from the type of GeneChip used. In all cases only SCCs 
exhibit the dramatic overexpression of CLCA2. For testing the Exon GeneChip 
generation only a subset of the human lung samples have been used. Although 
different types of arrays have been used for the expression profiling no statistically 
relevant variation can be observed in the mRNA levels of the same sample set 
among different GeneChips. It has to be indicated that for a given tissue sample the 
relative expression values between the different GeneChips cannot be directly 
compared with each other (e.g. median for CLCA2 in SCC on U133AB Array is ~ 
600, on U133 Plus 2.0 is ~ 800 and on Exon Array ~ 300, respectively).  
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Figure 11. Comparison of CLCA2 expression profiles of a set of human normal and lung tumour (AC and 
SCC) samples utilising different types of Affymetrix GeneChips 
Note that the identification code for CLCA2 is different, depending on the array type used. The expression levels 
of CLCA2 mRNA are shown in box-plots. The vertical centre line in the box indicates the median. The box itself 
represents the interquartile range (IQR) between the first and third quartiles. Whiskers extend to 1.5 times the 
IQR; the position of extreme values, if above the upper whisker limits, are marked by open circles. The human 
sample collection has been described by the originator of the BioExpress database (GeneLogic Inc.). Numbers in 
brackets indicate the sample numbers. All samples have been MAS5-normalised. Abbreviations see Figure 4. 
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The infiltration of a number of non-tumourous cell types (e.g. macrophages, 
lymphocytes) into the tumour tissue and the presence of surrounding non-tumourous 
tissue (tumour stroma) in whole tissue preparations often leads to falsification in the 
interpretation of ex vivo tissue expression data. To exclude relevant contribution of 
cells of the tumour stroma, the CLCA2 expression pattern in several laser-capture-
microdissected (LCM) tissue samples of lung carcinomas in comparison to non-
neoplastic lung tissue samples was analysed (Figure 12). Based on this in silico 
analysis, expression of CLCA2 in tumour stroma could be excluded and the tumour-
specific expression pattern of CLCA2 could be confirmed. For a better comparability 
the total RNA from all cell types and LCM-dissected epithelial cells from different 
sections of the identical frozen tumour samples was analysed. The expression of 
CLCA2 transcript is exclusively found in the epithelial tumour cell fraction and if 
indeed expressed in any stromal compartment, would have led to a decrease in 
normalised expression levels in epithelial tumour cells, when compared with the 
corresponding normal tissue. As the relative expression level in the tumour cell 
population even increased after LCM sample preparation, it can be argued that the 
detected expression of CLCA2 transcript in all other tissue samples of different origin, 
which were analysed without LCM dissection, originates exclusively from epithelial 
tumour cells (see also Figure 2 and Figure 3).  
 
 
 
 
 
 
 
 
 
 
Figure 12. CLCA2 mRNA expression in LCM-dissected lung tumour samples 
Samples were anaysed with and without LCM-dissection (with: +LCM / without: -LCM) of epithelial tumour cells. 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. 
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As expression of CLCA2 is detected in esophagus tissue, an interesting aspect was 
whether CLCA2 is also expressed in other parts of the digestive tract. Therefore the 
expression levels of CLCA2 were compared in various tissues of the entire digestive 
tract. As clearly seen in Figure 13, no additional expression is found in other parts of 
the digestive tract, again underlining the restricted expression pattern of CLCA2.  
 
 
 
Figure 13. CLCA2 mRNA expression in normal tissues of the digestive tract 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised.  
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That CLCA2 expression might have an influence on development of metastasis as 
shown in Figure 14. To analyse if there is a correlation of CLCA2 overexpression with 
development of metastases, it was made use of expression data derived from cell 
lines and their corresponding developing tumours in xenograft models. It is of great 
interest that xenografts originating from SSC cell lines such as A431 (cervix 
carcinoma), H520 (lung carcinoma) and HNOE (head and neck/ esophagus 
carcinoma) all exhibit a dramatic upregulation of CLCA2 (Figure 14). Except for the 
pancreatic cell line BxPC3 and MDA-MB-453 (mamma carcinoma) no AC-derived cell 
line leads to such a pronounced upregulation of CLCA2 in xenografts. In the case of 
MDA-MB-453 a high expression level of CLCA2 is already observed in 2D culture 
(Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
Figure 14. Induction of CLCA2 in xenografts versus 2D cell culture 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. The human sample collection has been described by the originator of 
the BioExpress database (GeneLogic Inc.). Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. 2D refers to cell lines cultivated in tissue culture and xeno the corresponding xenografts. 
Other abbreviations see Figure 4. 
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Expression Profiling of CLCA2 in Tumour Cell Lines 
Additional support for a restricted expression profile of CLCA2 comes from the 
expression profiling analysis of different human carcinoma cell lines (Figure 15). 
Expression was only detected in the human glioblastoma cell line SNB75, in two 
SCC cell lines HN5 (head and neck) and A431 (cervix carcinoma) and in the breast 
carcinoma cell line MDA-MB-453. 
Two cell lines were selected for knock-down experiments, HN5 a squamous head 
and neck carcinoma cell line and MDA-MB-453 (mamma carcinoma) as a 
representative of an AC cell line with high levels of CLCA2 expression.  
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Figure 15. CLCA2 mRNA expression in various human tumour cell lines 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open circles. Cell line description is according to the nomenclature of the provider 
(in most cases ATCC (American Type Culture Collection): http://www.atcc.org/home.cfm, DSMZ (Deutsche 
Sammlung für Mikroorg. und Zellkulturen): http://www.dsmz.de/index.html, and ECACC (European Collection of 
Animal Cell Cultures): http://fuseiv.star.co.uk/camr/). Numbers in brackets indicate the sample numbers. All 
samples have been MAS5-normalised. Corresponding tumour types to cell lines are shown in Appendix.  
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A correlation of CLCA2 expression in metastases of breast cancer with detection of 
metastases in different sites is shown in Figure 16. To exclude any interference of 
cells from the tumour stroma, only laser-capture-microdissected (LCM) tissue 
samples were used for this analysis (for details see Figure 3).  
Sample sets which showed no evidence of disease including metastases (NED) were 
compared to metastases-positive samples (POS). Only samples from patients with a 
five year observation time have been included in this analysis. Except for metastases 
to bone, CLCA2 overexpression is obviously needed for formation of metastases in 
brain, lung, liver, and lymph node respectively. The data shown in Figure 16 strongly 
supports the results in our xenograft models (Figure 14): CLCA2 expression plays a 
crucial role in tumour progression and metastasis.  
 
 
Figure 16. Correlation of metastasis status with CLCA2 expression in LCM breast cancer samples 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The Affymetrix identification 
code for CLCA2 is 206165_s_at. The expression levels of CLCA2 mRNA are shown in box-plots. The vertical 
centre line in the box indicates the median. The box itself represents the interquartile range (IQR) between the 
first and third quartiles. Whiskers extend to 1.5 times the IQR; the position of extreme values, if above the upper 
whisker limits, are marked by open squares. Numbers in brackets indicate the sample numbers. All samples have 
been MAS5-normalised. LCM: Laser-capture-microdissected, Meta: Metastases, NED: No evidence of disease 
(blue), POS: Metastases-positive (yellow). Data generated in the course of the GEN-AU Project (Joint Project: 
“Genomic Approaches to Tumour Invasion and Metastasis”).  
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A correlation was also found between CLCA2 expression and receptor- and 
lymphnode status in breast cancer (Figure 17). In the case of Her2 amplification 
(aggressive status; poor prognosis; [76]) CLCA2 expression is upregulated as 
compared to tumour samples where Her2 is not amplified. In contrast, if the tumour is 
still estrogen-sensitive (estrogen receptor status POS; good prognosis; [77]), CLCA2 
expression is very low, but becomes upregulated in samples of negative estrogen 
receptor status (insensitive to estrogen; poor prognosis).  
These results support the present view on the essential contribution of CLCA2 to 
tumour formation, progression, and induction of metastases (Figure 14, Figure 16, 
Figure 17). 
 
 
 
Figure 17. Correlation of receptor and lymphnode status with CLCA2 expression 
CLCA2 mRNA expression was analysed using Affymetrix GeneChip technology. The number of samples (n) for 
each tissue is given. The expression levels of CLCA2 (206165_s_at) mRNA in ER positive and ER negative, in 
Her2 amplified and Her2 non-amplified and in lymph node positive and negative breast cancer patient samples 
are shown in box-plots. The vertical centre line in the box indicates the median; the box itself represents the 
interquartile range (IQR) between the first and third quartiles. Whiskers extend to 1.5 times the IQR. Positions of 
extreme values are marked by open circles, if they were above the upper whisker limits. Only data from samples 
which have been laser-capture-microdissected were included in the in silico analysis. Data generated in the 
course of the GEN-AU Project (Joint Project: “Genomic Approaches to Tumour Invasion and Metastasis”).  
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Chromosomal Amplifications of CLCA2 Locus in Tumour Cell Lines 
Interestingly, most squamous cell carcinoma cell lines with an increased expression 
level of CLCA2 also exhibit amplification of the chromosomal locus of CLCA2:     
1p22-31 [63], possibly reflecting the link between genomic and transcriptional status 
in various SCCs. Using Affymetrix SNP-Chip analysis (SNP: Single nucleotide 
polymorphism), chromosomal amplification or deletion patterns in different human 
tumours and tumour cell lines were analysed and are shown in Figure 18 and Figure 
19. For instance, in FaDu, a head and neck SCC cell line, the copy number (CN) of 
the CLCA2 locus is amplified (CN ~ 3). 
 
 
Figure 18. Chromosomal amplification of CLCA2 locus in the SCC cell line FaDu 
Using Affymetrix SNP-Chip technology, the chromosomal amplification pattern was analysed in FaDu, a head and 
neck squamous cell carcinoma cell line. Position of CLCA2 is marked in red. For analysis two algorithms have 
been used (copy number and copy number smooth).  
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A set of various colon and breast carcinoma cell lines is shown in Figure 19. 
Whereas no colon carcinoma cell line contains amplified CLCA2 loci, breast 
carcinoma cell lines MDA-MB-231, BT-549, and HS-578T exhibit amplification of the 
CLCA2 loci (marked in yellow). 
 
 
Figure 19. Heatmap of amplification of the chromosomal CLCA2 locus in various human tumour cell lines 
Using Affymetrix SNP-Chip technology, the chromosomal amplification pattern was analysed in different human 
tumour cell lines. Yellow indicated amplified loci, black normal, and blue deleted loci. Corresponding tumour types 
to cell lines are shown in Appendix.  
 
 
Based on SNP-Chip data and utilising a new algorithm “GLAD” [78] the copy number 
of genes located at chromome 1 (chr1) has been studied in more detail (higher 
resolution) in breast cancer patient samples and three SCC cell lines. As shown in 
Figure 20, not only a small part of the chromosomal region around CLCA2 (1p32-
p22) is found to be amplified, but huge parts or even the entire chromosome arm are 
amplified. In contrast to Her2, no focal amplification pattern was identified.  
amplified normal 
Colon Carcinoma Tumour Cell Lines 
deleted 
Breast Carcinoma Tumour Cell Lines 
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Figure 20. Chromosomal status of chr1 in human breast cancer samples and SCC cell lines 
Using Affymetrix SNP-Chip technology, the chromosomal amplification pattern was analysed. Blue indicates 
amplification, red deletion and green refers to a normal chromosomal status. The red arrow indicates the position 
of CLCA2 at 1p32-p22. Tissue DNA copy numbers were analysed using the GLAD algorithm [78].  
Fadu (SCC)
KYSE30 (SCC)
Calu1 (SCC)
Breast Cancer (Patient Sample)
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Identification of Differential Gene Expression Profiles 
To identify transcripts which show a similar expression pattern to that of CLCA2, 
statistical analyses which correlated normalised expression values of the BioExpress 
database (GeneLogic Inc.) were performed. 
The expression values of CLCA2 were correlated to the expression values of all 
available probe sets. Thereby the relative differences between the mean expression 
values of normal and tumourous tissues were used for correlation. In a first analysis 
the relative expression differences of CLCA2 between normal tissues and SCCs of 
the lung, cervix, larynx, esophagus, lymphnode metastasis, and skin, respectively, 
were compared. During the second round of analyses, the focus was laid on the 
differences in normal tissues and SCCs of the lung, cervix, and lymph nodes.  
As expected, all four annotated probe sets for CLCA2 ranked first in both correlation 
analyses. Among the highest correlated probe sets within both analyses, different 
markers for stratified epithelia were found. These were, to name but a few, 
desmocollin (DSC3), desmoglein 3 (DSG3), TP53 apoptosis effector (PERP), 
plakophilin 1 (PKP1), and keratin 5 (KRT5. The expression of those epithelial 
differentiation markers seems to be maintained during the transition from a stratified 
epithelial cell into a hyper-proliferating SCC cell, and could therefore be essential for 
the establishment of SCCs.  
Genes already described to be involved in tumourigenesis, such as ladinin 1 
(LAD1/CD18), tripartite motif-containing 29 (TRIM29), stratifin (14-3-3 sigma/SDN), or 
RAB38, a member of the RAS oncogene family were also identified. 
Correlated probe sets which seem to represent yet unidentified markers for stratified 
epithelia and/or the tumourigenesis of SCCs were found as well. 
One of the identified probe sets (219936_s_at), which showed in both analyses 
nearly an identical expression profile as CLCA2, corresponds to GPR87 and has not 
been associated with stratified epithelia or the establishment of SCCs before.  
The investigation of GPR87 was basis for the PhD-Thesis of Sebastian Glatt with the 
title “Contribution of hGPR87 and hARHV to squamous cell carcinogenesis”, which 
was done in the Sommergruber lab at Boehringer Ingelheim. The work was recently 
published in the Int. J. of Cancer [79]. 
RESULTS 
 
 47
Knock-Down of CLCA2 in CLCA2-Positive Tumour Cells 
To minimise off-target effects of the siRNA treatment, commercially available non-
targeting control siRNA (siCONTROL#1, Dharmacon; further named “siCTRL”) and 
mock transfections were additionally performed in parallel for all siRNA experiments.  
siRNA Experiments in Human Head and Neck SCC Tumour Cell Line HN5 
Based on the relatively high expression level of CLCA2 (see section “Expression 
Profiling”), the cell line HN5 was chosen to study CLCA2 loss-of-function by siRNA-
mediated knock-down and its implication on cell survival and proliferation. 
Evaluation of CLCA2 siRNAs 
First, siGENOME SMART pool (Dharmacon) containing a mixture of four designed 
siRNAs targeting CLCA2 mRNA, was tested in HN5 cell line for efficient 
downregulation of the specific mRNA by performing RT-qPCR analysis.  
Downregulation of protein levels could not be tested in HN5, because untagged 
CLCA2 protein could not be detected on Western blots due to lack of an appropriate 
antibody. 
After SMART pool treatment, a reduction of CLCA2 mRNA transcript below 10 % 
could be determined in HN5 cells (Figure 21). 
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Figure 21. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Testing siGENOME SMART pool (RT-qPCR) 
150,000 cells per well of a 6-well-plate were transfected with CLCA2-siGENOME SMART pool of Dharmacon 
(siCLCA2-pool), at a concentration of 20 nM siRNA, using Dharmafect 4 transfection reagent. RNA was harvested 
24 h and 48 h post transfection. Transcribed cDNA was tested in RT-qPCR using a pool of CLCA2-specific 
oligonucleotides for the individual siRNAs siCLCA2-2, siCLCA2-4, siCLCA2-5 and siCLCA2-5 – all of Dharmacon; 
for sequence see section “Material and Methods”. CLCA2 mRNA levels were normalised against the endogenous 
control gene β-2-microglobulin. As control, CLCA2 expression was compared to HN5 cells transfected under 
same conditions with non-targeting control siRNA CONTROL#1 of Dharmacon (siCTRL).  
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In a next step, the four individual siRNAs were tested separately under identical 
conditions and both were shown to exhibit comparable and efficient downregulation 
of the specific mRNA in RT-qPCR (Figure 22). It was decided, to use only the two 
most efficient siRNA oligonucleotides, siCLCA2-2 and siCLCA2-4 for further 
experiments as they lead to a reduction of about 6 % or 10 % at 24 h, and 3 % or      
1 % at 48 h, respectively (Figure 22).  
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Figure 22. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Testing individual siRNAs of siGENOME SMART pool (RT-qPCR) 
150,000 HN5 cells per well of a 6-well-plate were transfected with CLCA2-siGENOME SMART pool (Dharmacon) 
(siCLCA2-pool) and in parallel with the individual siRNAs of CLCA2-siGENOME SMART pool (siCLCA2-2, 
siCLCA2-4, siCLCA2-5, siCLCA2-8) at a concentration of 20 nM siRNA using Dharmafect 4 transfection reagent. 
RNA was harvested 24 h and 48 h post transfection. cDNA was tested in RT-qPCR using a CLCA2-specific 
primer pair. CLCA2 mRNA levels were normalised against the endogenous control gene β-2-microglobulin. As 
control, CLCA2 expression was compared to HN5 cells transfected under identical conditions with non-targeting 
control siRNA CONTROL#1of Dharmacon (siCTRL). 
 
For optimisation of siRNA concentration, different concentrations of the two most 
efficient siRNA oligonucleotides were transfected into HN5 cells. In this experiment 
lysates were analysed after 48 h, because it was shown before, that in general the 
knock-down effect was more efficient 48 h post transfection (Figure 22). 
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Furthermore, the two most efficient siRNA oligonucleotides were pooled and 
analysed for a possible additive effect. As shown in Figure 23, the knock-down 
efficiency seems to be relatively independent of the siRNA concentration and ranges 
for all concentrations between 0 and 23 %.  
Pooling of the two most efficient siRNA oligonucleotides siCLCA2-2 and siCLCA2-4 
seems to slightly improve the knock-down effect (reduction of CLCA2 mRNA 
transcript to 4-10 %). 
In general, efficient knock-down could be achieved under all conditions and higher 
concentrations did not lead to better results. Therefore, it was decided to perform 
further experiments at the originally applied concentration of 20 nM siRNA.  
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Figure 23. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Testing different concentrations of siRNA (RT-qPCR) 
5,000 HN5 cells per well of a 96-well-plate were transfected with different concentrations of the individual siRNAs 
siCLCA2-2 and siCLCA2-4 and cells were also transfected with a pool of both (siCLCA2-2&4 pooled) using 
Dharmafect 4 transfection reagent. RNA was harvested 48 h post transfection. cDNA was tested in RT-qPCR 
using a CLCA2-specific primer pair. CLCA2 mRNA levels were normalised against the endogenous control gene 
β-2-microglobulin. As control, CLCA2 expression was compared to HN5 cells transfected under identical 
conditions with non-targeting control siRNA CONTROL#1of Dharmacon (siCTRL) to untreated HN5 cells 
(untreated), and to HN5 cells which were treated with transfection reagent alone (reagent). 
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To analyse if the cell number has an effect on the knock-down efficiency, different 
cell numbers of HN5 were transfected (6-well-plate) with the two most efficient siRNA 
oligonucleotides. No significant dependence of the knock-down efficiency on the cell 
number could be demonstrated (Figure 24). Transfecting either 50,000 or 100,000 
cells with siCLCA2-2, lead in both cases to a knock-down of CLCA2 mRNA transcript 
to 15 %. Using siRNA siCLCA2-4, a knock-down of the CLCA2 transcript to 31 % 
(50,000 cells) and to 18 % (100,000 cells), respectively, was achieved (Figure 24). 
Based on these data and previous results the cell number seems not to be the 
determining factor for knock-down efficacy. 
 
18%
31%
15%15%
0%
20%
40%
60%
80%
100%
120%
siC
TR
L
siC
LC
A2
-2
siC
LC
A2
-4
siC
TR
L
siC
LC
A2
-2
siC
LC
A2
-4
R
el
at
iv
e 
Tr
an
sc
rip
t L
ev
el
50,000 cells/well 100,000 cells/well
24h
 
Figure 24. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Testing different cell numbers (RT-qPCR) 
50,000 and 100,000 HN5 cells per well of a 6-well-plate were transfected with the individual siRNAs siCLCA2-2 
and siCLCA2-4 at a concentration of 20 nM siRNA using Dharmafect 4 transfection reagent. RNA was harvested 
24 h post transfection. cDNA was tested in RT-qPCR using a CLCA2-specific primer pair. CLCA2 mRNA levels 
were normalised against the endogenous control gene β-2-microglobulin. As control, CLCA2 expression was 
compared to HN5 cells transfected under identical conditions with non-targeting control siRNA CONTROL#1 of 
Dharmacon (siCTRL). 
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Proliferation Assay 
To analyse whether knock-down of CLCA2 has any effect on proliferation of HN5 
cells, the proliferation of CLCA2 siRNA-treated HN5 cells was analysed in an Alamar 
Blue Assay. Thereby GPR87 siRNA was used as a positive control. It has been 
shown previously that downregulation of GPR87 in HN5 cells lead to inhibition of 
proliferation, to reduction in viability and subsequently to induction of apoptosis [79]. 
As shown in Figure 25 the IC50 values of siCLCA2-2 and of siCLCA2-4 are in the 
same range of the IC50 value for siGPR87, indicating that both, CLCA2 and GPR87 
play an essential role for proliferation in HN5 cells. 
 
             
 
Figure 25. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Effect on proliferation (Alamar Blue Assay) 
5,000 HN5 cells per well of a 96-well-plate were transfected with the individual siRNAs siCLCA2-2 and siCLCA2-4 
and as negative control with non-targeting siRNA CONTROL#1 of Dharmacon (siCTRL) and as positive control 
with GPR87-targeting siRNA siGPR87 at concentrations of 390 pM up to 100 nM siRNA using Dharmafect 4 
transfection reagent. For normalisation untreated cells (non-altered proliferation level) and a boiled cell extract 
(background) was used. Alamar Blue Assay was performed 72 h post transfection. 
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Apoptosis 
Cleavage of PARP (Poly ADP-ribose polymerase), a protein involved in a number of 
cellular processes which are mainly linked to DNA repair and programmed cell death, 
is an appropriate indicator of apoptosis as PARP-clevage is observed upon induction 
of apoptosis. Protein lysates of siRNA-treated HN5 cells were analysed for PARP-
cleavage with an anti-PARP-antibody detecting both, full-length and cleaved PARP 
on Western blot. 
48 h after transfection with siCLCA2-4 a pronounced induction of apoptosis (Figure 
26) could be detected in HN5 cells, whereas PARP-cleavage in siCLCA2-2-
transfected cells was only comparable to the siCTRL-transfected cells. These data 
again support the previous findings (Figure 25) that siCLCA2-4 is more efficient in 
knocking-down than siCLCA2-2.  
 
Figure 26. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Effect on induction of apoptosis (PARP-cleavage) 
150,000 HN5 cells per well of a 6-well-plate were transfected with the individual siRNAs siCLCA2-2 and  
siCLCA2-4 and as control with non-targeting control siRNA CONTROL#1 of Dharmacon (siCTRL) at a 
concentration of 20 nM siRNA using Dharmafect 4 transfection reagent. Protein lysates were harvested 24 h and  
48 h post transfection. For Western blot 50 µg protein was loaded per lane; an anti-PARP antibody was used for 
detection of cleaved and uncleaved PARP. GAPDH served as loading control. 
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To not only rely on PARP-cleavage as a read out for induction of apoptosis, a 
detailed analysis of further effects on changes in apoptotic parameters of siRNA-
transfected HN5 cells was performed by investigating the change of nuclear area, 
nuclear fragmentation, membrane-permeability, mitochondrial status, and nuclear 
fragmentation. All these processes are linked with induction of apoptosis. For details 
on the high content screening technology see section “Material and Methods”.  
In siCLC2-4-transfected HN5 cells dramatical changes in membrane permeability 
(Figure 27, yellow bar), in the mitochondrial status (Figure 27, black bar) and the 
nuclear fragmentation (Figure 27, green bar) could be observed, supporting data 
obtained from PARP-cleavage experiments shown before. As already demonstrated 
for siCLC2-2-transfected HN5 cells (Figure 25, Figure 26), no significant changes 
could be detected (Figure 27). 
 
 
 
Figure 27. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Effects on apoptotic parameters (HCS Reader, Cellomics) 
5,000 HN5 cells per well of a 96-well-plate were transfected with the individual siRNAs siCLCA2-2 and siCLCA2-4 
and as control with non-targeting control siRNA CONTROL#1 of Dharmacon (siCTRL) at a concentration of       
20 nM siRNA using Dharmafect 4 transfection reagent. Further controls were untreated cells (untreated) and 
cells, which were treated with transfection reagent only (reagent). 72 h post transfection, cells were analysed for 
changes in the apoptotic parameters by using appropriate antibodies for respective stainings which could be 
evaluated by the ArryScan HCS Reader (Cellomics).  
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Cell Cycle 
The CLCA2 knock-down in siCLA2-2- and siCLCA2-4-treated HN5 cells, leads also 
to a significant shift in cell cycle 72 h after transfection in comparison to controls 
(Figure 28). The cell count in G1-phase (2n) was clearly reduced, and cells were 
arrested in G2, whereby polyploidy was increased. Most likely apoptosis is being 
initiated in these polyploidic cells (Figure 27). Again, for siCLC2-2-transfected HN5 
cells only minor changes of the cell cycle profile could be observed which is in line 
with previous observations (Figure 25, Figure 26, and Figure 27). 
 
 
Figure 28. siRNA-mediated knock-down of CLCA2 in human head and neck SCC tumour cell line HN5: 
Effects on cell cycle (HCS Reader, Cellomics) 
5,000 HN5 cells per well of a 96-well-plate were transfected with the individual siRNAs siCLCA2-2 and siCLCA2-4 
and as control with non-targeting control siRNA CONTROL#1 of Dharmacon (siCTRL) at a concentration of 20 
nM siRNA using Dharmafect 4 transfection reagent. Further controls were untreated cells (untreated) and cells, 
which were treated with transfection reagent only (reagent). 48 h and 72 h post transfection, cells were stained 
with DAPI and analysed on the ArryScan HCS Reader (Cellomics).  
Red lines indicate statistically relevant changes. 
X-axis: The abbreviations <2n, 2n, s, 4n, and >4n represent percentage of cells in sub G1- or G0-phase (<2n), in 
G1-phase (2n), in S-phase (S), in G2-phase (4n), and polyploidic cells (>4n), respectively. 
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siRNA Experiments in Human Breast Carcinoma Cell Line MDA-MB-453 
According to the BioExpress database (GeneLogic Inc.), the human breast 
carcinoma cell line MDA-MB-453 exhibits very high CLCA2 expression levels (Figure 
15) and was therefore selected for siRNA experiments as well.  
As shown in Figure 29, siRNA transfection utilising siCLCA2-2 and siCLCA2-4 
revealed that the high levels of naturally expressed CLCA2 in MDA-MB-453 cells 
could also be knocked-down with these siRNAs to 15 % (siCLCA2-2) and 31 % 
(siCLCA2-4), respectively, in comparison to non-targeting control siRNA (siCTRL). In 
contrast to HN5 cells, the efficiency of knock-down is more pronounced with 
siCLCA2-2 than with siCLCA2-4 (Figure 29, Figure 30). One explanation for this 
phenomena might be the different transfection reagent (for HN5: Dharmafect 4; for 
MDA-MB-453: Dharmafect 2) used in this approach (Table 7). 
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Figure 29. siRNA-mediated knock-down of CLCA2 in breast carcinoma cell line MDA-MB-453:  
Testing siCLCA2-2 and siCLCA2-4 of siGENOME SMART pool, Dharmacon (RT-qPCR) 
100,000 MDA-MB-453 cells per well of a 6-well-plate were transfected with the individual siRNAs siCLCA2-2 and 
siCLCA2-4, respectively, at a concentration of 20 nM siRNA using Dharmafect 2 transfection reagent. RNA was 
harvested 48 h post transfection. cDNA was tested in RT-qPCR using a CLCA2-specific primer pair. CLCA2 
mRNA levels were normalised against the endogenous control gene β-2-microglobulin. As control, CLCA2 
expression is compared to HN5 cells transfected under identical conditions with non-targeting control siRNA 
CONTROL#1 of Dharmacon (siCTRL). 
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Next, the siRNA concentration for an efficient downregulation in MDA-MB-453 cells 
was optimised (Figure 30). Transfection with 50 up to 200 nM siCLCA2-2 results in 
knock-down of CLCA2 mRNA transcript ranging between 3-12 % compared to cells 
transfected with non-targeting siRNA (siCTRL). For siCLCA2-4 the results are similar, 
ranging between 6-12 % but nevertheless siCLCA2-4 seems to be inferior to 
siCLCA2-2. Co-transfections with both siRNAs are resulting in knock-down of            
6-8 %. As the efficiency of downregulation was also demonstrated at lower 
concentrations of siRNA oligonucleotide and the off-target effects of control siRNA 
are also less at lower concentrations, it was decided to use a concentration of 20 nM 
siRNA throughout all further experiments.  
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Figure 30. siRNA-mediated knock-down of CLCA2 in human breast carcinoma cell line MDA-MB-453: 
Testing different concentrations of siRNA (RT-qPCR) 
5,000 MDA-MB-453 cells per well of a 96-well-plate were transfected with different concentrations of the individual 
siRNAs siCLCA2-2 and siCLCA2-4 and cells were transfected with a pool of both as well (siCLCA2-2 and 
siCLCA2-4 pooled) using Dharmafect 2 transfection reagent. RNA was harvested 48 h post transfection. 
Transcribed cDNA was tested in RT-qPCR using a CLCA2-specific primer pair. CLCA2 mRNA levels were 
normalised against the endogenous control gene β-2-microglobulin. As control, CLCA2 expression is compared to 
MDA-MB-453 cells transfected under same conditions with non-targeting control siRNA CONTROL#1 of 
Dharmacon (siCTRL), to untreated MDA-MB-453 cells (untreated), and to MDA-MB-453 cells which were treated 
with transfection reagent only (reagent). 
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Next, the question whether the cell number per well has an impact on the knock-
down efficiency of the CLCA2 mRNA transcript was addressed. As shown in Figure 
31, the optimal cell number per well of a 6-well-plate for an efficient knock-down to  
10 % is about 50,000. However, increasing the number of cells per well (75,000 to 
200,000) leads only to a knock-down efficiency ranging between 26 and 31 %. 
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Figure 31. siRNA-mediated knock-down of CLCA2 in human breast carcinoma cell line MDA-MB-453: 
Testing different cell numbers (RT-qPCR) 
As indicated, 50,000 up to 200,000 MDA-MB-453 cells per well of a 6-well-plate were transfected with the 
individual siRNA (siCLCA2-2) and the control siRNA (siCTRL) each at a concentration of 20 nM using Dharmafect 
2 transfection reagent. RNA was harvested 24 h post transfection. cDNA was tested in RT-qPCR using a CLCA2-
specific primer pair. CLCA2 mRNA levels were normalised against the endogenous control gene β-2-
microglobulin. As control, CLCA2 expression is compared to MDA-MB-453 cells transfected under same 
conditions with non-targeting control siRNA CONTROL#1 of Dharmacon (siCTRL). 
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In contrast to HN5 cells, MDA-MB-453 cells were insensitive towards knock-down of 
CLCA2 when tested in a proliferation assay (Alamar Blue Assay). However, it has to 
be mentioned that MDA-MB-453 cells only very weakly react with the Alamar Blue 
reagent and therefore normalisation to untreated MDA-MB-453 cells generated only 
a small “read out window” (Figure 32). 
 
Figure 32. siRNA-mediated knock-down of CLCA2 in human breast cancer cell line MDA-MB-453: Effect 
on proliferation/viability (Alamar Blue Assay) 
5,000 MDA-MB-453 cells per well of a 96-well-plate were transfected with the individual siRNAs siCLCA2-2 and 
siCLCA2-4 and as negative control with non-targeting siRNA CONTROL#1 of Dharmacon (siCTRL) and as 
positive control with GPR87-targeting siRNA siGPR87 at concentrations of 390 pM up to 100 nM siRNA using 
Dharmafect 2 transfection reagent. . For normalisation untreated cells (non-altered proliferation level) and a boiled 
cell extract (background) was used. Alamar Blue Assay was performed 72 h post transfection. 
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siRNA Experiments in a Stable CLCA2-Constitutively-Expressing T47D 
Clone 
Due to the lack of a specific antiserum against CLCA2 it was not possible to show 
siRNA-mediated knock-down on protein level for HN5 or MDA-MB-453 cells. 
To proof the efficiency of used CLCA2 siRNAs for knock-down of CLCA2 on the 
protein level, stable CLCA2-expressing T47D clones were established, with CLCA2 
being C-terminally HA-tagged. One of these recombinant cell lines constitutively 
expressing HA-tagged CLCA2 was used for siRNA transfections: “CLCA2-
constitutively-expressing T47D clone #47”. For generation of this clone see section 
“Establishment of Stable wt-CLCA2 Clones“. 
For Western blot (Figure 33) an anti-HA-antibody detecting both, the full-length 
CLCA2 and the cleaved C-terminal fragment was used, resulting in two bands on 
Western blot. In cells transfected with siCLCA2-2 or siCLCA2-4 no or only traces of 
CLCA2 protein could be detected, whereas in the control cells (untreated cells and 
cells transfected with non-targeting siRNA) the HA-tagged CLCA2 protein could be 
visualised as strong bands (Figure 33). 
 
 
 
Figure 33. siRNA-mediated knock-down of CLCA2 in CLCA2-constitutively-expressing T47D clone on 
protein level (Western blot) 
150,000 cells of the CLCA2-constitutively-expressing T47D clone #47 per well of a 6-well-plate were transfected 
with the individual siRNAs siCLCA2-2 and siCLCA2-4 at a concentration of 20 nM siRNA using Dharmafect 4 
transfection reagent. As control served untreated cells, and cells transfected with non-targeting siRNA 
CONTROL#1 of Dharmacon (siCTRL) under same conditions. Protein lysates were harvested 24 h and 48 h post 
transfection. For Western blot 50 µg protein was loaded per lane; an anti-HA-tag antibody was used for detection 
of HA-tagged CLCA2. β-Actin served as loading control. 
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The same protein lysates were further tested for siRNA-mediated PARP-cleavage. In 
contrast to HN5 cells, no PARP-cleavage could be detected in a CLCA2-
constitutively-expressing T47D clone that was treated with CLCA2 siRNA (Figure 
34). 
 
 
Figure 34. siRNA-mediated knock-down of CLCA2 in CLCA2-constitutively-expressing T47D clone: Effect 
on apoptosis (PARP-cleavage) 
150,000 cells of the CLCA2-constitutively-expressing T47D clone #47 per well of a 6-well-plate were transfected 
with the individual siRNAs siCLCA2-2 and siCLCA2-4 at a concentration of 20 nM siRNA using Dharmafect 4 
transfection reagent. As control non-targeting siRNA CONTROL#1 of Dharmacon (siCTRL) was transfected under 
same conditions. Protein lysates were harvested 24 h and 48 h post transfection. For Western blot 50 µg protein 
was loaded per lane; an anti-PARP antibody was used for detection of cleaved and uncleaved PARP. GAPDH 
served as loading control. 
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Antibody Generation 
Due to the lack of a commercially available CLCA2-specific antibody, it was 
repeatedly tried to generate specific antisera against human CLCA2. Rabbits were 
immunised with peptides derived from identified CLCA2-specific epitopes which 
discriminate between other members of the CLCA family (for details see chapter 
“Material and Methods”).  
However, fractions of affinity-purified sera tested on Western blot (data not shown), 
did not lead to generation of a specific signal. Also peptides linked to proteins such 
as KHL could not improve the specific immune response. Therefore, it was 
necessary to generate an HA-tagged CLCA2 expression vector, which – after 
transfection into the cell line of interest – allowed the detection of CLCA2 on Western 
blots. However, a polyclonal antiserum was generated which could be used 
successfully in immunohistochemistry (IHC) studies.  
Selection of Peptides for Generation of Antisera 
First, specific epitopes which can be used for synthesising small 10 to 20 AA long 
peptides and for immunisation of rabbits, had to be identified. Appropriate peptides 
have to exhibit a series of chemical, physical and immunological properties in order 
to serve as effective immunogens. Algorithms are available which allow the 
prediction of these characteristics for linear epitopes.  
In order to correlate the respective amino acid sequence to secondary structure 
motifs in CLCA2 (alpha, beta regions as well as turns and coils), mainly the 
prediction algorithms from Chou and Fasman or from Garnier and colleagues (Figure 
35) [80-82] were used. In addition both, hydrophobicity and hydrophilicity play an 
important role for solubility of the respective epitope peptide, features which 
essentially contribute to the successful generation of peptide antisera [83-85]. 
Another important tool for selection of peptide antigens is the determination of the 
accessability of selected protein regions. Those flexible regions are more likely 
exposed to the surface of a protein than highly structured regions [86]. The antigenic 
index prediction of linear/sequential peptide motifs is based on the knowledge of 
known and experimentally varified peptide epitopes [87]. This approach not only 
describes the antigenic behaviour of a peptide (protein region) alone, but also takes 
into account the structural characteristics such as the “protrusion index” [88-92]. 
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BLAST search was performed in order to learn more about the species specificity 
(“epitope overlapp”) of CLCA2; for example, percentage of identity within the CLCA2 
peptide epitope among other proteins of the same species (human) is a measure for 
the background signal to be expected on Western blots. If the epitope is conserved 
among other species, especially in those animals where the antisera have to be 
generated (e.g. rabbits), immune tolerance can lead to a weak or almost no immune 
reaction towards the epitope peptide in the animal. Furthermore, the generation of 
intra/intra-peptidale secondary structures (e.g. formation of disulfide bridges) was 
avoided by selecting peptide epitopes without Cys residues. Those secondary 
structures can efficiently reduce the spatial flexibility of a peptide allowing only a 
limited number of different configurations in solution and thereby reducing the 
number of different antibody species in a polyclonal antiserum. Finally, the PROSITE 
database was used to search for functional epitopes such as Ca-binding motifs, 
potential glycosylation sites, active sites, etc. within the selected peptide epitopes of 
CLCA2. For instance, targeting potential glycosylation sites, would lead to less 
efficient antibodies, as the bulky sugar residues “protect” the immune epitope and by 
this interfere with the recognition of the linear peptide motif within the CLCA2 [93]. In 
the absence of any 3D-structure for CLCA2 it could not be speculated, whether the 
selected peptide epitopes are in principle spatially accessible, as the minimal spatial 
requirement for an antibody to recognise its epitope is ~ 35 Å. Therefore, it is often 
observed that high titers towards the peptide can be generated, but the polyclonal 
antiserum recognises only the protein on IHC slides, but not on Western blots. Based 
on these algorithms putative peptide epitopes were selected for immunisation, 
utilising the program “LaserGene 6.1 Protean” comprising almost all algorithms 
discussed above (Figure 35 and Table 1). 
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Figure 35. Prediction of structural features of human CLCA2 protein 
 
The indicated programs were used to predict the most promising immunogenic 
peptide epitopes of CLCA2 for immunising rabbits. The selected peptide epitopes are 
listed in Table 1. 
 
Amino Acid Pos. in CLCA2 
Protein Sequence 
Peptide Sequence 
 
K94 – N110 KANNNSKIKQESYEKAN 
N179 – D199 NDKPFYINGQNQIKVTRCSSD 
E498 – T513 ESTGENVKPHHQLKNT 
H690 – H708 HVNHSPSISTPAHSIPGSH 
T643 – L656 TVEPETGDPVTLRL 
 
Table 1. Putative immune epitopes selected for synthesis of peptides used to generate antisera 
 
 
Anti-CLCA2 Polyclonal Peptide Antisera and Their Use for Western Blots 
Three rabbits were immunised, two of them with two peptides in parallel – rabbit #1 
(K94-N110 + N179-D199), rabbit #2 (E498-T513 + H690-H708) and rabbit #3 (T643-
L656). Fractions of affinity-purified sera were tested on Western blot (data not 
shown), but none of these antibodies generated a specific signal. Also peptides 
linked to proteins such as KHL could not improve the specific immune response. 
Therefore, it was necessary to generate an HA-tagged CLCA2 expression vector, 
which – after transfection into the cell line of interest – allowed a detection of CLCA2 
on Western blots.  
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Immunohistochemistry 
In contrast to CLCA2-specific antisera used for Western blotting, one of these affinity-
purified antisera exhibits a high titer towards peptide K94-N110 
(KANNNSKIKQESYEKAN) and showed a specific staining of tumour cells in human 
SCC lung tumour samples, utilising a pre-immune serum as a negative control 
(Figure 36). The different techniques used for antigen retrieval (citrate buffer or 
proteinase K treatment) lead to slightly different staining pattern; acidic retrieval 
generate a more spot-like pattern whereas Proteinase K treatment a more diffuse 
pattern. However, both retrieval methods lead to a specific and pronounced tumour 
cell staining.  
 
 
 
Figure 36. Immunohistochemistry analysis of two human SCC lung cancer samples (NSCLC) 
For antigen retrieval samples were either treated with citrate buffer (Citrate: 10 mM, pH: 6.0) or by incubation with 
Proteinase K (for details see “Material and Methods). As control a pre-immune serum was used for staining 
generating a weak and unspecific background signal (Control). 
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Cloning CLCA2 
Cloning Various Tags to Expression Vector pCMV-Tag1 
pCMV-Tag1 vector (Stratagene), an expression vector with a multiple cloning site 
and a FLAG-tag downstream was used as a basis vector to introduce other tag 
sequences than the original FLAG-tag. 
Single strand oligonucleotides with the tag sequences of 8F5-tag, HA-tag, V5-tag, 
myc-tag and His-tag were designed ordered and annealed. Thereby, the 
oligonucleotides were designed in a way, that each of the annealed fragments bear a 
BamHI-overhang at the 5’-end and an HindIII-overhang at the 3’-end. Furthermore, 
the oligonucleotides were designed in a way, that upstream of the HindIII-overhang 
at the 3’-end, an EcoRV-site was created. 
The pCMV-Tag1 vector (Stratagene) was digested with BamHI and HindIII, and the 
fragment with the respective tag sequence inserted instead of the excised fragment. 
After this cloning step a set of pCMV vectors with a multiple cloning site and 
downstream the tags 8F5, HA, V5, myc, and His were obtained. The created EcoRV-
site downstream of the Stop-Codon and downstream of the tag sequence was used 
for further cloning.  
Amplification of CLCA2 and TA-Cloning to pGEM T-Easy Vector 
The “CLCA2 Human Full-Length cDNA Clone in pCMV6-XL4” from Origene was 
used as template for amplification. 
Full-length CLCA2 was amplified with the primers EBI-15997 and EBI-15958, 
generating flanking NotI- and BamHI-sites at the ends of the amplified fragment. 
This PCR fragment was cloned via TA-cloning into the pGEM T-Easy vector. A 
schematic map of the resulting construct is shown in Figure 37. 
                           
Figure 37. Map of cloning vector pGEM with inserted CLCA2 cDNA 
CLCA2 is flanked by a NotI-site (5’) and a BamHI-site (3’). 
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The “pGEM T-Easy-CLCA2” vector was digested with BamHI (for cutting out CLCA2) 
and with ScaI for discriminating with another resulting fragment of nearly the same 
size. The resulting 1838bp fragment was discarded; the 4037bp fragment was 
isolated and cut with NotI. The resulting 2841bp fragment was inserted into each of 
the pCMV-tag vectors (as described above), which had been digested with NotI and 
BamHI before. As a result, a panel of pCMV expression vectors carrying various 
tagged CLCA2 genes, were obtained. Figure 38 exemplarily shows the pCMV-
CLCA2 vector wherein CLCA2 is tagged with 8F5.  
 
          
Figure 38. Map of expression vector pCMV-8F5 with inserted CLCA2 cDNA 
CLCA2 was inserted between the NotI- and BamHI-site.  
 
Cloning CLCA2-Tag to Expression Vector pTRE2pur 
To benefit from an inducible expression system, the differently tagged CLCA2 genes 
were finally cloned from the pCMV vectors to the pTRE2pur vector of the “Tet-on 
Gene Expression System” (Clontech) by restriction digestion with NotI and EcoRV, 
which both are single cutters in the used vectors. Exemplarily, a schematic map of 
pTRE2pur-CLCA2-HA is shown in Figure 39. 
 
 
Figure 39. Schematic map of expression vector pTRE2pur with the inserted CLCA2-HA cDNA 
The CLCA2-HA-fragment is inserted between the NotI- and EcoRV-site.  
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Evaluation of Tags on Western Blot 
All resulting pTRE2pur-CLCA2-tag expression vectors were individually transfected 
to T47D Tet-on cells, and lysates of induced and non-induced cells were analysed on 
Western blot with antibodies detecting the respective tags. As shown in Figure 40, 
best results were obtained with HA-tag and V5-tag. The cleaved and uncleaved 
CLCA2-fragment could be detected in the induced sample; the signal in the non-
induced sample is extremely low, which demonstrates the strict control of the Tet-on 
system in T47D Tet-on cells. The strongest signal was found for HA-tagged CLCA2 
protein. The antibodies for detection of 8F5 (monoclonal antibody recognising an 
epitope of VP2 in HRV2 [94]) and myc-tag did not give raise to a valid signal on 
Western blots and the antibody detecting the His-tag lead to detection of additional 
bands. Based on these data the construct with the HA-tag was chosen for further 
investigation. 
 
 
 
Figure 40. CLCA2 expression with various tags on Western blot 
150,000 T47D Tet-on cells were seeded into 6-well-plates and each of pTRE2pur expression vectors containing 
CLCA2 fused to an 8F5-, HA-, His-, V5-, or myc-tag respectively, was transiently transfected. Expression of 
tagged CLCA2 was non-induced (-) and induced (+) with Doxycycline 24 h after transfection. Protein lysates were 
harvested 48 h post induction. For Western blot 50 μg protein was loaded per lane; an antibody detecting the 
respective tag was used. 
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Establishment of Stable wt-CLCA2 Clones 
As the pTRE2pur-CLCA2-HA construct was chosen for further investigation, this 
construct was used for establishment of stable wt-CLCA2-expressing clones in the 
cell line T47D Tet-on, with CLCA2 being C-terminally HA-tagged. The cell line T47D 
Tet-on was chosen, to benefit from the inducible expression system. 
Therefore, 100 clones were picked after selection with Puromycin for 3 weeks and 
than analysed. All clones were induced and both, induced and non-induced protein 
lysates were analysed on Western blots with an anti-HA-antibody for detection of HA-
tagged CLCA2. The inducible clones were kept in culture and after testing all 100 
clones, the most efficiently expressing candidates were compared against each 
other. In Figure 41 one individual Western blot with five selected inducible clones (#3, 
4, 26, 44, 46) is shown, whereby only in induced lysates CLCA2 expression could be 
detected and non-induced cells did not express detectable amounts of CLCA2.  
During the selection process, one clone was identified as a constitutively CLCA2-
expressing clone, which wasn’t needed to be induced first: “CLCA2-constitutively-
expressing T47D clone #47”. This clone deemed to be useful to be kept for further 
experiments and was e.g. used for siRNA experiments (see section “siRNA 
Experiments in a Stable CLCA2-Constitutively-Expressing T47D Clone”). 
 
 
Figure 41. Stable CLCA2-expressing T47D Tet-on clones: Inducible/constitutive expression of  
HA-tagged CLCA2 
Clones #3, #4, #26, #44, #46 expresses CLCA2 inducibly; clone #47 expresses CLCA2 constitutively.  
Clones were selected for 3 weeks with Puromycin. 300,000 cells were seeded into 6-well-plates and induced with 
Doxycycline. Protein lysates were harvested 48 h post induction. For Western blot 50 µg protein was loaded per 
lane; an anti-HA-tag antibody was used for detection of HA-tagged CLCA2. GAPDH served as loading control. 
 
For experiments with an inducible clone, clone #3 (“CLCA2-expressing T47D Tet-on 
Clone #3”) was chosen for further investigations.  
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To evaluate the concentration of Doxycycline which is necessary for induction of 
expression of CLCA2, clone #3 was induced with various concentrations and CLCA2 
expression was analysed on Western blot. As shown in Figure 42 the expression of 
CLCA2 could not be dramatically enhanced, using more than 2 µg/ml Doxycycline in 
media. So this concentration was chosen for all further experiments. 
 
Figure 42. Doxycline-induced induction of CLCA2 expression in stable T47D Tet-on clone:  
Concentration-dependency 
300,000 cells were seeded into 6-well-plates and CLCA2 expression induced with 0, 0.1, 0.5, 1, 2, 5 µg/ml 
Doxycycline in media. Protein lysates were harvested 48 h post induction. For Western blot 50 µg protein was 
loaded per lane; an anti-HA-tag antibody was used for detection of HA-tagged CLCA2. β-Actin served as loading 
control. 
 
In Figure 43 a time-kinetic of expression of CLCA2 in clone #3 is shown. In parallel, 
cells were induced and non-induced and protein lysates harvested after variable 
time-periods. CLCA2 expression was analysed on Western blots.  
CLCA2 expression could be detected already 24 h post induction, after 48 h 
expression was not further increased. 
 
Figure 43. Doxycline-induced induction of CLCA2 expression in stable T47D Tet-on clone:  
Time-dependency 
300,000 cells were seeded into 6-well-plates and non-induced/induced with 2 µg/ml Doxycycline in media. Protein 
lysates were harvested 2 h, 4 h, 8 h, 24 h, 36 h, 48 h and 72 h post induction. For Western blot 50 µg protein was 
loaded per lane; an anti-HA-tag antibody was used for detection of HA-tagged CLCA2. GAPDH served as loading 
control. 
 
These results clearly demonstrate the time-dependent induction of CLCA2 
expression, which was only in induced lysates of clone #3 detectable, but no in 
protein lysates of non-induced cells. 
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Proteolytic Processing 
In May 2006 Pawlowski published that CLCA1 has a hydrolase domain responsible 
for processing mature full-length CLCA1 [65]. As from peptide-design for 
immunisation (see above) it was already known, that the homology within the CLCA 
family is quite high, it was assumed that CLCA2 might also contain such a hydrolase 
domain. Therefore, experiments with matrixmetalloprotease-inhibitors such as 
Phenantrolin, Diprotin B, Bestatin, Amastatin and others were performed as the 
internal hydrolase activity of CLCA1 was supposed to be a member of the 
metalloproteinase family (data not shown). Besides Phenantrolin, no effect on 
cleavage of CLCA2 by treatment with these inhibitors (at concentrations 
recommended by conventional literature) could be demonstrated. As Phenantrolin 
was quite toxic for the CLCA2-expressing T47D Tet-on cell line, no final conclusion 
could be drawn from this experiment. To learn more about the putative internal 
hydrolase activity of CLCA2, first an alignment of CLCA1 and CLCA2 protein 
sequence was made (Figure 45) with the idea that the hydrolase domain which was 
found by Pawlowski in CLCA1 might be conserved in the whole protein family. 
Indeed, a high homology within the hydrolase domain of CLCA1 and respective 
segment in CLCA2 (equivalent sequence in CLCA2 is located at AA 29-208) could be 
identified (Figure 44).  
 
 
Figure 44. Catalytic unit of hydrolase domain of CLCA1 and corresponding sites in CLCA2 
The Picture is modified from Pawlowski et al. 2006 [65]. Schematic representation showing polar interactions 
(dashed lines) between sTI (bold) and putative catalytic site residues. 
Black letters indicate the respective AA positions of CLCA1, blue ones refer to corresponding positions in CLCA2 
and red letters describe planed mutations within the catalytic center of the putative hydrolase domain of CLCA2. 
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Figure 45. Amino acid sequence alignment of CLCA1 and CLCA2 
Protein Sequences of CLCA1 and CLCA2 were aligned utilising CLC Bio. 
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As Cysteines not only play an essential role in the formation of protein structure, but 
also can be part of the catalytic site, those Cys residues within the proposed 
hydrolase domain were identified, which are conserved between CLCA1 and CLCA2. 
These Cysteines are in CLCA2 protein sequence located at the following amino acid 
(AA) positions: C132, C196, C206, C211, and C216 (Figure 46). These Cys residues 
were also selected for mutational analysis.  
 
Mutating Conserved Cysteines 
The conserved Cysteines within CLCA1 and CLCA2 protein structure (in CLCA2: 
C132, C196, C206, C211, and C216) were mutated to Alanine and in the case of 
C132 to Alanine and Serine. These point mutations were directly introduced into the 
expression vector pTRE2pur-CLCA2-HA carrying the HA-tagged wt-CLCA2, by 
utilisation of the “QuikChange II XL Site-Directed Mutagenesis Kit” (Stratagene). 
Mutation constructs were sequenced and transiently transfected into T47D Tet-on 
cells, where the expression of mutated CLCA2 was induced. Protein lysates were 
tested on Western blot using an anti-HA-antibody.  
As shown in Figure 46, cleavage of CLCA2-bearing mutations C211A or C216A is 
heavily impaired, whereas mutations at C132, C196, and C206 completely abolish 
the proteolytic processing.  
 
 
Figure 46. Mutations of conserved Cysteines of CLCA2 and their effects on its proteolytic processing 
150,000 T47D Tet-on cells were seeded into 6-well-plates and transiently transfected with various constructs of 
pTRE2pur expression vector, expressing either HA-tagged wt-CLCA2 or bearing one of the following mutations: 
C132A, C132S, C196A, C206A, C211A, and C216A. Expression was induced with Doxycycline 24 h post 
transfection. Protein lysates were harvested 48 h post induction. For Western blot 50 µg protein was loaded per 
lane; an anti-HA-tag antibody was used for detection of HA-tagged wt/mutant CLCA2. GAPDH served as loading 
control. 
RESULTS 
 
 73
Mutational Analysis of the Putative Hydrolase Domain 
As the homology search with CLCA1 and CLCA2 protein sequences predicted a 
putative hydrolase domain for CLCA2 for AA 29-208, it was decided to point mutate 
respective sites in CLCA2 which might be involved in the formation of the catalytic 
site. Figure 47 summarises the influence of the mutations within the putative 
hydrolase domain on the proteolytic cleavage of CLCA2. N186A is the only mutation 
being tolerated, all other mutations completely abolish cleavage of CLCA2. 
 
Figure 47. Mutations in the putative hydrolase domain of CLCA2 and their effects on its proteolytic 
processing  
150,000 T47D Tet-on cells were seeded into 6-well-plates and transiently transfected with various constructs of 
pTRE2pur expression vector, expressing either HA-tagged wt-CLCA2 or bearing one of the following mutations: 
H164C, H164N, H164Y, E165D, E165Q, H168C, H168N, H168Y, and N186A. Expression was induced with 
Doxycycline 24 h post transfection. Protein lysates were harvested 48 h post induction. For Western blot 50 µg 
protein was loaded per lane; an anti-HA-tag antibody was used for detection of HA-tagged wt/mutant CLCA2. 
GAPDH served as loading control. 
 
In Figure 48 a schematic overview of the impact on the proteolytic processing of all 
analysed mutations within the putative hydrolase domain of CLCA2 is presented.  
 
Figure 48. Summary of effects of mutations within the putative hydrolase domain of CLCA2 
+ indicates complete inhibition of CLCA2 cleavage as analysed on Western blots (no cleaved fragment 
detectable) 
- indicates no influence of the mutation on CLCA2 cleavage (Western blot pattern similar to that of wt-CLCA2) 
Red coloured amino acids have an acidic side chain, blue ones a basic side chain, yellow ones have a non-polar 
side chain and grey ones a polar side chain. 
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Mutational Analysis of the Putative Cleavage Site 
As known from bioinformatic analysis and literature [95], there is a mono basic 
cleavage site predicted at position R674. 
Mutational analyses were first done by Alanine-walking starting from predicted 
positions P5 to P4’ (R670 to R678) by subsequent and stepwise substitution of the 
respective amino acid to an Alanine. These studies were further improved by 
introducing (especially at position R674 of the predicted mono basic cleavage site) at 
least one of each class of amino acids (i.e. amino acids with either a basic, acidic, 
non-polar or uncharged polar side chain). Western blot data on cleavage efficiency of 
mutated CLCA2 proteins are shown in Figure 49 and the effects are summarised in 
Figure 50. These data indicate that position R674 might serve as the P1 cleavage 
site, as this position strictly not allows any exchange of Arginine, besides Lysine 
which is also tolerated, due to the fact, that both are amino acids with basic side 
chains. 
 
Figure 49. Mutations in the putative cleavage site of CLCA2 and their effects on its proteolytic processing 
150,000 T47D Tet-on cells were seeded into 6-well-plates and transiently transfected with various constructs of 
pTRE2pur expression vector, expressing either HA-tagged wt-CLCA2 or bearing one of the following mutations: 
670A, I671A/L, Y672A/E/F/K/Q, S673A, F676A/W/Y, F677A, F678A, R674A/E/F/I/K/Q/S/T/Y and Y675A/E/F/K/Q. 
Expression was induced with Doxycycline 24 h post transfection. Protein lysates were harvested 48 h post 
induction. For Western blot 50 µg protein was loaded per lane; an anti-HA-tag antibody was used for detection of 
HA-tagged wt/mutant CLCA2. GAPDH served as loading control. 
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Figure 50. Summary of effects of mutations in the putative cleavage site of CLCA2 on its proteolytic 
processing 
+ indicates complete inhibition of CLCA2 cleavage by analysis on Western blot (no cleaved fragment detectable) 
~ indicates impaired CLCA2 cleavage (detectable cleavage fragment on Western blot is reduced in comparison to 
wt-CLCA2) 
- indicates no influence on CLCA2 cleavage (pattern on Western blot is similar with that of wt-CLCA2) 
Red coloured amino acids have an acidic side chain, blue ones a basic side chain, yellow ones have a non-polar 
side chain and grey ones a polar side chain. Red-boxed positions indicate most sensitive residues within 
predicted cleavage site.  
 
 
Establishment of Stable Mutant-CLCA2 Clones 
As for wt-CLCA2, it was decided to establish stable cell lines, expressing mutated 
CLCA2, which are devoid of cleavage ability. Therefore, constructs with either point 
mutations in the catalytic unit (E165Q or H186N), or with a point mutation in the 
monobasic cleavage site were transfected into T47D Tet-on cells.  
All mutations were originally directly introduced into the expression vector pTRE2pur-
CLCA2-HA carrying the HA-tagged wt-CLCA2, by utilisation of the “QuikChange II XL 
Site-Directed Mutagenesis Kit” (Stratagene). The cell line T47D Tet-on was chosen, 
to benefit from the inducible expression system and to allow comparison to wt-
CLCA2 clones.  
For establishment of stable clones, 100 clones were picked after selection with 
Puromycin for 3 weeks and analysed. All clones were induced and protein lysates 
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(induced and non-induced) were analysed on Western blots utilising an anti-HA-
antibody for detection of (wild type/mutated) CLCA2. Inducible clones were kept in 
culture and after testing 100 clones, the most promising clones were compared 
against each other. In Figure 51 Western blot analysis of the most efficiently 
inducible clones for various CLCA2 mutants is shown. 
Double bands seen for HA-tagged CLCA2 on Western blots for e.g. clones #3 and 
#32 might be due to incomplete glycosylation as a result of tremendous 
overexpression. 
 
 
Figure 51. Stable mutant-CLCA2-expressing T47D Tet-on clones:  
Inducible/constitutive expression of HA-tagged CLCA2 mutants E165Q, H168N, Y675A 
Clones were selected for 3 weeks with Puromycin. 300,000 cells were seeded into 6-well-plates and induced with 
Doxycycline. Protein lysates were harvested 48 h post induction. For Western blot 50 µg protein was loaded per 
lane; an anti-HA-tag antibody was used for detection of HA-tagged wt/mutant CLCA2. GAPDH served as loading 
control. 
 
 
The following clones were chosen for further investigations: 
- mutant-CLCA2(E165Q)-expressing T47D Tet-on clone #7 
- mutant-CLCA2(H168N)-expressing T47D Tet-on clone #13 
- mutant-CLCA2(Y675A)-expressing T47D Tet-on clone #25 
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Inhibition of Post-Translational Modifications 
Most of cell surface proteins are post-translationally modified by the attachment of 
different sugar- and/or lipid-residues (glycosylation, isoprenylation) for transport 
and/or stabilisation of the correct conformation of proteins within the cell membrane. 
The stability and processing of CLCA2 was analysed in the presence of the 
glycosylation inhibitor Tunicamycin and the isoprenylation inhibitor Perillic acid, 
utilising stable CLCA2-expressing T47D Tet-on cell lines (inducible expression 
system). Cells were treated with increased concentrations of the corresponding 
inhibitors and protein lysates analysed on Western blot, by detection of CLCA2 
protein via the HA-tag, using an anti-HA-antibody. As seen in Figure 52 the stability 
of CLCA2 seems to be dependent on its post-translational glycosylation. 
Furthermore, glycosylation influences proteolytic processing: At a concentration of 
0.5 µg/µl of Tunicamycin no proteolytic processing is observed anymore. 
 
 
 
Figure 52. CLCA2 stability and post-translational proteolytic processing of CLCA2 in the presence of the 
glycosylation inhibitor Tunicamycin 
300,000 cells of CLCA2-expressing T47D Tet-on clones #3 were seeded into 6-well-plates and treated with 0, 0.1, 
0.5, 1, 2, 5 µg/ml Tunicamycin in media. CLCA2 expression was induced with Doxycycline. Protein lysates were 
harvested 48 h post induction. For Western blot 50 µg protein was loaded per lane; an anti-HA-tag antibody was 
used for detection of HA-tagged CLCA2. GAPDH served as loading control. 
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Analyses with several glycosylation site prediction software tools resulted in 
prediction of the putative glycosylation sites N150 and N822. However, mutation of 
these amino acids by exchanging Asparagine with Alanine did not influence the 
proteolytic processing of CLCA2 (Figure 53). Therefore, N150 and N822 seem not to 
be the major glycosylation sites in CLCA2. 
However, N822 is located within the C-terminal fragment of CLCA2 and interestingly, 
a point mutation at this position influences the proteolytic processing resulting in a 
shorter C-terminal fragment on Western blots (Figure 53). 
 
 
Figure 53. Mutations of putative glycosylation sites N150A and N822A of CLCA2 and their effects on its 
stability and proteolytic processing 
150,000 T47D Tet-on cells were seeded into 6-well-plates and transiently transfected with constructs of 
pTRE2pur expression vector, expressing either HA-tagged wt-CLCA2 or bearing one of the following mutations: 
N150A, N822A. Expression was non-induced (-) and induced (+) with Doxycycline 24 h post transfection. Protein 
lysates were harvested 24 h and 48 h post induction. For Western blot 50 µg protein was loaded per lane; an anti-
HA-tag antibody was used for detection of HA-tagged wt/mutant CLCA2. 
 
 
In contrast to inhibition of glycosylation (Figure 52), isoprenylation does not play an 
important role for stability or efficient proteolytic cleavage of CLCA2 (Figure 54).  
 
 
Figure 54. CLCA2 stability and post-translational proteolytic processing of CLCA2 in the presence of the 
isoprenylation inhibitor Perillic acid 
300,000 cells of CLCA2-expressing T47D Tet-on clones #3 were seeded into 6-well-plates and treated with  0, 
0.1, 0.5, 1, 2, 5 µg/ml Perillic acid in media. CLCA2 expression was induced with Doxycycline. Protein lysates 
were harvested 48 h post induction. For Western blot 50 µg protein was loaded per lane; an anti-HA-tag antibody 
was used for detection of HA-tagged CLCA2. GAPDH served as loading control. 
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Integrin β4 
Abdel-Ghany found Integrin β4 to be coprecipitated with CLCA2. He also described a 
strong correlation between the level of Integrin β4 and adhesion of HEK293 cells 
expressing CLCA2 and a correlation in vivo between Integrin β4 expression in 
tumourigenic cell lines and the number of lung metastases detected in nude mice 
[70]. Upregulated Integrin β4 levels were also found in microarray studies of lung 
cancer metastases [74]. 
It could be shown that induction of CLCA2 expression in CLCA2-expressing T47D 
Tet-on clones #3 leads to enhanced Integrin β4 expression (Figure 55). 
 
 
Figure 55. Expression of Integrin β4 upon induction of CLCA2 expression 
Expression of CLCA2 was induced in CLCA2-expressing T47D Tet-on clone #3 by addition of Doxycycline. 
Protein lysates were harvested at indicated time points post induction. CLCA2 expression of lysates was 
confirmed before use. For Western blot 50 µg protein was loaded per lane; an anti-Integrin β4 antibody was used 
for detection of Integrin β4. GAPDH served as loading control. 
 
 
Due to the lack of phospho-specific antibodies towards Intgerin β4, no conclusion 
could be drawn whether Integrin β4 becomes not only upregulated, but also activated 
upon induction of CLCA2. 
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Integrin-Mediated Cell Adhesion Assay 
Based on the data from Abdel-Ghany et al. [70] and to gain a more detailed 
understanding about the specific induction of integrins upon induced CLCA2 
expression, the “Integrin-Mediated Cell Adhesion Arrays” (Chemicon) were used. 
(For details see section “Material and Methods”.) 
Especially the protein family of integrins (cell surface receptors) is involved in cell 
attachment to proteins of the extracellular matrix. Integrins therefore play an 
important role during metastasis, regulating not only dissemination but also homing 
of metastasising tumour cells. The “Integrin-Mediated Cell Adhesion Arrays” from 
Chemicon are efficient tools to screen cell surface protein profiles. These kits are 
composed of stripwells with each well pre-coated with an antibody detecting an 
individual integrin or extracellular matrix protein and one negative control well coated 
with bovine serum albumin (BSA). Utilising the established inducible expression 
system for CLCA2, it was possible to screen for induction of α- and β-integrins in 
dependence on induction of wt or mutant CLCA2 expression in T47D Tet-on cells. As 
a control T47D cells with “empty” expression were used. As seen in Figure 56 out of 
the α-integrin family no specific induction could be detected, whereas for β-integrin 
family member B2 a specific induction depending on wt-CLCA2 induced expression 
could be demonstrated for Clone #4 (Figure 57).  
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Figure 56. α-integrin-mediated cell adhesion of CLCA2-expressing and non-expressing cells 
Expression of wt-CLCA2 was induced in T47D Tet-on clone #4 (red), T47D Tet-on clone #3 (orange);  
expression of mutant-CLCA2 (E165Q) was induced in T47D Tet-on clone #7 (yellow). As control served  
non-induced T47D Tet-on clone #3 (dark-blue) and T47D cells with the empty vector (light-blue). 
Lysates were tested in the “Alpha-Integrin-Mediated Cell Adhesion Array” from Chemicon. 
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Figure 57. β-integrin-mediated cell adhesion of CLCA2-expressing and non-expressing cells 
Expression of wt-CLCA2 was induced in T47D Tet-on clone #4 (red), T47D Tet-on clone #3 (orange);  
expression of mutant-CLCA2 (E165Q) was induced in T47D Tet-on clone #7 (yellow). As control served  
non-induced T47D Tet-on clone #3 (dark-blue) and T47D cells with the empty vector (light-blue). 
Lysates were tested in the “Beta-Integrin-Mediated Cell Adhesion Array” from Chemicon. 
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3D-In Vitro Carcinoma Assay: Spheroids 
For a better simulation of the situation in a tumour, CLCA2-expressing clones were 
not only grown in 2D cell culture, but also in multicellular tumour spheroids, which are 
in vitro 3D models that simulate malignant cell contacts within a tumour. Multicellular 
tumour spheroids can for instance also be used to evaluate tumour response to 
therapeutic agents. In this approach the in vitro 3D model was used for analysis of 
the influence of CLCA2 expression on cell growth and viability in a 3D model. 
For this purpose 250 cells, each of the various T47D-CLCA2 clones were cultivated 
with methylcellulose and transferred into 96-well-plates for suspension culture. The 
methylcellulose causes cells to grow in three-dimensional cultures as opposed to 
mono-layer, forming a spheroid.  
After forming stable spheroids, they were transferred to a collagen gel or Matrigel 
(Becton Dickinson) and grown until the spheroids became necrotic due to increased 
volume and the lack of supply with nutrients and oxygen in the centre of the 3D 
spheroid, as angiogenesis-induced vessels in a tumour would do. 
After 3, 5, 7, and 10 days in the gel, spheroids were monitored under the microscope. 
Growth was estimated by measurement of the area of spheroids with AxioVision 
Software (Zeiss). To analyse the apoptotic status of cells within a spheroid, cells 
were stained with the intercalating and fluorescent agent Propidium iodide that 
pervades cell membranes of dead cells only. 
Before forming spheroids, stable CLCA2 expression of T47D Tet-on clones was 
confirmed on Western blot (data not shown).  
The following cell clones were used in this study:  
- wt-CLCA2-expressing T47D Tet-on clone #3 (in induced/non-induced status) 
- wt-CLCA2-constitutively-expressing T47D clone #47 
- mutant-CLCA2(E165Q)-expressing T47D Tet-on clone #7 (in induced status) 
- control cells, which stably carry the “empty” expression vector pTRE2pur (no 
CLCA2 expression) and which were pseudo-induced with Doxycycline to search 
for any specific Doxycycline-dependent effect. 
Spheroids of non-induced wt-CLCA2-expressing T47D Tet-on clone #3 are shown in 
Figure 58 and can be directly compared with spheroids of the same clone, but in an 
induced status, as shown in Figure 59. Exemplarily, two representative pictures are 
shown for the time points 3, 5, 7, and 10 days growth of spheroids in Matrigel. No 
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distinct difference could be observed between induced and non-induced clone #3, 
but in contrast a pronounced difference in area, representative for cell growth and 
apoptotic status of cells within the spheroid was found, as compared to the 
constitutive expressing clone #47 (Figure 60). It seems that constitutive expression 
triggers cell growth in a way that these spheroids become considerably bigger from 
day 3 on in Matrigel. It is also of interest that in spheroids of clone #47 considerably 
more apoptotic cells were found than in clone #3, where CLCA2 expression was 
induced only when spheroids were transferred to the Matrigel. Therefore, constitutive 
CLCA2 expression during spheroid-formation lead to generation of larger spheroids 
and subsequently to more apoptosis activity due to enhanced cell growth, supporting 
previous findings that CLCA2 essentially contributes to proliferation and/or viability of 
tumour cells.  
Control cells, which stably carry the “empty” expression vector pTRE2pur and which 
were “pseudo-induced” with Doxycycline, are shown in Figure 61 and look very 
similar to non-induced clone #3 (Figure 58). Cells expressing mutant CLCA2 protein 
(E165Q), which are exhibiting a deficient proteolytic processing, were 
undistinguishable from other spheroids (Figure 62). Apparently proteolytic processing 
did not have any influence on spheroid formation or other properties of spheroids 
concerning cell growth or apoptotic status of cells within a spheroid. The same holds 
true for other CLCA2 expressed mutants (data not shown).  
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Figure 58. Spheroids of wt-CLCA2-expressing T47D Tet-on clone #3 – non-induced 
Exemplarily two pictures are shown after growth for 3 d, 5 d, 7 d, and 10 d in Matrigel. 
Red: Propidium iodide-stained apoptotic cells. 
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Figure 59. Spheroids of wt-CLCA2-expressing T47D Tet-on clone #3 – induced 
Exemplarily two pictures are shown after growth for 3 d, 5 d, 7 d, and 10 d in Matrigel. 
Red: Propidium iodide-stained apoptotic cells. 
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Figure 60. Spheroids of wt-CLCA2-constitutively-expressing T47D clone #47 
Exemplarily two pictures are shown after growth for 3 d, 5 d, 7 d, and 10 d in Matrigel. 
Red: Propidium iodide-stained apoptotic cells. 
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Figure 61. Spheroids of control cells (T47D Tet-on cells with empty vector, Doxycycline-treated) 
Control cells stably carrying the “empty” expression vector pTRE2pur were pseudo-induced with Doxycycline for 
analysis of any Doxycycline effect. Exemplarily two pictures are shown after growth for 3 d, 5 d, 7 d, and 10 d in 
Matrigel. Red: Propidium iodide-stained apoptotic cells. 
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Figure 62. Spheroids of mutant-CLCA2(E165Q)-expressing T47D Tet-on clone #7 – induced 
Exemplarily two pictures are shown after growth for 3 d, 5 d, 7 d, and 10 d in Matrigel. 
Red: Propidium iodide-stained apoptotic cells. 
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Growth Curve of CLCA2-Expressing Clones (T47D Tet-on): 2D versus 3D 
As it could be shown, that cell growth in the spheroid 3D-model is enhanced in 
CLCA2-consitutively-expressing T47D clone #47 compared to induced or non-
induced CLCA2-expressing T47D Tet-on clones #3. Cell growth of these clones was 
also compared in 2D-tissue culture. Therefore, 2D-growth curves were generated, 
based on cell numbers of cells which had been trypsinised and counted after 3-10 
days in 2D-cell culture. Interestingly, in 2D no distinct difference between non-
induced or induced clone #3 could be observed.  
Next, a 3D-growth curve was generated by measurement of the area of various 
spheroids, which was calculated with AxioVision Software after 3-10 days in Matrigel. 
In a statistically meaningful setting the relative cell growth of 2D- (counting viable 
cells) with that of 3D-cultures (determination of area [µm2]; Figure 63) were 
compared over a period of 3 to 10 days. Although, the relative cell growth of induced 
versus non-induced clone #3 did not show a difference in 2D-cultures, it indeed 
exhibited a pronounced difference (> 2.5-fold) between 2D- and 3D-culturing. In 
contrast to inducible clone #3, the constitutive clone #47 showed already an 
enhanced relative cell growth in 2D-culture, which was similar to that found in 3D-
cultures. Spheroids of inducible cell clones expressing other CLCA2-mutants were 
also analysed in this assay, but none of them showed a statistically relevant different 
behaviour in growth, when compared to inducible CLCA2 clones (data not shown). 
In general, the 3D-model is more sensitive than 2D-cultures to show differences in 
cell proliferation, and it allows to demonstrate the impact of CLCA2 on the three-
dimensional growth of tumour cells.  
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Figure 63. Relative cell growth in 2D and 3D of T47D clones with constitutive, induced, and non-induced 
CLCA2 expression 
Left:  CLCA2-constitutively-expressing T47D clone 
Middle:  CLCA2-expressing T47D Tet-on clones #3 – induced 
Right:  CLCA2-expressing T47D Tet-on clones #3 – non-induced 
For 2D-growth curve, cells were trypsinised and counted after 3-10 days in 2D-cell culture. 
For 3D-growth curve, area of spheroids was estimated with AxioVision Software after 3-10 d in Matrigel.  
The value of area is the average of all measured spheroids (5 up to 11 spheroids per time point). 
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Affymetrix Microarray Studies 
To study the effects of overexpression of CLCA2 on gene expression, expression 
profiling using the Affymetrix GeneChip Human Genome U133 Array was performed 
by testing stable cell clones with inducible expression of CLCA2. 
First, different wt-CLCA2-expressing T47D Tet-on clones (Figure 41) were tested for 
CLCA2 expression both, on the protein level performing Western blots and on the 
transcript level performing real-time quantitative PCR (RT-qPCR). Freshly thawn 
clones #3, #4 and #46 still proved as the best inducible cell lines as shown previously 
(Figure 41). These clones exhibit the most efficient induction profile (Figure 64). 
 
 
Figure 64. CLCA2 protein expression of inducible CLCA2-expressing T47D Tet-on clones used for 
Affymetrix microarray studies 
300,000 cells of CLCA2-expressing T47D Tet-on clone #3, #4, and #46 were seeded each into 6-well-plates and 
induced with Doxycycline. Protein lysates were harvested 24 h and 48 h post induction. For Western blot 50 µg 
protein was loaded per lane; an anti-HA-tag antibody was used for detection of HA-tagged CLCA2. GAPDH 
served as loading control. 
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Expression of CLCA2 transcript in clone #3 was monitored by performing RT-qPCR 
with cDNA samples taken at different time points. As shown in Figure 65 the CLCA2 
transcript could only be detected in induced lysates. CLCA2 transcript level increased 
between 8 h and 24 h post induction. In non-induced lysates the CLCA2 transcript 
stayed within the background level of control cells (Figure 65).  
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Figure 65. CLCA2 mRNA levels of induced and non-induced CLCA2-expressing T47D Tet-on clone #3 
versus control cells (T47D Tet-on cells with empty vector, Doxycycline-treated) 
300,000 cells were seeded into 6-well-plates and induced with Doxycycline. RNA lysates were harvested 24 h 
post induction and transcribed into cDNA. For detection of the CLCA2 transcript by RT-qPCR a CLCA2-specific 
primer pair (see “Material and Methods”) was used in a duplex assay together with the internal control                 
β-2 microglobulin for normalisation. 
 
After testing primer pairs for various housekeeping genes in these lysates (data not 
shown), β-2-microglobulin was chosen for use as the most robust internal reference 
for normalisation of CLCA2 transcript levels. 
Protein lysates were prepared at various time points and stored at -80°C. cDNA 
preparations of clones #4 and #46 were analysed on Affymetrix GeneChip Human 
Genome U133 Array (for details see “Material and Methods”). Expression profiles are 
shown in Figure 66.  
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Blue bars indicate CLCA2-trancript levels in non-induced cells and red bars CLCA2 
transcript levels in induced cells, respectively. In all three clones induction of CLCA2 
expression can be detected at 24 h and 48 h after treatment with Doxycycline. In 
contrast to other clones, clone #46 exhibits already elevated CLCA2 levels without 
induction. However, the relative induction range is similar compared to clone #3 and 
#4. Clone #46 obviously contains a “leaky” expression control for CLCA2. 
 
 
Figure 66. CLCA2 mRNA levels of inducible CLCA2-expressing T47D Tet-on clones #3, #4 and #46 
compared with T47D (control) on Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of CLCA2 (206166_s_at) mRNA is shown in box-plots. Red box-plots 
indicate CLCA2 transcript levels of cells with induced CLCA2 expression, blue box-plots represent CLCA2 
transcript levels of non-induced cells. The vertical centre line in the box indicates the median; the box itself 
represents the interquartile range (IQR) between the first and third quartiles. 
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In a next step, genes whose induction is dependent on the presence/induction of 
CLCA2 should be identified; i.e. these are transcripts which are induced in CLCA2-
inducibly-expressing cell lines, but not expressed in non-induced or control cells 
(“empty” vector bearing cells). Selected top hits are shown in Table 2. To reduce 
complexity of data this “correlation analysis” was only performed for clone #3.  
 
Probeset Gene Symbol Gene Title Chromosomal 
Location
Correlation 
Factor (r)
206166_s_at CLCA2 chloride channel, calcium activated, family member 2 1p31-p22 1
212134_at PHLDB1 pleckstrin homology-like domain, family B, member 1 11q23.3 0,98308
223212_at ZDHHC16 zinc finger, DHHC-type containing 16 10q24.1 0,98276
229399_at C10orf118 chromosome 10 open reading frame 118 10q25.3 0,98070
202733_at P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 
polypeptide II
5q31 0,97973
200974_at ACTA2 actin, alpha 2, smooth muscle, aorta 10q23.3 0,97693
215120_s_at SAMD4 sterile alpha motif domain containing 4 14q22.2 0,97123
209922_at BRAP BRCA1 associated protein 12q24 0,96837
1557104_at NA Zinc finger protein NA 0,96594
203408_s_at SATB1 special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-
associating DNA's)
3p23 0,95899
1552621_at POLR2J2 DNA directed RNA polymerase II polypeptide J-related gene 7q11.22 0,95825
203050_at TP53BP1 tumor protein p53 binding protein, 1 15q15-q21 0,95779
233750_s_at C1orf25 chromosome 1 open reading frame 25 1q25.2 0,95680
232754_at NA NA NA 0,95256
223629_at PCDHB5 protocadherin beta 5 5q31 0,95240
1556339_a_at NA NA NA 0,95147
224321_at TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 2 /// 
transmembrane protein with EGF-like and two follistatin-like domains 2
2q32.3 0,95135
201295_s_at WSB1 WD repeat and SOCS box-containing 1 17q11.1 0,95100
208589_at TRPC7 transient receptor potential cation channel, subfamily C, member 7 5q31.1 0,94950
1554895_a_at RHBDL2 rhomboid, veinlet-like 2 (Drosophila) 1p34.3 0,94919
211762_s_at KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) /// karyopherin alpha 2 
(RAG cohort 1, importin alpha 1)
17q23.1-q23.3 0,94716
235756_at NA CDNA FLJ26187 fis, clone ADG04782 NA 0,94685
224280_s_at FAM54B family with sequence similarity 54, member B 1p36.11 0,94434
207904_s_at LNPEP leucyl/cystinyl aminopeptidase 5q15 0,94389
1553740_a_at IRAK2 interleukin-1 receptor-associated kinase 2 3p25.3 0,94332  
 
Table 2. “Correlation Analysis” on expression pattern of microarray studies 
The Table lists an extract of genes with a high correlation factor showing an induction upon induced expression of 
CLCA2 in clone #3 after 0, 24 h and 48 h. A correlation factor of 1,000 represents the induction of CLCA2 
(probeset 206166_s_at). The right column refers to the respective correlation factor r.  
 
As clone #4 and #46 had also been analysed on Affymetrix GeneChips in parallel, 
the selected top-correlating probesets (genes) listed in Table 2 could be manually 
compared with the corresponding expression pattern of clone #4 and #46. Those 
genes showing a similar expression profile in clone #4 and #46 were selected and 
subjected to RT-qPCR to confirm the expression pattern by an independent method. 
Individual results are shown in Figure 67 to Figure 83, always comparing the 
respective expression profile from the Affymetrix GeneChip analysis with the 
corresponding one from RT-qPCR analysis. 
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SFI1 
SFI1 homolog, spindle assembly associated (yeast) is involved in initiation of 
centrosome duplication. SFI1 has been identified as a binding partner for the 
calcium-binding protein centrin suggesting a role in the dynamic behavior of 
centrosomes. SFI1 binds to multiple centrin molecules and the complex forms 
calcium sensitive contractile fibers that function to reorient centrioles and alter 
centrosome structure [96]. So far no correlation to tumour cell growth has been 
reported. However, according to our in silico analysis SFI1 is found upregulated in 
many tumors, with highest expression levels found in various B-cell lymphomas and 
B-cell leukemias (data not shown). 
Results from Affymetrix microarray analysis indicating an upregulation of SFI1 upon 
induction of CLCA2 expression could be confirmed in RT-qPCR as shown in Figure 
67.  
 
 
 
Figure 67. SFI1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of SFI1 mRNA are shown in box-plots. The vertical centre line in the box 
indicates the median; the box itself represents the interquartile range (IQR) between the first and third quartiles. 
Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D Tet-on) 
are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate SFI1 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
SFI1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised SFI1 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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TP53BP1 
Alteration of the tumour protein TP53BP1 (p53 binding protein 1), during skin 
carcinogenesis is associated with genomic instability [97]. The expression pattern of 
TP53BP1 from microarray analysis is shown in Figure 68, left side suggesting an 
overexpression of TP53BP1 if CLCA2 expression is induced. However, higher levels 
of TP53BP1 could also be detected in control cells after 48 h of treatment with 
Doxycycline. In addition, overexpression of TP53BP1 could also not be confirmed 
with RT-qPCR (Figure 68, right side). Therefore, expression of TP53BP1 has to be 
regarded as a non-specific induction. This example supports the application of an 
independent method for validation of expression profiles.  
 
 
 
Figure 68. TP53BP1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of TP53BP1 mRNA are shown in box-plots. The vertical centre line in 
the box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate TP53BP1 transcript levels of cells with induced CLCA2 expression; blue box-plots 
represent TP53BP1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in 
control cells at the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post 
induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised TP53BP1 mRNA levels of induced clone #3 is shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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CDIPT 
CDP-diacylglycerol-inositol 3-phosphatidyltransferase (phosphatidyinositol synthase) 
is a gene whose inhibition causes small cell lung carcinoma cells to arrest in G1 [98]. 
It further has been suggested to be involved in oral carcinogenesis [99]. Inostamycin, 
an inhibitor of CDIPT, led to a decrease in cyclin D1 mRNA and protein expression 
accompanied by suppression of phosphorylated retinoblastoma susceptibility gene 
product (pRB-P) levels. Inostamycin might be a useful agent for tumour dormant 
cytostatic therapy for oral SCC.  
Overexpression of CDIPT was found in microarray studies and was confirmed in   
RT-qPCR, as shown in Figure 69. 
 
 
 
Figure 69. CDIPT mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of CDIPT mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate CDIPT transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
CDIPT transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised CDIPT mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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MLL2  
Myeloid/lymphoid or mixed-lineage leukemia 2 gene plays a role in apoptosis and in 
alterations of cell adhesion. MLL2 is a member of the human MLL family, which 
belongs to a larger SET1 family of histone methyltransferases. MML2 is a 
transcriptional activator that induces the transcription of target genes by covalent 
histone modification. It appears to be involved in the regulation of adhesion-related 
cytoskeletal events, which might affect cell growth and survival [100]. Members of the 
MLL protein family have been found to cause acute leukemia. Deletion studies 
revealed that alterations of the CxxC domain (Zn-binding domain) disrupts its 
oncogenic potential [101]. Loss-of-function mutations within the coding sequence of 
NF-kappaB inhibitory molecules such as IkappaBalpha or p100 leads to constitutive 
NF-kappaB activation in haematological malignancies. Hut-78, a truncated form of 
p100, constitutively generates p52 and contributes to the development of T-cell 
lymphomas and was recently shown to induce MMP9 gene expression. Conversely, 
MMP9 gene expression is impaired in p52-depleted HUT-78 cells. Interestingly, 
MLL1 and MLL2 H3K4 methyltransferase complexes are tethered by p52 on the 
MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase 
activity recruited on the MMP9 promoter is impaired in p52-depleted HUT-78 cells. 
Moreover, MLL1 and MLL2 are associated with Hut-78 in a native chromatin-
enriched extract. This molecular mechanism recruits a H3K4 histone 
methyltransferase complex on the promoter of a NF-kappaB-dependent gene 
induces its expression and potentially the invasive potential of lymphoma cells 
harbouring constitutive activity of the alternative NF-kappaB-activating pathway [102]. 
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Overexpression following CLCA2 induction could be observed in microarray studies 
and was confirmed by RT-qPCT (Figure 70). 
 
 
 
Figure 70. MLL2 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of MLL2 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate MLL2 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
MLL2 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised MLL2 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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AFF4 (MCEF) 
AF4/MR2 family member 4 (also known as MCEF), the newest member of the AF4 
family of transcription factors involved in leukemia, is a positive transcription 
elongation factor-b-associated protein [103]. 
Its overexpression after CLCA2 induction shown on microarray arrays was confirmed 
by RT-qPCR (Figure 71). 
 
 
 
Figure 71. AFF4 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of AFF4 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate AFF4  transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
AFF4 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised AFF4 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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UNC84A 
UNC84A belongs to the conserved family of SUN proteins. Human UNC84A (Sun1) 
is a homolog of C. elegans UNC-84, a protein involved in nuclear anchorage and 
migration. Targeting of UNC84A to the nuclear envelope revealed that the N-terminal 
300 amino acids are crucial for efficient nuclear envelope localisation of UNC84A 
whereas the conserved C-terminal SUN domain is not required. Localisation and 
anchoring of UNC84A is not dependent on the lamin proteins, in contrast to what had 
been observed for C. elegans UNC-84. If UNC84A can also interact with cytoplasmic 
tracts of transmembrane proteins such as CLCA2 to contribute to ECM 
interaction/migration is not yet known [104]. 
The transcript is found upregulated both, by Affymetrix GeneChip analysis and RT-
qPCR (Figure 72).  
 
 
 
Figure 72. UNC84A mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of UNC84A mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 are represented. 
Red box-plots indicate UNC84A  transcript levels of cells with induced CLCA2 expression; blue box-plots 
represent UNC84A transcript levels of non-induced cells. The yellow box plot represents the transcript level in 
control cells at the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post 
induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised UNC84A mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells 
(T47D Tet-on with empty expression vector). 
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DTX2 (Deltex2) 
The deltex null mutant indicates tissue-specific deltex-dependent Notch signaling in 
drosophila. It was further shown, that in drosophila deltex mediates suppressor of 
hairless-independent and late-endosomal activation of Notch signaling. In addition, 
the drosophila Nedd4-like protein suppressor of Deltex, Su(dx), has been 
characterised as a negative regulator of Notch receptor signaling, an intercellular 
signaling pathway of fundamental importance for multiple cell fate decisions 
[105;106]. 
Upregulation of DTX2 could be confirmed on the Affymetrix GeneChip and by RT-
qPCR (Figure 73). 
 
 
 
Figure 73. DTX2 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of DTX2 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate DTX2  transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
DTX2 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised DTX2 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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C10orf118 
Chromosome 10 open reading frame 118 of unknown function was found 
upregulated after CLCA2-induction on the Affymetrix GeneChip and was confirmed 
by RT-qPCR (Figure 74). 
 
 
 
Figure 74. C10orf118 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of C10orf118 mRNA areshown in box-plots. The vertical centre line in 
the box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate C10orf118  transcript levels of cells with induced CLCA2 expression; blue box-plots 
represent C10orf118 transcript levels of non-induced cells. The yellow box plot represents the transcript level in 
control cells at the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post 
induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised C10orf118 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells 
(T47D Tet-on with empty expression vector). 
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SATB1 
SATB1 is a genome organizer that tethers multiple genomic loci and recruits 
chromatin-remodelling enzymes to regulate chromatin structure and gene 
expression. It was shown that SATB1 is expressed by aggressive breast cancer cells 
and its expression level has high prognostic significance, independent of lymph-node 
status [107]. Knock-down of SATB1 in highly aggressive cancer cells altered the 
expression of lots of genes, reversing tumourigenesis by restoring breast-like acinar 
polarity and inhibiting tumour growth and metastasis in vivo. Conversely, ectopic 
SATB1 expression in non-aggressive cells led to gene expression patterns consistent 
with aggressive-tumour phenotypes, acquiring metastatic activity in vivo. SATB1 
delineates specific epigenetic modifications at target gene loci, directly upregulating 
metastasis-associated genes while downregulating tumour-suppressor genes. 
SATB1 reprogrammes chromatin organisation and the expression profiles of breast 
tumours to promote growth and metastasis [107].  
The upregulation found on Affymetrix GeneChip could not be confirmed by RT-qPCR 
(Figure 75). 
 
 
 
Figure 75. SATB1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of SATB1 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate SATB1 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
SATB1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised SATB1 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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EP300 
The transcriptional coactivator E1A binding protein p300 is a ubiquitous nuclear 
phosphoprotein and transcriptional cofactor with intrinsic acetyltransferase activity. 
p300 controls the expression of numerous genes in cell-type and signal-specific 
manner, and plays a pivotal role in cellular proliferation, apoptosis, and 
embryogenesis [108]. 
Although the expression profile of EP300 was contradictory, it was analysed by   RT-
qPCR and found to be downregulated (Figure 76). One reason for this discrepancy 
might be the presence of various isoforms or splice variants of EP300, generating a 
contradictory profile on Affymetrix GeneChips. 
 
 
 
Figure 76. EP300 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of EP300 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate EP300 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
EP300 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised EP300 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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LTBP1 
Overexpression of Latent transforming growth factor beta binding protein 1 (LTBP1) 
in association with TGF-beta 1 was found in ovarian carcinoma [109]. 
LTBP1 is impressively upregulated when analysed on GeneChips. Although          
RT-qPCR confirmed upregulation, the level of upregulation is significantly lower 
(Figure 77). 
 
 
 
Figure 77. LTBP1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of LTBP1 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate LTBP1 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
LTBP1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duple xassay with β-2-microglobulin as internal reference for normalisation 
Normalised LTBP1 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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TSC1 
Tuberous sclerosis complex 1 is a tumour suppressor gene which is involved in the 
mTOR pathway. Interestingly, a recently published study suggests the involvement of 
TSC genes and other members of the mTOR signaling pathway in the pathogenesis 
of oral squamous cell carcinoma [110].  
TSC1 was also shown to be involved in induction of autophagy. The role of 
autophagy in oncogenesis is manifold: At the early stages of tumor formation, 
autophagy acts as a tumor suppressor. During tumor progression, autophagy 
contributes to tumor growth. For instance, inhibition of autophagy by siRNAs 
targeting essential autophagy genes such as TSC1, sensitises cancer cells to the 
induction of apoptosis by radiotherapy and a wide range of chemotherapeutic agents. 
Inhibition of autophagy sensitises breast cancer cells to killing by the estrogen 
receptor antagonist tamoxifen, prostate cancer cells to androgen deprivation, colon 
cancer cells to amino-acid or glucose deprivation, and Bax-/- HCT116 cells to TRAIL-
induced apoptosis. Similar effects have been observed sensitising tumor cells to 
anoikis (apoptosis due to detachment from the extracellular matrix) [111]. 
Upregulation of TSC1 in cells with induced CLCA2 expression could be confirmed by 
both methods (Figure 78). 
 
 
 
Figure 78. TSC1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of TSC1 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate TSC1 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
TSC1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised TSC1 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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MACF1 
Microtuble-actin crosslinking factor 1 is involved in the Wnt signaling pathway [112].  
An upregulation after CLCA2-induction could be observed on the Affymetrix 
GeneChip and at later time points applying RT-qPCR (Figure 79). 
 
 
 
Figure 79. MACF1 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of MACF1 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate MACF1 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
MACF1 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised MACF1 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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CHD6 
Chromodomain helicase DNA binding protein 6 is a DNA-dependent ATPase that 
localises at nuclear sites of mRNA synthesis [113]. CHD proteins have drawn 
increased attention, because some of them were found to form large multi-subunit 
complexes, involved in transcription-related events like gene activation, suppression, 
or histone modification [113]. 
CHD6 was found upregulated after CLCA2-induction both, on the Affymetrix 
GeneChips and by RT-qPCR (Figure 80). 
 
 
 
Figure 80. CHD6 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of CHD6 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate CHD6 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
CHD6 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised CHD6 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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RUTBC3 
RUN and TBC1 domain containing 3 gene belongs to the RUN domain protein family 
[114]. RUN domains are present in several proteins that are linked particularly to the 
functions of GTPases in the Rap and Rab families. They could hence play an 
important role in multiple Ras-like GTPase signaling pathways [115]. 
RUTBC3 was found to be upregulated after induction of CLCA2 expression in both 
assays (Figure 81).  
 
 
 
Figure 81. RUTBC3 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of RUTBC3 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate RUTBC3 transcript levels of cells with induced CLCA2 expression; blue box-plots 
represent RUTBC3 transcript levels of non-induced cells. The yellow box plot represents the transcript level in 
control cells at the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post 
induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised RUTBC3 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells 
(T47D Tet-on with empty expression vector). 
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P4HA2 
Prolyl-4 hydroxylase-2 belonging to the procollagen hydroxylase protein family was 
shown earlier to be differentially regulated upon ERBB2 (HER2/neu) overexpression 
in human mammary luminal epithelial cells [116]. Furthermore, P4HA2 is suggested 
to be a potent molecular classifier able to discriminate between papillary thyroid 
carcinoma and non-malignant thyroid [117]. In this study P4HA2 was found to be 
upregulated after CLCA2-induction when analysed on Affymetrix GeneChips. 
However, no specific CLCA2-driven induction of this gene was detected in the RT-
qPCR (Figure 82).  
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Figure 82. P4HA2 mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of P4HA2 mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate P4HA2 transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
P4HA2 transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised P4HA2 mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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ASPM 
Asp (abnormal spindle)-like, microcephaly associated (drosophila) gene was recently 
found as a novel marker for vascular invasion, early recurrence, and poor prognosis 
of hepatocellular carcinoma [118]. Overexpression after CLCA2-induction was found 
on the Affymetrix GeneChip. Although a similar expression profile in CLCA2-induced 
and control cells was shown by RT-qPCR, the levels of CLCA2 transcript were higher 
in CLCA2-expressing cells (Figure 83). 
 
 
 
Figure 83. ASPM mRNA levels in induced CLCA2-expressing T47D Tet-on clone #3 versus control 
Left: Affymetrix microarray studies using Affymetrix GeneChip Human Genome U133 Array 
The MAS5-normalised expression levels of ASPM mRNA are shown in box-plots. The vertical centre line in the 
box indicates the median; the box itself represents the interquartile range (IQR) between the first and third 
quartiles. Whiskers extend to 1.5 times the IQR. In the left dark grey field, expression levels in control cells (T47D 
Tet-on) are shown. In the right light grey field, expression levels in T47D Tet-on clone #3 (k3) are represented. 
Red box-plots indicate ASPM transcript levels of cells with induced CLCA2 expression; blue box-plots represent 
ASPM transcript levels of non-induced cells. The yellow box plot represents the transcript level in control cells at 
the time point of induction. 0, 24 and 48 indicate the time points (h) of lysate preparation post induction. 
Right: RT-qPCR in duplex assay with β-2-microglobulin as internal reference for normalisation 
Normalised ASPM mRNA levels of induced clone #3 are shown in relation to mRNA levels in control cells (T47D 
Tet-on with empty expression vector). 
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To identify CLCA2 coregulated genes upon induced CLCA2 expression, expression 
profiles at different time points were analysed and mainly confirmed by RT-qPCR. 
These analyses were performed with two limitations: i) only a small number of genes 
out of a about 250 statistically relevant and differentially induced genes were 
selected for detailed analysis and ii) both assays (hybridisation on GeneChips and 
RT-qPCR) were performed only once, but samples from different time points were 
analysed. Nevertheless, as seen in Table 3 a good correlation between both 
approaches was achieved, only 2 out of 18 analysed expression profiles are 
questionable (Table 3). 
 
                                
GENE ID Chip qPCR
AFF4 u u
ASPM u u?
C10orf118 u u
CDIPT u u
CHD6 u u
CLCA2 u u
DTX2 u u
EP300 d/i d
LTBP1 u u
MACF1 u u
MLL2 u u
P4HA2 i i
RUTBC3 u u
SATB1 i i
SFI1 u u
TP53BP1 i i
TSC1 u u
UNC84A u u   
upregulated
downregulated
indifferet  
 
Table 3. Comparison of expression data derived from Affymetrix microarray analysis and RT-qPCR 
Status of gene regulation from microarray and RT-qPCR studies are opposed. 
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Linking Profiles of Cells with Induced CLCA2 Expression to Canonical 
Pathways 
As described above, a comprehensive study was performed on Affymetrix 
GeneChips in clones with inducible CLCA2 expression. Approximately 150 genes 
were shown to be specifically up- or downregulated in a statistically relevant mode 
(fold change > 1.8; p-value < 0.0001). In order to link these expression profiles of 
regulated genes to canonical pathways and bring them into a biological context, 
these data were analysed with the Ingenuity Pathways Analysis (IPA; Software of 
Ingenuity Systems Inc.). This program is a text- and data-mining program, which not 
only links gene and protein functions/interactions based on the knowledge of 
published data in the most relevant journals, but also allows to bring these 
interactions into a context of biological functions, regulatory cascades and functional 
groups (e.g. oncology/metastasis/prostate). It has to be mentioned that the presented 
studies can only be regarded as preliminary as the outcome of these in silico 
analyses have to be proven in experimental settings. On the other hand these data 
allow a much more focussed procedure for future experiments as this program not 
only describes protein-protein interactions, but also other types of reciprocal action 
such as protein-nucleic acid interactions. Based on these in silico analyses several 
interaction-networks were identified. Some exemplary statistically relevant networks 
are shown in Figure 85, Figure 86, Figure 87, and Figure 88. 
For understanding the display of the following networks, an overview of the used 
symbols is given in Figure 84. 
 
 
 
 
 
 
 
 
 
 
 
Figure 84. Abbreviations and explanation of relationships and network shapes used for Ingenuity 
Pathway Analyst (IPA) Software of Ingenuity Systems, Inc. 
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Network I (Figure 85) indicates that a group of specifically induced genes upon 
induction of CLCA2 is strongly linked to the interaction-axis of SMAD3–TP53–MYC. 
 
 
 
Figure 85. Network I: Link to the interaction-axis of SMAD3–TP53–MYC 
Display of interactions based on the Ingenuity Pathway Analyst (IPA) Software of Ingenuity Systems, Inc. 
Grey-coloured genes have been identified on Affymetrix GeneChips as differentially expressed upon CLCA2 
overexpression. A detailed description of symbols and abbreviations used is given in Figure 84.  
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Network II (Figure 86) indicates a link to the TNF–IL2–IL10 interaction network. 
Interestingly, it has been shown recently that treatment of SCCs of the skin with a 
Toll-like receptor agonist such as imiquimod lead to a decrease in regulatory T (T 
reg) cells, producing less IL10 and TGF-beta, thereby inhibiting their suppressive 
activity. This means that SCCs evade the immune response at least in part by 
recruiting T reg cells via modulation of the IL10 pathway [119]. Additionally, in this 
network also CLCA2 is interacted via an indirect mode of action.  
 
 
 
Figure 86. Network II: Link to the TNF–IL2–IL10 interaction network 
Display of interactions based on the Ingenuity Pathway Analyst (IPA) Software of Ingenuity Systems, Inc. 
Grey-coloured genes have been identified on Affymetrix GeneChips as differentially expressed upon CLCA2 
overexpression. A detailed description of symbols and abbreviations used is given Figure 84. 
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Network III (Figure 87) brings some of the differentially upregulated genes into the 
context of the ERK–MAPK signaling cascade with ERK as the knot of this network. 
 
 
 
Figure 87. Network III: Link to the ERK–MAPK pathway 
Display of interactions based on the Ingenuity Pathway Analyst (IPA) Software of Ingenuity Systems, Inc. 
Red-coloured genes have been identified on Affymetrix GeneChips as differentially expressed upon CLCA2 
overexpression. A detailed description of symbols and abbreviations used is given in Figure 84. Lines/arrows in 
blue indicate interactions of ERK.  
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In Figure 88 merging of the most significant networks is shown, focussing excusively 
on protein-protein interactions. As already mentioned, utilising this program, also 
other interactions such as protein-DNA interactions can be visualised. For the sake of 
simplicity only the protein-protein interaction is presented, highlightening biologically 
interesting clusters such as the cluster of v-src (involved in regulation of many 
different signaling cascades) or the polypyrimidine tract binding protein 1 (PTBP1) 
which is essentially involved in translational control (Figure 88).  
 
 
 
 
Figure 88. Merging most significant networks 
Display of interactions based on the Ingenuity Pathway Analyst (IPA) Software of Ingenuity Systems, Inc. 
Red-coloured genes have been identified on Affymetrix GeneChips as differentially expressed upon CLCA2 
overexpression. The intensity of the red colour indicates the level of differential regulation on GeneChips. A 
detailed description of symbols and abbreviations used is given in Figure 84. 
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Phospho-Proteomic Studies: Canonical Signaling Transduction 
Pathways 
Utilising the IPA software (see above), only data derived from expression profiling 
were applied so far. In order to learn more about the contribution of some important 
executer proteins of canonical pathways, which might be found activated/deactivated 
(=phosphorylated/dephosphorylated) in the experimental setting of CLCA2 induction, 
cell lysates which were taken at various time points of induced and non-induced 
T47D Tet-on clone #3 cells, were analysed on Western blots and on phospho-
proteomic antibody arrays. 
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Western Blots  
Antibodies listed in Table 4 were used for Western blots.  
 
       
phosphorylated
phosphorylated ?
dephosphorylated
dephosphorylated ?  
 
Table 4. Phospho-antibodies tested on protein lysates of induced/non-induced CLCA2-expressing  
T47D Tet-on clone #3 
Genes marked in green were found to be phosphorylated upon induction of CLCA2 expression. 
Genes marked in yellow were found to be dephosphorylated upon induction of CLCA2 expression. 
Target Protein Name Phospho Site Company Cat. No.
Akt S473 Cell Signaling #9271
Akt S308 Cell Signaling #9275
Akt Y326 Cell Signaling #2968
Akt pan Cell Signaling #9272
GSK-3beta S9 Cell Signaling #9336
PTEN S380 Cell Signaling #9551
PDK1 S241 Cell Signaling #3061
PDK1 pan Cell Signaling #3062
PI3K p85 Y458 / p55 Y199 Cell Signaling #4228
FAK Y861 Biosource 44-626G
iKKalpha/beta S176/180 Cell Signaling #2697S
NF-KB p65 S536 Cell Signaling #3031
NF-KB p65 pan Cell Signaling #3034
MEK 1/2 S217/221 Cell Signaling #9121
p44/42 MAP Kinase T202/Y204 Cell Signaling #9101
p38 MAPK T180/Y182 Cell Signaling #9211
p90RSK S380 Cell Signaling #9341 
RSK1 S221/S227 Biosource 44-924G
RSK1 S363/S369 Biosource 44-926G
Elk1 S383 Cell Signaling #9181
Raf S259 Cell Signaling #9421
c-Raf S338 Biosource #9427
ERK 1 & 2 T185/Y187 Biosource 44-680G
Erk 1&2 pan Biosource 44-654G
p70 S6 Kinase T389 Cell Signaling #9234S
p70 S6 Kinase pan Cell Signaling #9202
mTOR S2448 Cell Signaling #2971
mTOR S2481 Cell Signaling #2974
4E-BP1 T37/46 Cell Signaling #2855
4E-BP1 T70 Cell Signaling #9455
4E-BP1 S65 Cell Signaling #9451
FoxO1 S319 Cell Signaling #2487
FoxO3a S318/321 Cell Signaling #9465
FoxO3a S253 Cell Signaling #9466
Stat1 Y701 Cell Signaling #9171
Stat2 Y690 Cell Signaling #4471
Stat3 Y705 Cell Signaling #9131
Stat3 S727 Cell Signaling #9134
Stat3 Y705 Cell Signaling #9131
Stat5 Y694 Cell Signaling #9351
Stat6 Y641 Cell Signaling #9361
NPM/B23 (Nucleophosmin 1) T234/T237 BioLegend #619101
PKCe pan Biosource AHO0743
p27 pan novocastra NCL-p27
Histon H3 S10 Upstate #06-570
TSC2 T1462 Cell Signaling #3611
TSC2 S1254 Cell Signaling #3616
KI67 pan Dako Cytomation M7240
RESULTS 
 
 121
In Figure 89 Western blots of proteins which were found to be phopshorylated upon 
CLCA2-induction are shown. An increase in phosphorylation of AKT (S473; Figure 
89a), ERK 1&2 (T185/Y187; Figure 89c), MAPK (T202/Y204; Figure 89d), RAF 
(S259; Figure 89e), CRAF (S338; Figure 89f), and PDK1 (S241; Figure 89g) was 
observed. No change in the phosphorylation pattern was seen for AKT at position 
S308. These data confirm previous predictions made through the usage of the IPA 
software, indicating a link to the ERK–MAPK canonical pathway. 
 
 
 
Figure 89. Proteins involved in the AKT–ERK–MEK canonical pathway exhibiting an increase in 
phosphorylation upon induction of CLCA2 expression 
Expression of CLCA2 was induced in CLCA2-expressing T47D Tet-on clone #3 by addition of Doxycycline. 
Protein lysates were harvested at indicated time points post induction. CLCA2 expression of lysates was 
confirmed before use. For Western blot 50 µg protein was loaded per lane; the phosphorylation status of indicated 
proteins was tested with a respectiv phospho-antibody (for detailed information on antibodies see Table 4). 
GAPDH served as loading control. 
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In Figure 90 Western blots of identical protein lysates are shown. In contrast to 
Figure 83, proteins analysed were found dephosphorylated upon CLCA2-induction 
including mTOR (p2448; Figure 90a), 4E-BP1 (T37/T47; Figure 90b), STAT1 (Y701; 
Figure 90c), and NPM (T234/T237; Figure 90d), respectively. Nucleophosmin (NPM), 
for instance, is involved in cytoskeletal regulation [120], whereas deregulation of 
STAT1 indicates a link of CLCA2 expression to translational control. 
 
 
 
Figure 90. Proteins exhibiting a decrease in phosphorylation upon induction of CLCA2 expression 
Expression of CLCA2 was induced in CLCA2-expressing T47D Tet-on clone #3 by addition of Doxycycline. 
Protein lysates were harvested at indicated time points post induction. CLCA2 expression of lysates was 
confirmed before use. For Western blot 50 µg protein was loaded per lane; the phosphorylation status of indicated 
proteins was tested with a respectiv phospho-antibody (for detailed information on antibodies see Table 4). 
GAPDH served as loading control. 
 
Western blots of those antibodies listed in Table 4 which did not show any effect on 
the phosphorylation status of the respective protein upon CLCA2-induction, are not 
shown. 
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Antibody Arrays: Proteome Profiler  
“Human Phospho-MAPK Array Kit” (Cat.# ARY002) and “Human Phospho-RTK Array 
Kit” (Cat.# ARY001) of R&D Systems were tested on lysates of CLCA2-expressing 
T47D Tet-on clones and on CLCA2-constitutively-expressing T47D clone.  
The principle of the assays is that capture and control antibodies have been spotted 
in duplicates on nitrocellulose membranes. Cell lysates are diluted and incubated 
with the “Human Phospho-Array Kit”. After binding both, phosphorylated and non-
phosphorylated proteins, unbound material is washed off. A cocktail of phospho-site-
specific biotinylated antibodies is then used to detect phosphorylated kinases via 
Streptavidin-HRP and chemiluminescence.  
The phosphorylation status of all three major families of mitogen-activated protein 
kinases (MAPKs), the extracellular signal-regulated kinases (ERK1/2), c-Jun           
N-terminal kinases (JNK1-3), different p38 isoforms (α/β/δ/γ), other intracellular 
kinases such as Akt, GSK-3, and p70 S6 kinases was analysed, using the “Human 
Phospho-MAPK Array Kit” from R&D Systems and for analysis of the relative levels 
of phosphorylation of 42 different receptor tyrosine kinases, the “Human Phospho-
RTK Array Kit” from R&D Systems (Cat.# ARY001) was used. 
As shown in Figure 91, the duplicates of B3 and B4, representing ERK1 and the 
duplicates C3 and C4, representing ERK3 (red squares) show a higher 
phosphorylation level in CLCA2-constitutively-expressing T47D clone #47, than in 
contol cells with the empty vector (blue squares). 
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      CLCA2-constitutively-expressing T47D clone #47 
 
       
      Control cells (empty vector) 
 
Figure 91. Phosphorylation status of MAPKs, ERK1/2, JNK1-3, different p38 isoforms and other 
intracellular kinases upon expression of CLCA2 on antibody arrays 
Protein lysates of CLCA2-constitutively-expressing T47D Clone #47 and “pseudo-induced” control cells with 
empty vector were harvested; CLCA2 expression of lysates was confirmed before use. 
The lysates were tested for the phosphorylation status of various proteins of the MAPK pathway using the 
“Human Phospho-MAPK Array Kit” from R&D Systems (Cat.# ARY002). 
 
 
As shown in Figure 92 the duplicates of B3 and B4, representing EGF-R and the 
duplicates B17 and B18, representing Insulin-R and the duplicated B19 and B20, 
representing IGF-I R (red squares) show a higher phosphorylation level in CLCA2-
inducibly-expressing T47D clone #3, than in contol cells with the empty vector (blue 
squares). These data point to a possible activation of these three RTKs by CLCA2. 
 
         CLCA2-expressing T47D Tet-on clone #3 
 
          
         Control cells (empty vector) 
 
Figure 92. Phosphorylation status of different receptor tyrosine kinases upon induction of CLCA2 
expression on antibody arrays 
Protein lysates of induced CLCA2-expressing T47D Tet-on Clone #3 and “pseudo-induced” control cells with the 
empty vector were harvested 48 h post induction; CLCA2 expression of lysates was confirmed before use.  
The lysates were tested for the phosphorylation status of 42 different receptor tyrosine kinases using the “Human 
Phospho-RTK Array Kit” from R&D Systems (Cat.# ARY001). 
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DISCUSSION 
Introductory Remarks: General Reflections on Targeted 
Therapy in Oncology 
Cancer incidence is increasing worldwide with a tendency to be concentrated in 
developing countries (WHO estimation: 66 % of all new cases will be diagnosed 
within such regions). As the majority of patients are diagnosed in advanced stage, 
“classical” chemotherapy very often is still the first choice in treatment modality. As 
this therapy acts mainly in a non-specific manner, significant toxicity is observed. 
Indisputably, there is a high medical need to identify novel target molecules for more 
focused therapies in oncology. However, identification of such novel molecular 
targets requires a better understanding of the biology of cancer cells and their 
metabolic functioning. The knowledge about molecules and processes that are 
unique to cancerous cells or at least to a given cancer type is a prerequisite in the 
development of novel therapeutic approaches in cancer patients, leading to “targeted 
therapy”.  
Over the last few years, a set of potential targets for cancer-directed therapy has 
been explored. Targeted therapy is defined as a drug or molecule causing tumour 
cell kill by interacting with predefined target(s) present on malignant cells [121]. 
Besides others, such an approach has the obvious advantage that it would 
selectively attack molecules and/or signaling transduction cascades that are unique 
to the tumour cells. Such kind of therapy has the potential to exclude normal cells to 
be hit, resulting in the reduction of side effects and general toxicity of the therapy, to 
have greater efficacy and to improve quality of life. Depending on the mode of action 
and the defined targets, various agents can be classified in subcategories such as 
monoclonal antibodies like Tratuzimab [122], tyrosine kinase inhibitors [123-127], 
antiangiogenic agents [128;129], cyclin-dependent kinases (CDK) and mitotic kinase 
inhibitors [130-132], proteasome inhibitors [133], and Cox-2 inhibitors [134] to name 
but a few.  
Targeted therapies generate additional benefits and a higher efficacy in tumour 
patients. However, both, benefits and efficacy need to be evaluated carefully [121].  
Cancer is a multistep process and genetic events (deletions, amplifications, 
rearrangements, mutations, epigenetic regulation etc.) result in the activation of 
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(proto-)oncogenes or the inactivation of tumour suppressor genes. As a result, the 
proliferation and growth of a tumour cell increases. It is of interest that the 
experimental inactivation of even a single oncogene can be sufficient to induce 
sustained tumour regression or vice versa, although tumourigenesis is thought to be 
a multistep process. Tumours become irrevocably addicted to these oncogenes. 
“Oncogene addiction” describes therefore, the phenomenon by which some cancers 
that contain multiple genetic and epigenetic abnormalities remain dependent on 
(addicted to) one or a few genes for both maintenance of the malignant phenotype 
and cell survival/proliferation. One explanation for this phenomenon is that activated 
oncogenes (e.g. mutated EGFR) result in a constitutive activation of a signaling 
cascade leading to sustained proliferation and survival [28]. On the other hand, a 
single oncogene is not sufficient to fulfill all requirements of a “full-blown” tumour cell 
and to overcome all physiologic barriers and safety mechanisms [16;135]. Therefore, 
it was suggested that oncogene activation initiates tumourigenesis mainly because it 
directly overrides physiologic programs inducing a state of “cellular amnesia”, not 
only inducing constitutive proliferation, but also bypassing checkpoint mechanisms 
that are essential for cellular mortality, self-renewal, and genomic integrity [136;137]. 
Correspondingly, in a tumour exhibiting the status of “oncogene addiction”, the 
inactivation of a single oncogene can restore some of these pathways resulting in 
proliferative arrest, differentiation, cellular senescence, and/or apoptosis. According 
to Felsher and colleagues “oncogenes induce cancer because they induce a cellular 
state of enforced oncogenic amnesia in which, only upon oncogene inactivation, the 
tumour becomes aware of its transgression” [138]. Novel techniques of systems 
biology will provide methods for analysing the entire circuitry of cancer cells and thus 
facilitate identification of these pathways of “oncogene addiction” or “oncogene 
amnesia” in specific types of human cancer. Regardless whether we call it “oncogene 
addiction” or “oncogene amnesia”, a prerequisite for the development of a targeted 
therapy is the identification of tumour-specific target genes which might not only be 
used as targets for mono-therapies but also be applied in combination with other 
anticancer agents [139].  
Oncogenes and tumour suppressors are derived from all protein families, not only 
bearing an enzymatic function such as kinases, GPCRs, phosphatases, 
oxidoreductases, proteases etc., but also exhibiting transport [140;141], 
transcriptional [142;143] or structural/topologic functions [144;145]. For many of 
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these proteins the contribution to carcinogenesis has been univocally demonstrated 
(e.g. receptor tyrosine kinases), for others it remains to be determined (e.g. 
transporters, ion channels).   
Often tumour-associated overexpression is the first hint that a gene might be 
involved in tumourigenesis. However, overexpression per se explains neither its 
essential contribution to tumour growth, survival or maintenance nor whether a gene 
(gene function) is able to drive tumour formation (“oncogene addiction”). A 
expression profile also does not allow to draw any conclusions about the mode of 
action of how a certain gene becomes overexpressed (e.g. chromosomal 
amplification, epigenetic regulation).  
In the context of targeted therapy, ion channels are representing promising players. 
Specific stages of cancer progression are marked and regulated by expression and 
activity of different channels. Their contribution to the neoplastic phenotype ranges 
from control of cell proliferation and apoptosis, to regulation of invasiveness and 
metastatic spread. Often the contribution of these channels are independent of ion 
flow (e.g. shown for potassium (K+) channels) but the underlying molecular 
mechanisms are poorly understood [146]. Ion channels frequently exert pleiotropic 
effects on the tumour cell such as regulating membrane potential and thereby 
controlling calcium ion (Ca2+) fluxes and subsequently interfering with the cell cycle 
machinery [146;147]. The effect on mitosis might depend on the regulation of cell 
volume as shown in HeLa cells [146;148]. However, ion channels seem also to play 
an important role at late stage tumourigenesis by supporting angiogenesis, mediating 
the cell-matrix interaction, and regulating cell motility e.g. AQP1-null mice show 
defective tumour angiogenesis resulting from impaired endothelial cell migration 
whereas AQP3-null mice are resistant to skin tumourigenesis [140]. This is of interest 
as during this study it was found that CLCA2 might play an important role during 
colonisation of mycosis fungoides (cutaneous T cell lymphoma) into the skin (see 
section “In Silico Analysis of Expression Data”). 
Another important contribution of ion channels to tumourigenesis is executed via 
formation of protein complexes with other membrane proteins such as integrins or 
growth factor receptors. These interactions may trigger a variety of different signaling 
cascades. First evidence that calcium channel blockers suppress the growth of 
human cancer cells, both in vitro and in vivo has been published recently [149]. A 
major drawback of all these approaches is that often ion channel blockers produce 
DISCUSSION 
 
 128
serious side effects, such as cardiac arrhythmias and are not yet sufficiently specific 
enough [146]. This also holds true for members of the CLCA protein family for which 
no specific blocking compounds are available yet.  
In Silico Analysis of Expression Data 
Prior to the biological characterisation of CLCA2 a detailed in silico expression profile 
analysis was performed to learn more about its contribution to tumourigenesis. Based 
on the PhD-Thesis of Ulrich König and the Diploma Thesis of Stefan Amatschek [1], 
a lung SCC-specific expression profile of the human calcium-activated chloride 
channel, family member 2 (CLCA2) was suggested. Therefore, it was started to 
analyse the expression levels of CLCA2 mRNA in normal and tumourous tissue 
samples, as well as in tumour cell lines and xenografts thereof by utilising Boehringer 
Ingelheims proprietary BioExpress database (GeneLogic Inc.), which includes 
expression data from ~ 14.000 human tissue samples, analysed on Affymetrix 
GeneChips. Although different types of GeneChips have been used for the 
expression profiling, no statistically relevant variation was observed in the mRNA 
levels of the corresponding sample set among different GeneChips. 
Analyses of the expression pattern in the BioExpress database (GeneLogic Inc.) 
indicated a preferential overexpression of CLCA2 not only in SCCs of the lung, but 
also in  SCCs of the cervix, the larynx, the head and neck region, in lymph node 
metastasis of SCCs, in mycosis fungoides a cutaneous T cell lymphoma and in a 
subset of infiltrating ductal breast cancers. 
Interestingly, adenocarcinomas of the esophagus show only minimal levels of CLCA2 
transcript in comparison to their corresponding normal esophageal tissue, whereas 
laryngeal SCC maintain the high expression level of CLCA2 transcript throughout 
transformation. It cannot be excluded, that the relatively high CLCA2 transcript levels 
in normal esophageal and laryngeal tissue stems from the presence of an adjacent 
SCC and/or an inflammatory disease due to the fact that often the “normal” tissue is 
excised from the adjacent tissue of a tumour. Also a parakrine induction of CLCA2 in 
the surrounding tissue cannot be excluded. The uncategorised head and neck SCCs 
show an elevation of CLCA2 transcript levels in comparison to the corresponding 
normal tissue samples. 
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Comparison of the expression pattern of CLCA2 in esophagus with that in other 
tissues of the digestive tract, exhibits no additional expression in other parts of the 
digestive tract, underlining the restricted expression pattern of CLCA2. 
In breast cancer a subpopulation of the infiltrating ductal carcinomas shows 
overexpression of CLCA2. It remains unclear whether distinct chromosomal 
aberrations or various differentiation stages lead to the induction of and/or 
dependence on CLCA2 in this subset of breast cancer samples. In this context it has 
to be mentioned that Her2 amplification is also found only in a subset of breast 
cancer samples [150-152]. 
In the view of elevated CLCA2 transcript levels in tumour-associated skin biopsies, it 
is of interest that a dramatic increase of CLCA2 mRNA was identified in mycosis 
fungoides, which is the most common type of cutaneous T cell lymphoma. It is a 
Non-Hodgkin lymphoma, which is predominantly related to skin. It generally affects 
the skin, but may progress internally over time. Disease may also progress involving 
nodes, blood and internal organs, or transform into a higher-grade lymphoma. As 
shown in this study, expression of CLCA2 seems to be induced in tumour-associated 
skin rather than in normal skin. Similarly, mycosis fungoides might make use of 
CLCA2 for its colonisation of the skin during its course of progression. In contrast, no 
CLCA2 expression is found in Hodgkin lymphomas. 
To exclude relevant contribution of cells of the tumour stroma, the CLCA2 expression 
pattern was also investigated in several laser-capture-microdissected (LCM) tissue 
samples of lung carcinomas in comparison to non-neoplastic lung tissue samples. 
Based on data from the in silico analysis, an expression of CLCA2 in tumour stroma 
could be excluded and the tumour-specific expression pattern of CLCA2 was 
confirmed.  
It seems that formation of SCC-derived metastases are somehow linked with CLCA2 
expression, supporting the idea that CLCA2 might play a crucial role in the formation 
of SCC-derived metastases and being essentially involved in the progression of 
mucosis fungoides. In contrast to mycosis fungoides no (elevated) expression of 
CLCA2 was detectable in B cell and T cell lymphomas and their corresponding 
normal tissues/cells.  
The analysis of CLCA2 transcript levels in lymph node metastases from different 
primary tumour subtypes showed, that SCC cells, which metastasise into the lymph 
node, maintain their high CLCA2 transcript levels during the infiltration of the lymph 
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node. Again a highly specific expression pattern was found as lymph node 
metastases descending from primary melanomas and adenocarcinomas do not 
express CLCA2. 
All SCC tissues with elevated levels of CLCA2 transcript (as compared to their 
corresponding normal tissues) do not show overexpression in their corresponding 
adenocarcinomas; CLCA2 overexpression is clearly restricted to SCCs. 
By comparison of the CLCA2 expression level in breast cancer specimens with that 
in their corresponding metastases, it was found that CLCA2 overexpression in breast 
cancer seems to be needed for formation of brain-, lung-, liver-, and lymphnode-
metastases (see Figure 16). A correlation between CLCA2 overexpression and the 
development of metastases, was also indicated by analysis of expression data 
derived from cell lines and their corresponding developing tumours in xenograft 
models. All xenografts originating from SCC cell lines such as A431 (cervix 
carcinoma), H520 (lung carcinoma) and HNOE (head and neck/esophagus 
carcinoma) exhibit a dramatic upregulation of CLCA2 when xenografted into nude 
mice (Figure 14). Except for the pancreatic tumour cell line BxPC3 and MDA-MB-453 
(breast cancer cell line) none of the adenocarcinoma-derived cell lines lead to such a 
pronounced upregulation of CLCA2 in xenografts. In the case of MDA-MB-453 a high 
expression level of CLCA2 is already detectable in 2D culture (Figure 14). Altogether, 
these data support the idea that CLCA2 plays a crucial role in tumour progression. 
In addition, correlation of CLCA2 expression with receptor- and lymph node status in 
human breast cancer samples reveals that CLCA2 expression is mainly found in 
estrogen receptor-negative or in Her2-positive specimens.  
Analysis of a panel of different human carcinoma cell lines again underlines the 
restricted expression of CLCA2 as it is limited to SCC or human breast cancer cell 
lines (Figure 15). 
Analysis of chromsomal amplifications of the CLCA2 locus on Affymetrix SNP-Chips 
in human tumour cell lines showed that most SCC cell lines with an increased 
expression level of CLCA2 also exhibit amplification of 1p22-31 [63]. A copy number 
of 3 of the CLCA2 loci was found e.g. for FaDu, a head and neck SCC cell line, 
possibly reflecting the link between genomic and expressional status in various 
SCCs. 
In statistical analyses – correlating normalised expression values of the BioExpress 
database (GeneLogic Inc.) – the next step was to search for transcripts exhibiting a 
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similar expression pattern. Among those genes various markers of stratified epithelia, 
such as desmocollin (DSC3), desmoglein 3 (DSG3), TP53 apoptosis effector 
(PERP), plakophilin 1 (PKP1), and keratin 5 (KRT5) were extracted. The expression 
of those epithelial differentiation markers seems to be maintained during the 
transition from a stratified epithelial cell into a hyper-proliferating SCC cell, and could 
therefore be essential for the establishment of SCCs. Further identified genes, which 
were already described to be involved in tumourigenesis, are: Ladinin 1 
(LAD1/CD18), tripartite motif-containing 29 (TRIM29), stratifin (14-3-3 sigma/SDN), or 
RAB38, a member of the RAS oncogene family. Another set of genes with a similar 
expression profile may represent yet unidentified markers for stratified epithelia 
and/or genes involved in the tumourigenesis of SCCs. One of these genes, which 
showed a more or less identical expression profile is the G-protein-coupled receptor 
GPR87. Its association with stratified epithelia and essential contribution to SCC 
carcinogenesis was shown recently by S. Glatt, a PhD student of our group [79]. 
Whether GPR87 and CLCA2 are directly interacting with each other is not known yet. 
However, interaction of GPCRs and ion channels for regulation of signal transduction 
has already been demonstrated [153;154]. 
Knock-Down of CLCA2 in CLCA2-Positive Tumour Cells 
With loss-of-function studies by siRNA-mediated knock-down of CLCA2, the 
implication on cell survival and proliferation of CLCA2 was investigated. In 
proliferation assays could be shown that downregulation of CLCA2 in HN5 cells 
(SCC cell line) leads to inhibition of proliferation, to reduction in viability and 
subsequently to induction of apoptosis. The same holds true for GPR87 [79], which 
exhibits a nearly identical expression profile as CLCA2 and was used as a control 
target gene for siRNA experiments. Downregulation was monitored by RT-qPCR. 
Testing different siRNA oligonucleotides, the two most efficient ones (siCLCA2-2 and 
siCLCA2-4) were selected for further studies. In general, siRNA oligonucleotide 
siCLCA2-4 lead to the most pronounced biological effects in all experimental 
settings.  
Investigation of various apoptosis parameters by a high content screening approach 
(Cellomics) utilising siRNA-transfected HN5 cells revealed dramatic changes in the 
membrane permeability and in the mitochondrial status. In addition, a pronounced 
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nuclear fragmentation could be observed, which supports data obtained from PARP-
cleavage experiments on Western blots reflecting induction of apoptotic events. 
CLCA2 knock-down in siRNA-treated HN5 cells also lead to a significant shift in the 
cell cycle. The cell count in G1-phase (2n) was clearly reduced, and cells were 
arrested in G2, whereby polyploidy increased. Most likely apoptosis was already 
initiated in these polyploidic cells. Altogether, these data indicate that both, CLCA2 
and GPR87 play an essential role for proliferation of HN5 cells. 
As MDA-MB-453 cells (breast cancer cell line) exhibit much higher CLCA2 
expression levels than HN5 cells, they were also used in siRNA experiments. 
Interestingly, in contrast to HN5 cells, MDA-MB-453 cells were insensitive towards 
knock-down of CLCA2 when tested in a proliferation assay.  
Furthermore, no PARP-cleavage could be detected in siRNA-treated, CLCA2-
constitutively-expressing T47D clone #47. T47D is also a breast cancer cell line 
which – in contrast to MDA-MB-453 – has only a hundred-fold lower expression level 
for CLCA2.  
In contrast to the SCC cell lines HN5, the breast cancer cell line MDA-MB-453 
(although exhibiting high levels of CLCA2 transcript) seems not to be dependent on 
CLCA2 for proliferation and survival in 2D-culture. Also gain-of-function in the breast 
cancer cell line T47D did not change the growth behaviour or generates a sensitivity 
towards siRNA-mediated downregulation of CLCA2. As both breast cancer cell lines 
are derived from adenocarcinomas, we conclude that downregulation of CLCA2 
leads only to severe effects in cell lines of SCC origin (as e.g. HN5).  
Antibody Generation and Immunohistochemistry 
Due to the lack of commercially available CLCA2-specific antisera it was repeatedly 
tried to generate specific antisera against human CLCA2. Rabbits were immunised 
with peptides derived from identified CLCA2-specific epitopes which discriminate 
between other members of the CLCA family (for details see “Results”). 
Fractions of affinity-purified sera of immunised rabbits were tested on Western Blot, 
but none of these antibodies generated a specific signal. Therefore, it was decided to 
recombinantly introduce an HA-tag to the wild type CLCA2 coding sequence in order 
to allow detection of CLCA2 expression at least in stably or transiently transfected 
cells utilising an anti-HA-antibody. The time-dependent induction of inducible HA-
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tagged CLCA2 expression could be confirmed with HA-specific antibodies in stably 
transfected T47D. 
Interestingly, one of the affinity-purified antisera, which was not suitable for detection 
of CLCA2 on Western blots but exhibiting a high titer towards peptide K94-N110 of 
CLCA2, showed a specific staining of tumour cells in human SCC lung tumour 
samples confirming its tumour-specific expression (tumour stroma and normal tissue 
is negative). A pre-immune serum was used as a negative control. The signal could 
also be competed with a peptide which was applied for generating the antiserum. 
Staining of adenocarcinomas, however, are not conclusive yet, as 
immunohistochemical analyses of these tumour types lead to aggregation of the 
antiserum. Therefore, these data have to be regarded as preliminary, also because 
(due to availability) only a small number of human SCCs have been analysed yet.  
Proteolytic Processing 
Putative Hydrolase Domain 
Pawlowski and colleagues published in 2006 that CLCA1 contains a hydrolase 
domain which is responsible for the processing of mature full-length CLCA1 [65]. 
Detailed sequence comparison revealed that the homology within the CLCA family is 
quite high. Making use of the etstablished inducible expression of HA-tagged CLCA2 
in T47-D cells, it was first tried to detect a C-terminal fragment on Western blots. 
Indeed, the cleavage product could only be detected upon Tet-induced CLCA2 
expression in a time- and concentration-dependent manner. Non-induced cells under 
the same conditions did not show any specific band on Western blots (Figure 41,  
Figure 43). An alignment of CLCA1 and CLCA2 protein sequence exhibited a high 
homology within the segment where the proposed hydrolase is located (in CLCA2 at 
AA 29-208). As the essential residues which might be involved in the formation of the 
predicted hydrolase domain are conserved, it was started to analyse the proteolytic 
activity of CLCA2 in more detail. Experiments with matrixmetalloprotease-inhibitors 
such as Phenantrolin, Diprotin B, Bestatin, Amastatin and others did not allow to 
draw any valid conclusions as most of these compounds are quite toxic and can only 
be used at very low and thus uneffective concentrations in tissue culture. Next, all 
conserved Cysteine residues in the coding region of CLCA2 which are located within 
the region where the putative hydrolase domain is embedded were exchanged. 
Mutation of conserved Cysteines at position C211 and C216 still allowed a residual 
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proteolytic activity to take place although at a very low level. Mutations at C132, 
C196, and C206 completely abolish the proteolytic processing (Figure 46, Figure 48). 
Whether the inhibitory effects of the respective mutations are due to the influence on 
the correct formation of the active site or are due to a more general influence on the 
overall structure and/or stability is not clear yet. C132 corresponds to the Cysteine 
residue which is suggested to keep H140 (equivalent AA in CLCA1: H133) the 
proposed structural metal site (Zn2+ coordination) in correct orientation. Next, the 
corresponding sites in CLCA2 which might be directly involved in the formation of the 
catalytic site were mutated. The exchange of basic Histidines H164 and H168 with 
Cysteine (polar), Tyrosine (polar) or Asparagine (polar) completely inhibits cleavage 
of CLCA2. Exchange of Glutamic acid E165 with Aspartic acid or Glutamine also 
completely inhibits cleavage. Based on the modelling data from Pawlowski et al. [65] 
these residues are supposed to take part in the formation of the putative catalytic 
site. These results strongly supports the presence of a zincin-like hydrolase domain 
in the N-terminal region of CLCA2 as well. Furthermore, by generating hydrolase 
dead mutants it could be shown that the proteolytic activity is an autocleavage rather 
than a trans cleavage event managed by an additional cellular protease. Whether 
this autocatalytic activity is performed in cis or trans is still open. However, to clearly 
demonstrate a 1/1 molar ratio of the CLCA2 protein and Zn2+ further experiments are 
needed [155]. 
Putative Cleavage Site  
As known from bioinformatic analyses and literature [95], a mono basic cleavage site 
is predicted at position AA674. Mutational analysis by “Alanine-walking”, starting from 
predicted positions P5 to P4’ (AA670 to AA678) by subsequent and stepwise 
substitution of the respective amino acid to an Alanine, were performed. Additionally, 
at those positions where the cleavage activity could be abolished after introduction of 
an Alanaine, additional exchanges were performed at the respective position. In 
particular at positions P3, P1, P1’, and P2’ all classes of amino acids i.e. amino acids 
with basic, acidic, non-polar or uncharged polar side chain) were introduced. These 
positions have been chosen as they are in most cases the cleavage specificity-
determining amino acids [156]. Data from this study support this idea as predicted 
position P1 (AA674) strictly not allows any exchange of Arginine with others than 
Lysine (both AA contain a basic side chains). According to the mutational analysis 
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the cleavage recognition site might be as follows: P3(Tyr/Phe) – P2(X) – P1(Arg/Lys) 
– P1’(Tyr/Phe) – P2’(Phe/Ala). 
Inhibition of Post-Translational Modifications 
For investigation of post-translational modifications of CLCA2 (glycosylation, 
isoprenylation) and their contribution to stabilisation and/or proteolytical processing, 
expression of CLCA2 was studied in the presence of the glycosylation inhibitor 
Tunicamycin and the isoprenylation inhibitor Perillic acid. By utilising the T47D Tet-on 
inducible expression system for wt-CLCA2 it could be shown that both, the stability 
and the proteolytic processing are impaired when glycosylation is inhibited. How 
glycosylation influences the post-translational processing is unclear. Two scenarios 
are conceivable: Either impaired glycosylation leads to incorrect folding and 
protection of the cleavage site or leads to a misguided cellular localisation where 
proteolytic processing cannot take place. Another explanation would be that the 
cleavage product of non-glycosylated CLCA2 becomes degraded and therefore 
cannot be detected on Western blots.  
Based on these data it was decided to mutate the putative glycosylation sites in 
CLCA2. The use of several glycosylation site prediction software tools resulted in 
prediction of the putative glycosylation sites N150 (located within the predicted 
hydrolase domain) and N822. Point mutations resulting in exchange of Asparagine to 
Alanine of these two sites had no influence on the cleaving efficacy. However, 
mutating N822 resulted in a shorter C-terminal fragment after cleavage, indicating 
that an incorrect positioning of the cleavage site (e.g. triggered by loss of 
gylcosylation) leads to processing at another site with a related amino acid motif. 
Integrin β4 
Abdel-Ghany found Integrin β4 to be coprecipitated with CLCA2 [70]. He also 
identified a strong correlation between the level of Integrin β4 and adhesion of 
HEK293 cells expressing CLCA2, and a correlation between Integrin β4 expression 
in tumourigenic cell lines in vivo and the number of lung metastases detected in nude 
mice [70]. Upregulated Integrin β4 levels were also found in microarray studies of 
lung cancer metastases [74]. 
Based on data of expression profiling on Affymetrix GeneChips, it could also be 
identified an enhanced Integrin β4 expression upon induction of CLCA2 expression. 
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Whether the upregulation leads also to an enhanced activation status of Integrin β4 
or not, could not be answered due to the lack of any functional phosho-specific 
antibodies for Integrin β4. As members of the integrin protein family are known to be 
involved in cell attachment to proteins of the extracellular matrix, integrins therefore 
play an important role in metastasis, regulating not only dissemination, but also 
homing of metastasising tumour cells [157]. To gain a more detailed understanding 
about the specific induction of integrins upon induced CLCA2 expression, integrin-
mediated cell adhesion assays were performed. The “Integrin-Mediated Cell 
Adhesion Arrays” (Chemicon) are efficient tools to screen cell surface protein 
profiles. The method is based on stripwells with each well pre-coated with an 
antibody detecting an individual integrin or extracellular matrix protein. Utilising the 
established inducible expression system for CLCA2, it was possible to screen for 
induction of α- and β-integrins in dependence on induction of wt- or mutant-CLCA2 
expression in T47D Tet-on cells (control: T47D cells which stably carry the “empty” 
expression vector). Out of the α-integrin family no specific induction could be 
detected, whereas for β-integrin family member B2 a specific induction upon CLCA2-
induced expression could be demonstrated (Figure 56, Figure 57).  
3D-In Vitro Carcinoma Assay: Spheroids 
For a better simulation of the situation in a tumour, CLCA2-expressing clones were 
also grown in multicellular tumour spheroids, which are in vitro 3D models that 
recapitulate malignant cell contacts within a tumour. Multicellular tumour spheroids 
can for instance also be used to evaluate the tumour’s response to therapeutic 
agents or the interaction with cells of the tumour stroma, e.g. the von Willebrand 
factor domain in CLCA2 was previously shown to have a role in adhesion by binding 
at Integrin β4 [158] and preliminary experiments confirmed at least the interaction 
with members of the β-integrin family (see above).  
In the corse of this study the in vitro 3D model [159] was used for analysis of the 
influence of expression of active and inactive CLCA2 on three-dimensional cell 
growth and viability. Since not all cell lines or cell types are capable of forming 
spheroids, first a cell line capable of spheroid formation had to be selected. 
Fortunately, cell line T47D which was used to establish constitutive and inducible 
CLCA2-expressing clones could be cultivated as spheroids. Stable spheroids were 
transferred to a collagen gel or Matrigel and grown until they became necrotic and/or 
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apoptotic due to the lack of supply with nutrients and oxygen in the centre of the 3D 
spheroid, which are normally provided by de novo formed vessels, docking the 
growing tumour to the existing blood vessel system of the organism 
(neoangiogenesis).  
In a statistically meaningful setting the relative cell growth of 2D- (counting viable 
cells) with that of 3D-cultures (determination of area [µm2]; Figure 63) was compared 
over a period of 3 to 10 days. Although, the relative cell growth of CLCA2-expressing 
T47D Tet-on clone #3 in induced versus non-induced status did not show a 
difference in 2D-cultures, it indeed exhibited a pronounced difference (> 2.5-fold) 
between 2D- and 3D-culturing. In contrast to CLCA2-inducible clone #3, the 
constitutive clone #47 showed already an enhanced relative cell growth in 2D-culture 
which was similar to that found in 3D-cultures. In general, constitutive CLCA2 
expression during spheroid-formation lead to generation of larger spheroids and 
subsequently to enhanced apoptosis due to a higher proliferation rate. Without using 
the 3D-spheroid model, detection of the essential contribution of CLCA2 for a three-
dimensional growth wouldn’t have been possible. It is also of interest that CLCA2 
mutants defective in their proteolytic processing apparently had no influence on 
spheroid formation or growth properties of spheroids. Therefore, maturation 
processing of CLCA2 seems not to have an impact on the three-dimensional growth 
of this cell line.  
Affymetrix Microarray Studies 
To study the effects of overexpression of CLCA2 on gene expression, expression 
profiling using the Affymetrix GeneChip Human Genome U133 Array was performed 
by comparing cell clones with induced expression of CLCA2 with their uninduced 
counterparts. In a separate experimental setting, the expression pattern for selected 
transcripts was confirmed by RT-qPCR. Among those (and besides CLCA2, which 
served as an internal control), genes such as CDIPT, MLL2 and SFI1 were identified. 
CDIPT (CDP-diacylglycerol-inositol 3-phosphatidyltransferase; phosphatidy inositol 
synthase) is a gene whose inhibition causes small cell lung carcinoma cells to arrest 
in G1 [98]. It further has been suggested to be involved in oral carcinogenesis [99]. 
MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2) plays a role in apoptosis and 
in alterations of cell adhesion. MLL2 is a member of the human MLL family, which 
belongs to a larger SET1 family of histone methyltransferases. MLL2 is a 
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transcriptional activator that induces the transcription of target genes by covalent 
histone modification. MLL2 appears to be involved in the regulation of adhesion-
related cytoskeletal events, which might affect cell growth and survival [100]. 
Members of the MLL protein family have been found to cause acute leukemia. 
Recently, deletion studies revealed that alterations of the CxxC domain (Zn-binding 
domain) disrupts its oncogenic potential [101]. SFI1 (SFI1 homolog, spindle 
assembly associated; yeast) is involved in initiation of centrosome duplication. SFI1 
has been identified as a binding partner for the Ca2+-binding protein centrin, 
suggesting a role in the dynamic behavior of centrosomes. SFI1 binds to multiple 
centrin molecules and the complex forms Ca2+-sensitive contractile fibers that 
function to reorient centrioles and alter centrosome structure [96]. So far no 
correlation to tumour cell growth has been reported. However, according to the in 
silico analysis of this study, SFI1 is found upregulated in many tumours, with highest 
expression levels found in various B cell lymphomas and B cell leukemias (data not 
shown).  
In total, approximately 150 genes were shown to be differentially up- or 
downregulated in a statistically relevant mode (fold change > 1.8; p-value < 0,0001). 
In order to link these expression profiles of regulated genes to canonical pathways 
and bring them into a biological context, these data were analysed with the Ingenuity 
Pathways Analysis Software (IPA; of Ingenuity Systems Inc.). This program is a text- 
and data-mining program which not only links gene and protein functions/interactions 
based on the knowledge of published data in the most relevant journals, but also 
allows to bring these interactions into a context of biological functions, regulatory 
cascades and functional groups (e.g. oncology/metastasis/prostate). It has to be 
mentioned that the presented studies can only be regarded as preliminary as the 
outcome of these in silico analyses has to be proven in experimental settings. On the 
other hand these data allow a much more focused proceeding for future experiments 
as this text- and data-mining program not only describes protein-protein interactions, 
but also other types of reciprocal action such as protein-nucleic acid interactions.  
Based on these in silico analyses several interaction-networks were identified. 
Network I (Figure 85) indicates that a group of specifically induced genes upon 
induction of CLCA2 is strongly linked to the interaction-axis of SMAD3–TP53–MYC– 
HNF4A–ERBB2. It has been shown recently that HNF4alpha1 (HNFA4) and the 
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proliferation factor c-Myc may compete for control of genes involved in cell 
proliferation and differentiation [160]. 
Network II (Figure 86) comprises a link to the TNF–IL2–IL10 interaction network. 
Interestingly, treatment of SCCs of the skin with a Toll-like receptor agonist such as 
imiquimod contained a decreased percentage of regulatory T (T reg) cells producing 
less IL10 and TGF-beta, thereby inhibiting their suppressive activity. This means that 
SCCs evade the immune response at least in part by recruiting T reg cells via 
modulation of the IL10 pathway [119].  
Network III (Figure 87) brings some of the differentially upregulated genes into the 
context of the ERK–MAPK signaling cascade with ERK as the center of this network. 
The most significant networks were then merged (Figure 88), for the sake of 
simplicity focusing exclusively on protein-protein interactions, highlighting biologically 
interesting clusters such as the cluster of v-src (involved in regulation of many 
different signaling cascades), HNFA4, ERBB2, and KPNA2. Karyopherin 2 (KPNA2), 
for instance, is a member of the karyopherin (importin) family, which is part of the 
nuclear transport protein complex. KPNA2 is responsible for transfer of the repair 
complex RAD50–MRE11–NBS1 into the nucleus. The cytoplsamic portion of NBS1 
promotes tumourigenesis through the binding and activation of the PI3-kinase/AKT 
pathway which is dependent on KPNA2 [161]. Previously KPNA2 overexpression 
was identified as a prognostic marker in breast cancer correlating with poor survival 
[162]. KPNA2 was also shown to be highly upregulated in esophageal cancer [163].  
In a next step, the involvement of canonical signaling transduction pathways were 
investigated by phospho-proteomic studies. To learn more about the contribution of 
some important executer proteins of canonical pathways, which might be found 
activated/deactivated (=phosphorylated/dephosphorylated) in experimental settings 
of CLCA2 induction, cell lysates of induced and non-induced T47D Tet-on clone #3 
cells (taken at various time points) were analysed an Western blots utilising phospho-
specific antisera. 
An increase in phosphorylation of AKT (S473), ERK 1&2 (T185/Y187), MAPK 
(T202/Y204), RAF (S259), CRAF (S338), and PDK1 (S241) was observed. No 
change in the phosphorylation pattern was seen for AKT at position S308. These 
data confirm the predictions made through the usage of the IPA software, indicating a 
link to the ERK–MAPK canonical pathway. From literature it is known that in 
oropharyngeal squamous cell cancer patients phopshorylation of AKT at S473 is 
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linked with a poor clinical outcome [164]. The malignant potential of SCC cell lines 
was shown to be significantly higher in CRAF-expressing cells and CRAF expression 
maintained also the radiation-resistant phenotype indicating that CRAF plays an 
important role in the squamous cell carcinogenesis [165]. Phosphoinositide-
dependent kinase 1 (PDK1), a downstream target of PI3-K, has been recently 
suggested to take part in the signaling cascade of gastrin releasing peptide [(GRP)-
Src-PI3K-PDK1-TACE-amphiregulin-EGFR] with multiple points of interaction leading 
to induction of proliferation of human head and neck squamous cells [166].  
Analysed proteins which were found to be dephosphorylated upon CLCA2-induction 
are: mTOR (p2448), 4E-BP1 (T37/T47), STAT1 (Y701), and NPM (T234/T237). 
Deregulation of mTOR, 4E-BP1, STAT1 indicates a strong impact of CLCA2 to 
translational modulation whereas nucleophosmin (NPM) is involved in cytoskeletal 
regulation [120].  
The phosphorylation and dephosphorylation upon CLCA2-induction of selected 
proteins was also analysed with the “Human Phospho-MAPK Array Kit” and “Human 
Phospho-RTK Array Kit” of R&D Systems. Performing these assays, a higher 
phosphorylation and therefore activation level for ERK1 and ERK3 could be 
confirmed in CLCA2-constitutively-expressing T47D clone #47 compared to control 
cells (empty vector). In addition, a higher phosphorylation level of EGF-R, Insulin-R, 
and IGF-I R was found in T47D clone #3 cells upon induction of CLCA2. The 
biological meaning of these findings is supported by recent publications e.g. showing 
that a worse tumour differentiation and a positive nodal stage in head and neck SCC 
are significantly associated with EGFR overexpression. In contrast to NSCLC, protein 
overexpression rather than mutation might be responsible for activation of the EGFR 
pathway in head and neck SCC [167]. 
Summary 
In the context of targeted therapy, ion channels are representing promising players. 
However, very little is known about their specific contribution to tumourigenesis. In 
the course of this Thesis a preferential overexpression of CLCA2 in human 
squamous cell carcinomas (SCC) of different origins including their lymph node 
metastases could be demonstrated. In addition, overexpression was also detected in 
mycosis fungoides, a cutaneous T cell lymphoma and in a subset of infiltrating ductal 
breast cancers. Preliminary IHC analyses confirmed expression in human SCC 
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samples. In silico expression analyses identified a dramatic increase in CLCA2 
expression when SCC cell lines are xenografted into nude mice supporting that 
CLCA2 plays an important role in late stage tumourigenesis.  
Loss-of-function studies in SCC cell lines by siRNA-mediated knock-down of CLCA2 
leads to inhibition of proliferation, to reduction in viability, subsequently to induction of 
apoptotic processes, and to an arrest in G2. In contrast, breast cancer cell lines 
stayed unaffected at least in 2D-tissue culture. Inducible expression of CLCA2 in 
tumour cells in combination with a detailed mutational analysis demonstrated a 
proteolytic (most likely autocatalytic) processing (hydrolase) activity of CLCA2 and 
proposed a structural metal site for Zn2+ coordination. Altogether, these data strongly 
supports the presence of a zincin-like hydrolase domain in the N-terminal region of 
CLCA2. As predicted by bioinformatic analyses and in analogy to CLCA1 a mono 
basic cleavage site was predicted and could be confirmed by “Alanine-walking” 
mutagenesis with a predicted cleavage recognition site of P3(Tyr/Phe) – P2(X) – 
P1(Arg/Lys) – P1’(Tyr/Phe) – P2’(Phe/Ala). Inhibition of glycosylation revealed that 
both, the stability and the proteolytic processing are impaired when glycosylation is 
inhibited.  
For a better simulation of the situation in a tumour, CLCA2-expressing clones were 
also grown in multicellular tumour spheroids. In statistically meaningful experimental 
settings, the relative cell growth rate of 2D- and 3D-cultures was compared and 
indeed a > 2.5-fold increase in proliferation in the three-dimensional system could be 
demonstrated upon induction of CLCA2 expression. 
For a better understanding of the involvement of CLCA2 in signal transduction a 
comprehensive expression profiling study on Affymetrix GeneChips was performed, 
followed by RT-qPCR and phospho-proteom studies with selected genes. In total      
~ 150 genes were shown to be differentially regulated upon induction of CLCA2 
expression. Among those genes are CDIPT, MLL2, and SFI1, which play an 
important role in cell cycle regulation. Utilising Ingenuity Pathways Analysis – a text- 
and data-mining program – several interaction-networks were identified. All of them 
could be linked with important canonical signal transduction cascades or interaction 
networks such as the TNF–IL2–IL10 interaction network or the ERK–MAPK signaling 
cascade. Phospho-proteom studies confirmed these findings and additionally 
identified a strong impact of CLCA2 on translational modulation.  
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Although these expression profiling data can only be regarded as preliminary, they 
however, offer the basis for further focused studies for the characterisation of CLCA2 
as a promising target in SCC tumourigenesis. 
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MATERIAL AND METHODS 
Molecular Biology 
Total RNA Isolation 
The medium was removed and cells were directly lysed on the plates using 1 ml 
Trizol reagent (Invitrogen, Cat.# 15596-018) per 10 cm² of tissue plate. To ensure 
total lysis of the cells the suspension was pipetted up and down several times. The 
lysate was stored at -20°C, or used directly for RNA isolation. 
For RNA isolation, the lysate was incubated for at least 5 min at RT (room 
temperature) to ensure complete dissociation of nucleoprotein complexes. 0.2 ml 
Chloroform (CHCl3) per ml Trizol was added, vortexed for about 15 sec and 
incubated for 2-3 min at RT. Afterwards the lysate was centrifuged at 10,000 rpm for 
5 min at 4°C and the upper aqueous phase was transferred into a fresh RNAse free 
tube.  
The RNA was precipitated using 0.5 ml isopropanol per ml Trizol by incubating at 
least 10-15 min at 4°C. Subsequently the RNA was spun down by centrifugation at 
15,000 rpm for 5 min at 4°C. The RNA pellet was washed with 75 % RNAse-free 
Ethanol and centrifuged at 15,000 rpm for 5 min at 4°C. The supernatant was then 
removed and the pellet was air dried.  
Finally, the RNA was resuspended in 10 µl DEPC-H2O and frozen at -20°C or used 
immediately for single strand cDNA (ss cDNA) synthesis.  
Frozen tumour samples were sectioned and subsequently lysed in 200 µl RLT buffer 
of RNAeasy Kit (Qiagen, Cat.# 74104) and total RNA was isolated following 
instructions of the provider. 
Single Strand cDNA Synthesis (First Strand Synthesis) 
For ss cDNA synthesis the extracted total RNA was reverse transcribed using the 
“SprintTM PowerScriptTM PrePrimed SingleShots with Random Hexamer Primers” 
from Clontech (Cat.# 639562). 
To eliminate putative contaminations with genomic DNA, 1 ug total RNA was 
digested with 1 U DNAseI for 30 min at 37°C. The reaction was stopped by the 
addition of 2.5 mM EDTA and incubation at 65°C for 10 min. For ss cDNA synthesis 
10 µl DEPC-H2O (di-ethyl-propyl carbonate-treated H2O) was added to the 
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lyophilised kit components and the DNA-free RNA was also added. The reaction was 
incubated for 60 min on 42°C. The ss cDNA was stored at -20°C, or used for further 
investigations. 
Real-Time Quantitative PCR (RT-qPCR) 
For RT-qPCR cDNA samples were prepared following the instructions as described 
above. Analyses were performed with commercially available gene-specific “TaqMan 
Gene Expression Assays” of Applied Biosystems for the genes listed in Table 5. 
 
Gene of Interest Cat.# and Label 
CLCA2 Hs00197957, FAM 
SATB1 Hs00161515, FAM 
SFI1 Hs00826823, FAM 
MLL2 Hs00231606, FAM 
EP300 Hs00914223, FAM 
CDIPT Hs00197004, FAM 
TP53BP1 Hs00996818, FAM 
LTBP1 Hs00386448, FAM 
TSC1 Hs00184423, FAM 
MACF1 Hs00201468, FAM 
DTX2 Hs00539707, FAM 
CHD6 Hs00260089, FAM 
AFF4 Hs00232683, FAM 
UNC84A Hs00391956, FAM 
RUTBC3 Hs00210437, FAM 
P4HA2 Hs00188349, FAM 
C10orf118 Hs00215984, FAM 
ASPM Hs00411505, FAM 
 
Table 5. Genes which were tested in “TaqMan Gene Expression Assays” (Applied Biosystems) 
 
In all gene expression assays, a FAM-dye labelled minor-groove-binder probe linked 
to a non-fluorescent quencher is used in combination with two non-labelled flanking 
primers. Probe and primers are sequence-specific for the respective gene of interest. 
The fluorescent signal is generated due to the release of the quencher from the FAM-
labelled probe after the induction of DNA-synthesis from the two flanking primers.  
As endogenous control the “Taq Man Gene Expression Assays” of the 
“housekeeping gene” β-2-microglobulin (Applied Biosystems, Cat.# 4326319E) was 
used, which is VIC-labelled and can be measured parallel to the FAM-channel. 
For all assays the “Taq Man Gene Expression Master Mix” (Applied Biosystems, 
Cat.# 4369016) was used. Quantification and analyses were performed by the 
Mx4000 device from Stratagene, using the provided software package. 
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For RT-qPCR the following reagents were combined: 
 
reagent       µl per reaction tube 
cDNA-sample   2 
2x TaqMan Gene Expression Master Mix 12.5 
20x target primers and probe   1.25 
20x control primers and probe (of B2M)   1.25 
nuclease-free water   8 
total volume 25 
 
Cycling Parameters for RT-qPCR using MX4000, Stratagene: 
1 cycle: 10 min 95°C
40 cycles: 15 sec 95°C
  1 min 60°C
hold at:    4°C
 
PCR (Polymerase Chain Reaction) 
PCR-Amplification 
This method was used to amplify specific DNA-fragments by using rapid changes in 
temperature and a DNA-Polymerase in connection with dNTPs and specific primers 
for the DNA sequences of interest. 
For amplification of CLCA2, the commercially available vector „Human Full-Length 
cDNA Clone in pCMV6-XL4” from Origene (Cat.# TC116023,  Acc. NM_006536: 
Human calcium-activated chloride channel, family member 2 (CLCA2)) was used as 
template.  
 
For the amplification reaction the following reagents were combined: 
 
reagent µl per reaction tube 
aqua dest.            30 
10x Pfx amplification buffer 5 
10 mM dNTP mixture  1.5 
PCR primer forward (5 pmol/µl) 5 
PCR primer reverse (5 pmol/µl) 5 
50 mM MgSO4 1 
DNA template (plasmid: 10 ng/µl) 2 
Platinum Pfx DNA polymerase (2.5 U/µl) 0.5 
total volume 50 
 
The following amplification parameters were designed to be used in a “PE GeneAmp 
PCR System 2400” or “PE GeneAmp PCR System 9700”: 
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1 cycle:   2 min 94°C
30 cycles: 15 sec 94°C
30 sec 55°C
  3 min 68°C
1 cycle: 10 min 68°C
hold at:    4°C
 
Aliquots of 5 µl per reaction were analysed by electrophoresis on ethidiumbromide- 
(EtBr) stained 4 % agarose gels and amplified DNA-fragments were visualised on an 
UV-transilluminator. 
Colony Screening 
Colony PCR screening was used for rapid determination of positive transformants. 
Bacterial colonies were picked from the agar plate, boiled for 10 min in 100 µl TE, 
either in water bath or in a thermocycler. The suspension was cooled down on ice 
and 2 µl suspension was pipetted into a PCR tube for amplification. 
The following reagents were combined: 
 
reagent       µl per reaction tube 
aqua dest. 12.2 
10x PCR buffer 2 
dNTP mix (2.5 mM each) 1.6 
PCR primer down (5 pmol/µl) 1 
PCR primer up (5 pmol/µl) 1 
boiled E. coli solution 2 
Taq polymerase (5 U/µl) 0.2 
total volume 20 
 
The following amplification parameters were chosen in a “PE GeneAmp PCR System 
2400” or “PE GeneAmp PCR System 9700” with a minimum of 1 min of elongation 
time and per additional 1000 bp one extra min for elongation. 
 
1 cycle: 3 min 94°C
28 cycles: 1 min 94°C
1 min 55°C
1 min 72°C
1 cycle: 7 min 72°C
hold at:    4°C
 
Aliquots of 5 µl per reaction were analysed by electrophoresis on EtBr-stained 4 % 
agarose gels and amplified DNA-fragments were visualised on an UV-
transilluminator. Colonies corresponding to samples, which showed an amplification 
product of the correct size, were picked and grown in 2 ml respective medium o/n 
and used for plasmid purification. 
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Cloning PCR Products (TA-Cloning) 
The method is based on the non-template-dependent activity of Taq polymerase 
which adds a single desoxadenosine to the 3’-end of a PCR product. The fragment 
can then be ligated to a vector (pGEM-T Easy Vector of the “pGEM-T Easy Vector 
System” (Promega, Cat.# A1380)) containing a desoxythymidine residue overhang.  
Usually, 3 µl of fresh PCR product (10-20 ng/µl) was directly ligated to the pGEM-T 
Easy Vector (50 ng/µl). 
If the PCR product was amplified via a polymerase with proof-reading activity (e.g.  
Platinum Pfx from Invitrogen), a desoxadenosine had to be added to the 3’-end of the 
purified PCR product (see “A-Tailing of PCR-Products”).  
The ligation reaction was performed o/n at 14°C into 50 ng vector in a total volume of 
10 µl containing 1 µl 10x ligation buffer, 1 µl pGEM-T Easy Vector (50 ng) and 1 µl T4 
DNA ligase (3 U/µl). For highest efficacy the molar ratio (vector : PCR product) 
should be between 1:1 and 1:3. The ligation product was immediately used for 
transformation or stored at -20°C. 
A-Tailing of PCR Products 
To add a desoxadenosine to the 3’-end of the purified PCR product, which is relevant 
if such PCR product should be directly cloned to the pGEM-T Easy Vector, the 
following reagents were combined: 
 
reagent       µl per reaction tube 
purified DNA-sample 7 
dATP 2 mM 1 
10x buffer 1 
rTaq-polymerase (e.g. TakaRa) 5 U/µl 1 
total volume 10 
 
The reaction mixture was incubated for 30 min at 70°C and then directly ligated to the 
pGEM-T Easy Vector. For this, the following reagents were combined: 
 
reagent       µl per reaction tube 
A-getailte DNA-Lsg. 7 
pGEM-T Easy Vector 1 
10x Ligation buffer (Fermentas) 1 
T4-Ligase (Fermentas) 1 
total volume 10 
 
The ligation was performed at 14°C o/n. 
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Restriction Digestion 
DNA was digested with restriction endonucleases for about 2 h at 37°C in the 
appropriate buffer with 3-fold excess (3 U/µg DNA) of restriction enzyme; standard 
enzymes from e.g. Fermentas, New England Biolabs, Invitrogen were used. 
After digestion the enzymes were heat-inactivated at 70°C for 10 min. 
The reaction mixture was directly used for further reactions, purified with “QIAquick 
PCR Purification Kit”, or the DNA was precipitated or separated on agarose gels. 
Filling 5’-Overhangs with dNTPs 
The 5’-3’ polymerase activity of “DNA Polymerase I Large (Klenow) Fragment" can 
be used to fill in 5’-protruding ends, which result from restriction digestion with 
dNTPs. The optimal reaction conditions are: 
 
1-4 µg digested DNA 
50 mM Tris-HCl (pH 7.2) 
10 mM MgSO4 
0.1 mM DTT 
40 µM of each dNTP 
20 µg/µl acetylated BSA 
1 U/µg DNA Klenow fragment 
 
Klenow fragment is active in many restriction enzyme buffers, so in most cases the 
heat-inactivated reaction mix from restriction digestion was directly taken for filling, 
1.5 µl dNTP mix (2.5 mM each) and 1 µl Klenow fragment (5 U/µl) were added.  
In some cases DNA was first purified by phenol/chloroform extraction and ethanol 
precipitation or by using the QIAquick PCR purification Kit. After resuspending DNA 
the Klenow 10 x Buffer, 1.5 µl dNTP mix (2.5 mM each) and 1 µl Klenow fragment 
(5 U/µl) were added.  
The reaction mix was incubated at RT for 10 min.  
The reaction was stopped by heating the mixture for 10 min at 75°C. 
Converting a 3’-Overhang to a Blunt End 
T4 DNA Polymerase exhibits 5’-3’ polymerase activity, and 3’-5’ exonuclease activity 
as well, and can be used for the generation of blunt ends from DNA molecules with 
3’-overhangs, or for fill 5’-protruding ends with dNTPs. 
For converting a 3’-overhang to a blunt end, DNA was digested in a volume of 50 µl 
with a restriction enzyme that generates a 3’-overhang. 
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The optimal reaction conditions are: 
 
0.5-2 µg digested DNA 
33 mM Tris-Ac (pH 7.9) 
66 mM KAc 
10 mM MgAc2 
0.5 mM DTT 
0.1 mg/ml BSA 
5 U/µg DNA T4 DNA polymerase 
 
T4 DNA Polymerase can also be used directly in restriction enzyme buffer. 
In most cases 2 µl T4 DNA Polymerase (3 U/µl) was added directly to the heat- 
inactivated reaction mix of the restriction enzyme digestion. 
This reaction mix was then incubated at 37°C for 5 min. 
The reaction was stopped by heating the mixture for 10 min at 75°C. 
In Vitro Site-Directed Mutagenesis 
Site-specific mutations in double stranded (expression-) plasmids were inserted by 
using the „QuikChange II XL Site-Directed Mutagenesis Kit” from Stratagene (Cat.# 
200522). 
The method is based on the utilisation of PfuUltra high-fidelity (HF) DNA polymerase 
for mutagenic primer-directed replication of both plasmid strands. The basic 
procedure utilises a supercoiled double-stranded DNA vector with an insert of 
interest and two synthetic oligonucleotide primers, both containing the desired 
mutation. The primers, each complementary to opposite strands of the vector, are 
extended during temperature cycling by DNA polymerase, without primer 
displacement. Extension of the oligonucleotide primers generates a mutated plasmid 
containing staggered nicks. Following temperature cycling, the product is treated with 
DpnI, an endonuclease specific for methylated and hemimethylated DNA, which is 
used to digest the parental DNA template and to select for mutation-containing 
synthesised DNA. The nicked vector DNA containing the desired mutations is then 
transformed into competent cells. 
The primer length should be between 25 and 45 bases, with a melting temperature 
(Tm) of ≥ 78°C. The desired mutation should be in the middle of the primer with        
~ 10-15 bases of correct sequence on both sides. The primers should have a 
minimum GC content of 40 % and should terminate in one or more C or G bases. 
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For mutant strand synthesis reaction the following reagents were combined: 
 
reagent       µl per reaction tube 
10x reaction buffer 5 
template (50 ng/µl) 1 
forward Primer (5 pmol/µl)  2.5 
reverse Primer (5 pmol/µl) 2.5 
dNTPmix 1 
QuikSolution reagent 3 
H2O 34 
PfuUltra polymerase (2.5 U/µl) 1 
total volume 50 
 
The following amplification parameters were chosen in a “PE GeneAmp PCR System 
2400” or “PE GeneAmp PCR System 9700”: 
 
1 cycle:   1 min 95°C
18 cycles: 50 sec 95°C
50 sec 60°C
  9 min 68°C
1 cycle:   7 min 68°C
hold at:    4°C
 
1 µl of the DpnI restriction enzyme (10 U/µl) was added directly to each amplification 
reaction and incubated for 60 min at 37°C. 2 µl of the DpnI-treated amplified DNA 
was transformed to E. coli (for details see “Transformation of Bacteria”). The DNA of 
at least 3 colonies was isolated by “Miniprep” and sequenced. 
Purification of DNA  
For purification of DNA, the “QIAquick PCR Purification Kit” of Qiagen (Cat.# 28104) 
was used. This method is adapted to purify single- or double-stranded DNA-
fragments from PCR and other enzymatic reactions. Fragments ranging from 100 bp 
to 10 kb are purified from primers, nucleotides, polymerases, and salts. 
5 volumes of buffer PB was added to 1 volume of the sample and mixed. The sample 
was then applied to a QIAquick column and centrifuged for 30-60 sec at 13,000 rpm. 
The flow-through was discarded and the column placed back to the same tube.  To 
wash bound DNA, 0.75 ml buffer PE was added to the QIAquick column and 
centrifuged for 30-60 sec. The flow-through was discarded, the column placed back 
to the same tube. Then the column was centrifuged for additional 1 min, the flow-
through was again discarded and the column placed in a clean 1.5 ml tube. To elute 
DNA, first 15 µl buffer EB was added to the centre of the QIAquick membrane and 
after 1 min centrifuged for 1 min. To increase DNA concentration another 10 µl buffer 
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EB was added and after 1 min centrifuged for 1 min. The average eluate volume is 
22 µl from 25 µl elution buffer volume. 
Phenol/Chloroform Extraction of DNA 
This method removes proteins from nucleic acid solutions. 
Equal volumes of phenol/chloroform/isoamylalcohol 25:24:1 (v/v/v) and DNA solution 
were mixed by vortexing for 20 sec and centrifuged 5 min at RT with 15,000 rpm. The 
upper aqueous phase was transferred to a fresh tube and extracted with 24:1 (v/v) 
chloroform/isoamylalcohol. The sample was again mixed by vortexing for 20 sec, 
centrifuged for 5 min at RT and the aqueous upper phase transferred to another 
fresh tube. DNA was precipitated with ethanol. 
Precipitation of DNA/RNA 
DNA was precipitated by adding 0.1 volumes of 3 M NaAc, pH 5.2 and 2.5 volumes 
of ice-cold 96 % ethanol for at least 3 h at -80°C. The most quantitative precipitation 
will be achieved when incubating at -20°C o/n and centrifugation for 30 min at 
15,000 rpm at 4°C. The supernatant was removed and the pellet was washed with 
500 µl 70 % ethanol (-20°C) and air dried or briefly dried under vacuum in a vacuum 
concentrator (Speedvac). The DNA pellet was dissolved in an appropriate amount of 
elution buffer EB (10 mM Tris-HCl, pH 8.5). For precipitation of RNA the same 
protocol is valid, but DEPC-treated solutions have to be used. 
Alternatively, DNA or RNA can be precipitated with 1 volume of isopropanol without 
sodium acetate. This is of advantage for large volumes. 
Agarose Gel Electrophoresis 
Depending on the expected DNA-fragment length agarose-gels ranging from  
0.7-4 % agarose were prepared. The agarose was suspended in 1x TBE and shortly 
boiled in the microwave until the agarose was completely dissolved. The agarose 
solution was cooled to approximately 50°C and supplemented with EtBr from a stock 
solution (10 mg/ml) to a final concentration of 1 µg/ml. The mixture was pored into a 
gel tray and an appropriate comb was stacked into the tray. When the gel was 
completely solidified the comb was removed and the gel tray was put into the gel 
chamber containing 1x TBE as running buffer. The samples were mixed in a ratio of 
6:1 with 6x loading buffer. Gels were run at 50-200 V depending on the gel size      
(3-5 V/cm in horizontal configuration). 
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Recovery of DNA from Agarose Gels 
With the “QIAEX II Agarose Gel Extraction Kit” of Qiagen (Cat.# 20021), DNA of 
40 bp to 50 kb can be extracted and purified from standard or low-melting agarose 
gels in TAE or TBE buffers. Up to 400 mg Agarose can be processed per spin 
column. 
The DNA fragments were separated on an agarose gel and fragments of interest 
were excised with a clean, sharp scalpel. The agarose pieces were transferred into 
2 ml Eppendorf tubes and weighted before filling and afterwards. 3 volumes of buffer 
QG was added to 1 volume of agarose gel and incubated for 10 min in an Eppendorf 
thermoblock at 50°C to achieve total dissolution of the gel matrix. Then 1 gel volume 
isopropanol was added and the solution was mixed. A QIAquick spin column was 
placed in a 2 ml collection tube. The samples were applied onto these columns and 
centrifuged for 1 min at 15,000 rpm. The flow-through was discarded. To remove all 
traces of agarose 0.5 ml buffer QG was added and the column centrifuged again for 
1 min at 15,000 rpm. The column was washed with 0.75 ml buffer PE. After 2-5 min 
the column was centrifuged for 1 min at 15,000 rpm. The flow-through was discarded 
and the QIAquick column was centrifuged for an additional min to remove residual 
ethanol of the PE buffer. Then the column was placed into a fresh 1.5 ml Eppendorf 
tube. To elute DNA 30 µl buffer EB was transferred directly on the center of the 
column. After 1 min incubation, the column was centrifuged for 1 min at 15,000 rpm. 
Alternatively to the described method, the “QIAquick Gel Extraction Kit” of Qiagen 
(Cat.# 28704) was used and performed according to the instructions in the manual. 
Ligation of DNA 
An insert of interest could be amplified by PCR or “restricted out” from a plasmid 
containing the insert. Prior to ligation DNA had to be purified using a “QIAquick PCR 
Purification Kit” or “QIAEX II Agarose Gel Extraction Kit”. 
150 ng insert was ligated o/n at 14°C into 50 ng vector in a total volume of 10 µl 
containing 1 µl 10x ligation buffer, 1 µl vector (50 ng) and 1 µl T4 DNA ligase (3 U/µl). 
For highest efficacy the molar ratio between vector and insert should be between 1:1 
and 1:3. 
The ligation product was immediately used for transformation or stored at -20°C. 
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Transformation of Bacteria 
Bacterial Strains 
? JM109 High Efficiency Competent Cells with the genotype: recA1, endA1, 
gryA96, thi, hsdR17 (rK-mK+), relA1, supE44, Δ(lac-proAB), [F´,traD36, proAB, 
laclqZΔM15] 
 > 108 cfu/µg  (Promega, Cat.# L2001) 
? JM110 Competent Cells with the genotype: rpsL (Strr) thr leu thi-l lacY galK galT 
ara tonA tsx dam dcm supE44 Δ(lac-proAB) [F´ traD36 proAB laclqZΔM15]  
> 5x106 cfu/µg  (Strategene, Cat.# 200239) 
Transformation of JM109 
E. coli cells were thawed on ice. 
2 µl ligation reaction was added to an aliquote of 50 µl competent cells and incubated 
20 min on ice. Following a 45-50 sec heat shock at 42°C, cells were incubated for 
further 2 min on ice. Then 950 µl SOC medium (Invitrogen, Cat.# 15544-034) was 
added and the cells were incubated 1 h at 37°C with shaking (220 rpm). 100 µl of 
each transformation-culture were plated on agar plates containing the appropriate 
antibiotic for selection. The plates were incubated o/n at 37°C.  
Positive clones were analysed by “Colony Screening (PCR)”. The DNA of 
transformed cells was isolated by “Miniprep” and sequenced. 
Transformation of JM110 
JM110 E. coli cells were used for obtaining plasmids which further needed to be cut 
with dam- or dcm-sensitive restriction enzymes. 
E. coli cells were thawed on ice. 
An aliquote of 100 µl of competent cells was mixed with 1.7 µl of β-mercaptoethanol, 
provided with the kit, and incubated for 10 min on ice, swirling gently every 2 min. 
2 µl ligation reaction was added to competent cells and incubated 30 min on ice. 
Following a 45-50 sec heat shock at 42°C, cells were incubated for further 2 min on 
ice. Then 950 µl SOC medium (Invitrogen, Cat.# 15544-034) was added and the cells 
were incubated 1 h at 37°C with shaking (220 rpm). 100 µl transformation-culture 
was plated on agar plates containing the appropriate antibiotic for selection. The 
plates were incubated o/n at 37°C.  
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Positive clones were analysed by “Colony Screening (PCR)”. The DNA of 
transformed cells was isolated by “Miniprep” and sequenced. 
Plasmid Preparations 
Miniprep 
For plasmid preparation, the “QIAprep Spin Miniprep Kit” of Qiagen (Cat.# 27106) 
was used. The protocol is designed for purification of up to 20 µg of high-copy 
plasmid DNA from 1-5 ml overnight cultures of E. coli in LB-medium. 
E. coli cells were incubated o/n in 2.5 ml LB-amp medium at 37°C in an air-incubator 
at 225 rpm. The cell suspension was centrifuged for 30 sec at 6,000 rpm. Pelleted 
bacterial cells were resuspended in 250 µl buffer P1. 250 µl lysis buffer P2 was 
added and the tube was gently inverted 4-6 times. Then 350 µl buffer N3 was added 
and the tube was again gently inverted 4-6 times. After 10 min centrifugation at 
15,000 rpm, the supernatant was applied to the QIAprep column and centrifuged for 
1 min at 15,000 rpm. The flow-through was discarded and the plasmid DNA which 
was bound to the column matrix was washed once with 0.5 ml buffer PB and once 
with 0.75 ml buffer PE. Between washing steps, the columns were centrifuged and 
the flow-through was discarded. After washing steps the column was again 
centrifuged for 1 min to remove residual wash buffer. Then the QIAprep column was 
placed into a clean 1.5 ml tube and the DNA was eluted with 50 µl buffer EB (10 mM 
Tris-HCl, pH 8.5). After 1 min incubation, the column was centrifuged for 1 min. 
The DNA-solutions were stored at -20°C. 
Maxiprep 
For preparation of larger amounts of DNA, the “EndoFree Plasmid Maxi Kit” from 
Qiagen (Cat.# 12362) was used. The protocol is designed for purification of 500 µg of 
endotoxin-free plasmid DNA. 
300 ml overnight bacteria culture was centrifuged for 30 min at 4°C at 6,000 rpm in a 
“Sorvall RC-5B Refrigerated Superspeed Centrifuge”. 
The pellets were resuspended in 10 ml P1 buffer. Then 10 ml P2 buffer was added 
and the tube was gently mixed. After 5 min incubation at RT, 10 ml of chilled P3 
buffer was added and the reaction mixture again gently mixed. 
The lysate (but not the plunger) was transferred to the barrel of the QIAfilter Maxi 
cartridge, placed in a convenient tube and incubated at RT for 10 min.  
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The QIAfilter cartridge was then hold over the previously equilibrated QIAGEN-tip 
and the cap was removed from the QIAfilter outlet nozzle. The Plunger was gently 
inserted to the QIAfilter Maxi cartridge to filter the cell lysate into a 50 ml tube. Then 
2.5 ml endotoxin removal buffer ER was added to the filtered lysate, the sample 
mixed by inverting the tube about 10 times and incubated on ice for 30 min. 
During incubation a QIAGEN-tip 500 was equilibrated by applying 10 ml buffer QBT 
and the column was allowed to empty by gravity flow. 
Then the incubated filtrate was applied to the QIAGEN-tip and allowed to enter the 
resin by gravity flow. The QUIAGEN-tip was then washed with 2 x 30 ml buffer QC. 
DNA was eluted with 15 ml buffer QN (into an endotoxin-free 30 ml Nalgene-tube). 
Plasmid DNA was precipitated with 10.5 ml isopropanol at RT and centrifuged at 
11,000 rpm (Sorvall RC-5B, rotor HB-4 11,000 rpm) at 4°C for 30 min. 
The pellet was briefly washed with 70 % ethanol and again centrifuged at 11,000 rpm 
at 4°C for 15 min. Finally, the pellet was air dried and DNA was dissolved in a 
suitable volume of buffer EB (10 mM Tris-HCl, pH 8.5). 
Determination of DNA/RNA Concentration 
The concentration and purity of nucleic acids was determined by measuring the 
optical density (OD) at 260 nm and 280 nm in a SmartSpec 3000 spectrometer 
(Biorad). An OD260 of 1 represents either 40 µg/ml RNA or ssDNA or 50 µg/ml 
dsDNA. The OD260/OD280 ratio between 1.8 and 2 indicates high purity of nucleic 
acid. Contaminants that absorb at 280 nm (e.g. protein) will lower this ratio. 
DNA Sequencing 
Sequencing of dsDNA was performed with “ABI PRISM Big Dye Terminator v3.1 
Cycle Sequencing Kit” according to manufacturer guidelines provided with the kit. 
The following reagents were combined: 
 
reagent       µl per reaction tube 
250-500 ng DNA diluted in aqua dest. 4.4 
sequence primer (5 pmol/µl) 1.6 
terminator ready reaction mix 4 
total volume 10 
 
The following amplification parameters were chosen in a “PE GeneAmp PCR System 
2400” or “PE GeneAmp PCR System 9700”: 
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1 cycle:   1 min 96°C
28 cycles: 10 sec 96°C
15 sec 50°C
  2 min 60°C
hold at:    4°C
 
Samples were transferred to the “in house sequencing lab”, where DNA sequencing 
was performed on an ABI-Prism 3100 System (Applied Biosystems). 
Specific sequencing primers were chosen for each approach. As the maximal 
fragment length being analysed does not exceed 500-800 bp, analyses of longer 
sequences of interest were divided into 500 bp intersections. 
Sequence data were edited and analysed with the software VectorNTI of Invitrogen. 
Freezing of Bacteria 
800 µl of cultured bacteria suspension was mixed with 800 µl of sterile glycerol in a 
cryotube and mixed to ensure that the glycerol was homogenously dispensed.  
The cultures were stored at -80°C. 
 
Cell Biology 
Cell Lines 
All used cell lines were grown in an atmosphere containing 5 % (v/v) CO2 and 95 % 
relative humidity. All cell lines except HN5 and T47D Tet-on were obtained from 
ATCC and were propagated according to provider’s instructions. 
HN5 
HN5 is a human head and neck squamous cell carcinoma cell line which was 
originally obtained from Invitrogen, CA, USA.  
For medium condition see chapter “Media and Buffers”. 
T47D Tet-on 
T47D Tet-on cell line (BD Pharmingen) stably expressing a tet-repressor, was 
propagated following provider’s instructions. “Tet System Approved Fetal Bovine 
Serum” from Clontech (Cat.# 631101) was used for cultivation of the tet-sensitive cell 
line. For induction, Doxycycline (Clontech, Cat# 631311) was used at a concentration 
of   2 µg/ml media. 
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Thawing and Freezing of Cells 
At least 1.106 cells in excellent condition (derived from log growth phase) were 
centrifuged at 1,000 rpm for 2 min in a Megafuge 2.0R (Haereus). Afterwards the 
supernatant was removed. The pellet was resuspended gently in 1 ml of the pre-
cooled freeze-medium “Cryo-SFM” (PromoCell, Cat.# C-29912) and transferred into 
a cryovial which was labelled with an ethanol-resistant marker. Then the vial was put 
into a freeze container (NALGENE™ 1°C Cryo Freezing Container) and transferred 
into a -80°C freezer, whereby the temperature drops 1°C per min avoiding ice crystal 
formation. If cells should be stored longer than 6 months, they should be transferred 
to liquid nitrogen afterwards. 
For thawing, frozen cells were put immediately from dry ice into a 37°C water bath, 
until the freeze-medium thawed. When only a small lump of ice was left, the vial was 
removed from the water bath and sprayed briefly with 70 % ethanol to avoid 
contamination. The vial was opened in a laminar flow and the cells were immediately 
transferred to a T25 cell culture flask and resuspended with 5 ml of their respective 
growth medium. After 24 h, the cells were washed with 1x PBS and the medium was 
changed. After one week in culture, usually the cells are in a good condition and 
ready for experiments. 
Propagation of Adherent Cells 
The cells were trypsinised when confluency of ~ 90 % was reached. 
For this, the cell culture medium was removed and cells were washed with 1x PBS. 
Then 1 ml (T75 flask) or 2.5 ml (T175 flask) of Trypsin-EDTA solution (“Trypsin-EDTA 
(1x), liquid - 0.05 % trypsin” of Invitrogen, Cat.# 25300-054) was added and the 
flasks incubated at RT (or at 37°C) until the cells were detached. 
The cells were “split” according to their density and growth rate. Fresh culture 
medium was added and dispensed into new culture flasks. 
Determination of Cell Count 
For determination of cell count, cells were detached with Trypsin-EDTA solution as 
described above and the trypsinisation reaction stopped with the respective cell 
medium. A homogenised cell solution or dilution thereof was measured with the “Vi-
CELL™ Cell Viability Analyzer” from Beckman Coulter. 
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Determination of Growth Curve 
For determination of cell growth, in 2D cell culture, a defined number of cells were 
seeded into a cell culture flask or plate or well and after a certain period of time 
tyrpsinised and the cell solution counted with the “Vi-CELL™ Cell Viability Analyzer” 
from Beckman Coulter. With enough time points a growth curve could be compiled in 
MS Excel. 
For experiments in 3D cell culture systems with spheroids, the area of spheroids was 
determined on different days by using the software „AxioVision Rel.4.6“ from Carl 
Zeiss Imaging Solutions. 
Transient Transfection of Plasmid DNA to Eukaryotic Cells 
For transient transfection of eukaryotic cells with plasmid DNA the “Lipofectamine 
2000” reagent of Invitrogen (Cat.# 11668-019) was used.  
The day before transfection, cells were trypsinised and cultivated at a confluency of  
~ 70 % o/n. For transfection of cells in 6-well-cell culture plates, 200,000 cells were 
seeded and grown in 2 ml of the appropriate media for at least one day. 2 µg plasmid 
per reaction was diluted with 200 µl OptiMEM (Invitrogen, Cat.# 51985-026), and 5 µl 
Lipofectamine 2000 was diluted with 200 µl OptiMEM. After 15 min incubation at RT 
both solutions were combined and incubated for further 15 min at RT. The cells were 
washed once with PBS and then treated with the lipofectamine-plasmid solution for   
4 h in the incubator. 4 h after transfection, media was changed to the respective cell 
medium.  
Usually cells were incubated for 24-48 h in the incubator prior to testing for transgene 
expression. 
Generation of Stable Cell Lines 
For the establishment of CLCA2 stably transfected inducible T47D Tet-on cell lines, 
or cell lines with distinct mutations in CLCA2, the ORF’s of CLCA2 with an HA-tag at 
the C-terminal end and various mutated CLCA2-ORF’s were cloned to the pTRE2pur 
vector of the “Tet-on Gene Expression System” of Clontech (Cat.# 630922) and 
transfected to the T47D Tet-on cell line. 
In the Tet-on System, rtTA (reverse tetracycline-controlled transactivator) binds the 
TRE (Tet response element) and activates transcription only in the presence of 
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Doxycycline (a Tetracycline derivative), whereby in the used T47D Tet-on cell line, 
the appropriate regulatory protein is already stably expressed. 
CLCA2-HA-expressing stable cell clones, having the puromycin restistance gene 
from the transfected vector pTRE2pur, were selected for at least 2 weeks with        
0.5 µg/ml Puromycin (Sigma, Cat.# P9620) in cultivation medium. Approximately 100 
cell clones were analysed for Doxycycline-dependent expression of CLCA2-HA by 
using an anti-HA-antibody in Western blot analyses with induced versus non-induced 
cell lysates, which were generated 48 h post induction.  
Those clones with no expression in uninduced cell lysates, but distinct expression in 
induced cell lysates were used for further analysis. 
Generation of Cell Lysates from Human Tumour Cells 
To generate lysates of adherent cells, the medium and the detached cells were 
removed. The remaining attached cells were washed once with PBS, and then 150 µl 
lysis buffer was added to each well of a 6-well-plate or 1 ml lysis buffer to cells which 
were grown in a 13.5 cm culture dish. The lysis buffer was pipetted up and down, 
until all cells were detached. Then the lysate was immediately put to the freezer and 
stored for at least 2 h at -20°C. 
Inhibition of Post-Translational Modifications 
The glycosylation inhibitor Tunicamycin and isoprenylation-inhibitor Perillic acid were 
obtained from Sigma. The inhibitors were dissolved in DMSO and added directly to 
the cell culture medium at different concentrations. Final DMSO concentration in all 
samples was adjusted to 1 %. 48 h after treatment cells were harvested and protein 
lysates tested in Western blot analysis. 
Proliferation Assay (Alamar Blue) 
1,000-5,000 cells in 100 µl medium were seeded per well of a 96-well-plate. 
Proliferation assays were performed by adding 100 µl of 20 % Alamar reagent 
(Invitrogen, Cat.# DAL1100) in medium into each well. After subsequent incubation at 
37°C the measurements were performed in a standard microtiter well plate reader 
such as EnVision 2101 multi label reader (Perkin Elmer).  
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siRNA Experiments 
siRNAs 
siGENOME SMART pool (Dharmacon, Cat.# MQ-003813-01-0005, human CLCA2, 
NM_006536, 5nmol x 4) containing a mixture of four designed siRNAs targeting 
CLCA2 mRNA was tested in different cell lines for efficient downregulation of the 
specific mRNA and protein levels. Afterwards the individual siRNAs, shown in Table 
6 were tested individually. 
 
Name of siRNA Sequence (5' → 3') Dharmacon 
Cat.# 
siCLCA2-2 GGAAUCAUUUGCCUUAUUAUU D-003813-02 
siCLCA2-4 GAUCGAAAGUUGCUGGUUUUU D-003813-04 
siCLCA2-5 UGACAAACCUUUCUACAUAUU D-003813-05 
siCLCA2-8 GCUACAAGCUAUGAAAUAAUU D-003813-08 
 
Table 6. Sequences of commercial available (Dharmacon) siRNAs, which were used for CLCA2 knock-
down experiments 
 
The most efficient siRNA oligonucleotides, siCLCA2-2 and siCLCA2-4, were used for 
further experiments. 
Non-targeting siRNA “siCONTROL#1” (herein named siCTRL) of Dharmacon (Cat.# 
D-001210-0105) was also purchased and used as a control for normalisation. 
siRNA Transfection in 6-Well-Plates 
For each siRNA transfection approximately 150,000 cells were seeded into each well 
of a 6-well-cell culture plate and cultured for 24 h to yield 40-50 % confluency.  
siRNA duplexes were dissolved and diluted with siRNA buffer (Dharmacon, Cat.# B-
002000-UB) and nuclease free water to a concentration of 20 µM.  
Cells were transfected with siRNAs dependent on the cell line with the indicated 
amount of appropriate DharmaFECTTM reagent at a final concentration of 25 nM 
siRNA.  
For this, 2.5 µl siRNA solution (20 µM) was diluted in 200 µl of a serum-fee 
respective cell culture medium. In parallel, 4 µl DharmaFECT was diluted in 200 µl of 
the serum-free respective cell culture medium. Both solutions were incubated 
separately. After 5 min of incubation the solutions were combined and incubated at 
RT for further 20 min. Then 1.6 ml of the corresponding full cell culture medium 
(including serum) was added to 400 µl of the mixture to obtain 2 ml transfection 
medium. After washing the target cells once with PBS, the medium of the target cells 
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was replaced with 2 ml of the transfection medium. After 24 h of incubation, the 
transfection medium was discarded and 2 ml respective cell culture medium was 
added.  
The cells were harvested 24-72 h after siRNA transfection and analysed via 
quantitative PCR or Western blot analysis. 
siRNA Transfection in 96-Well-Plates 
For performing an Alamar Blue Assay with siRNA-transfected cells, siRNA 
transfections were performed in 96-well-plates. Therefore 5,000 cell per well were 
seeded into each well and final siRNA concentrations ranging from 390 pM up to 100 
nM were tested for optimal transfection. (In detail, the following concentrations were 
used: 390 pM, 780 pm, 1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM) 
100 µl transfection reagent was added to each well of a 96-well-plate. 
If RNA was isolated from such an experiment, the “FastLane Cell cDNA Kit” from 
Qiagen (Cat.# 215011) was used following the instructions in the manual. 
DharmaFECT Reagents 
Table 7 lists all transfected cell lines used in this study and the respective 
DharmaFECT reagent, which was used for transfection. 
 
Cell Line DharmaFECT Dharmacon Cat.# 
HN5 4 T-2004 
MDA-MB-453 1 or 2 T-2001 & T2002 
T47D Tet-on 4 T-2004 
 
Table 7. Optimal transfection reagents (Dharmacon) for cell lines used in this study 
 
Live-Cell High-Content Screening (HCS) with Cellomics ArrayScan® 
HCS Reader is an automated fluorescence microscopic imaging system designed for 
high content screening and high content analysis. The instrument features include 
optics by Carl Zeiss, broad white-light source, 12-bit cooled CCD camera, and 
controller software. All Cellomics instruments are designed to work with image 
analysis modules (BioApplications) that automatically convert images into numeric 
data that capture changes in cell size, shape, intensity, and other properties.  
The following Standard Operating Procedures for cell cycle and apoptosis analysis 
(CCYAPO) have been applied:  
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Tissue Culture 
Cells of interest were grown in maxi plates (175 cm2) using EMEM medium 
supplemented with 10 % heat-inactivated fetal calf serum, 0.15 % NaHCO3, 1 % Na 
pyruvate solution, 1% NEAA (100x) and 2 mM L-Glutamine. Cultures were incubated 
at 37°C and 5 % CO2 in a humidified atmosphere. 
Cell were transfected according the standard protocol (see previous chapters). 
Staining Procedure 
All liquid handling was performed with Cybiwell instruments. 
Apoptosis staining was performed on the life cells by adding 50 µl/well medium 
containing 500 nM Mitotracker Red CMXRos (1mM stock in DMSO, Invitrogen M-
7512) and 100 nM SytoxGreen (100 µM stock in DMSO; Invitrogen S-7020). Then 
the cells were kept in the incubator for 60 minutes. After incubation the cell layer was 
washed 2 times with 100 µl PBS. Then cells were fixed by adding 100 µl                 
3.7 % formaldehyde/ 0.1 % TX100 in PBS for 10 min at RT. The cell layer was 
washed 2 times with 100 µl PBS. The nuclei were stained with 5 µg/ml Hoechst 
33342 (stock 10 mg/ml in PBS; Invitrogen H1399) for 60 min. Then the cell layer was 
washed 1 x with 100 µl 0.1 % Triton X100 in PBS and 2 x with 100 µl PBS. The wells 
were filled with 100 µl PBS and the plates sealed with an adhesive sheet. 
The measurement was performed with Cellomics “ArrayScan® VTI Live” (Protocol: 
Morphology Analysis  TV_APO_20x) as follows: 
Settings 
• objective: 20x 
• acquisition camera mode: standard 
• filter XF93: DAPI, FITC and TRIC channels 
• autofocus interval = 2 
• 600 cells, max 30 fields/well 
• max 5 sparse fields per well 
• fixed exposure time, set to 25 % saturation for the negative controls 
• fixed threshold - adjusted to the actual staining intensities 
• SegmetationCh1 = 6 
• background correction = 0 
• NucSmoothFactorCh1 = 0 
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Features 
• ObjectTotalIntenCh1 Hoechst stain: DAPI channel 
• ObjectAreaCh1 
• ObjectVarIntenCh1 
• TotalIntenCh2  Sytox stain: FITC channel 
• TotalIntenCh3  MitoTracker: TRITC channel 
• CellsPerField 
Sytox intensities were generated by dividing – on the single cell level – the  
TotalIntenCh2 by TotalIntenCh1 values. 
Integrin-Mediated Cell Adhesion Assays 
Integrin-mediated cell adhesion assays were performed by using „Beta Integrin-
Mediated Cell Adhesion Array” (Chemicon, Cat.# ECM531) and „Alpha Integrin-
Mediated Cell Adhesion Array” (Chemicon, Cat.# ECM530). 
The „Alpha Integrin-Mediated Cell Adhesion Array“ uses mouse monoclonal 
antibodies, generated against human α-integrins/subunits (α1, α2, α3, α4, α5, αV 
and αVβ3) and the „Beta Integrin-Mediated Cell Adhesion Array“ uses mouse 
monoclonal antibodies, generated against human β-integrins/subunits (β1, β2, β3, β4, 
β6, αVβ5, and α5β1), which are immobilised onto a goat anti-mouse antibody coated 
microtiter plate. The plate is used to capture cells expressing these integrines on 
their cell surface. Cells were seeded onto the coated substrate and incubated. 
Unbound cells were washed away and adherent cells were fixed and stained. 
Relative cell attachment was determined using absorbance readings, measured in a 
standard microtiter well plate reader. 
The assays were performed according to the assay instructions in the manual. 
For cell suspension 1.0 x 106 cells/ml were used. 
Human Tissue Samples 
Human tissues were collected at the Institute of Pathology, Medical University of 
Vienna, Austria, following institutional guidelines. In addition, ten cases of cervical 
SCCs were obtained from Oridis Biomed. 
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3D-In Vitro Carcinoma Assay: Spheroids 
For investigation of CLCA2-expressing cell lines in a 3D model, cells were grown in 
the form of spheroids. To achieve growth in this tumour similar format, cells have to 
be cultivated with methylcellulose in wells of a 96-well-plate for suspension culture, 
where cells could not attach at the surface of the plate. When spheroids were 
formed, they were transferred to a gel, where growth in all directions is possible. 
Methylcellulose  
1.8 g methylcellulose (Sigma, Cat.# M-0512-100G, 4000 centipoises) was weighted 
into a 100 ml flask containing a magnetic stirrer and autoclaved (the methylcellulose 
powder is resistant to this procedure). The autoclaved methylcellulose was resolved 
in 100 ml sterile basal medium (using a magnetic stirrer) o/n at 4°C. After clearing by 
centrifugation at 5,000 g for 2 h at RT, a final stock solution was aliquoted, whereby 
only the clear highly viscous supernatant was used for the spheroid assay (about    
90 - 95 % of the stock solution). For spheroid generation, 20 % of the stock solution 
and 80 % culture medium were used. 
Spheroid Formation 
Cells were trypsinised and counted. For one spheroid 250 cells were used, so 25,000 
cells were isolated, centrifuged at 1,000 g for 3 min at RT and resuspended in 10 ml 
appropriate medium (containing serum and all needed “goodies” such as L-
glutamine, Na-pyruvate etc.) with 20 % Methylcellulose stock solution. 100 µl cell 
suspension was added into each well of a U-shaped 96-well-plate for suspension 
culture from Greiner (Cat.# 650185). The cells were incubated for 48 h at 37°C in an 
atmosphere containing 5 % (v/v) CO2 and 95 % relative humidity. 
Harvesting of Spheroids 
The spheroids were collected by removing 50-100 µl of the medium near the deepest 
point of the well of the U-shaped 96-well-plate with a 200 µl Gilson/Eppendorf pipette 
and collected into a 1.5 ml Eppendorf tube. The collected spheroids were centrifuged 
carefully at 100 g for 3 min at RT and the medium was removed with a pipette. 
Gel Pouring Device 
For growing spheroids in collagen gel, a gel pouring devices is needed to keep the 
stability of the gel. 
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For this, silicon gaskets were cut out in quadratical (2 cm x 2 cm) pieces from silicon 
gasket (Biorad silicone gasket for gel dryers) and a hole (diameter 1.5 cm, with a 
hollow punch) was made in the middle. The gaskets were autoclaved (45 min, 
120°C) before use. The supporting nylon mesh was taken of Becton Dickinson 
Filcons (100 µm mesh size, Cat.# 340611) and autoclaved (45 min, 120°C). 
To be used as a form for 3D-spheroid-gels, the silicone gaskets were placed onto the 
lid of a 4 cm cell culture dish with a nylon mesh placed into the hole and incubated 
for 30 min at 37°C before use. 
Collagen Gel Preparation 
For collagen gels, “Collagen I, Rat Tail Tendon” from BD Biosciences (Cat.# 354236) 
was used. 
 
The following reagents (for 2 ml collagen gel mix) were put on ice and mixed carefully 
by pipetting up and down for about 10 times avoiding production of bubbles: 
 
0.2 ml 10x PBS 
0.9 ml Methylcellulose (20 %) in desired culture medium 
0.9 ml Collagen I 
23 µl 1M NaOH 
 
180 µl of ice cold collagen gel mix was added to desired spheroids and mixed 
carefully by pipetting up and down for about 10 times without producing bubbles. 
The fluid spheroid gel was then pipetted into the pre-warmed pouring device with 
mesh and immediately put back to incubator, where the collagen hardens over a 
period of 30 min. Then, with the help of a sterile foreceps the silicone foil was 
carefully remove and the collagen gel transferred into a 24-well-plate with the 
appropriate culture medium. Thereby the gel was only touched at the mesh 
supported border. 
The 3D-spheroid-gel was incubated at 37°C and the growth monitored every day with 
the microscope. 
Matrigel 
As alternative to collagen, spheroids were also grown in “Growth Factor Reduced 
Matrigel” of BD Biosciences (Cat.# 356231).  
150 µl Matrigel was used for one gel. Silicon gaskets and the nylon mesh were not 
used, because Matrigel very quickly hardens; so it was sufficient to form a drop and 
transfer the gel pouring device immediately to the 37°C incubator. 
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Probidium Iodide Staining 
To observe the status of apoptotic cells in spheroids within a spheroid-gel, probidium 
iodide was added directly to the media (ratio 1:4000). This treatment easily allows 
observation with a fluorescence-microscope utilising the appropriate filter, exhibiting 
apoptotic cells as red points. 
Measuring of Diameter and Volume of Spheroids 
Photographs of the spheroids were taken every two days after embedding spheroids 
into the gel, with the microscope. The area of the spheroids were determined with the 
software „AxioVision Rel.4.6“ from Carl Zeiss Imaging Solutions. Growth curves were 
calculated with MS Excel. 
 
Biochemistry 
Determination of Protein Concentration in Cell Lysates (Bradford Assay) 
To normalise the different protein concentration for quantitative analysis of Western 
blots, first the protein concentration of protein lysates were analysed in a Bradford 
assay. 
Protein lysates were pre-cleared by centrifugation at 14,000 rpm for 10 min at 4°C. 
The amount of whole protein content was measured by a standard Bradford assay, 
purchased of Biorad (Cat.# 500-0006). The sample was measured in parallel to 
samples of a calibration curve, consisting of samples with defined amounts of BSA  
(0 / 1 / 5 / 7 / 10 / 15 µg/ml BSA). 5 µl of each protein sample was mixed with 1 ml   
1x Bradford solution and incubated for 5 min at RT. The optical density of each 
sample was measured at a wavelength of 595 nm in a SmartSpec 3000 
spectrophotometer. The gradient of the calibration curve was calculated and used to 
assess the protein concentration of the samples. 
SDS-PAGE 
All SDS-PAGE analyses were performed using pre-cast Criterion XT Bis-Tris,            
4-12 % gradient gels, 18-well, 30 µl, acquired from Biorad (Cat.# 345-0124), using 
the Biorad gel chamber for Criterion gels.  
Depending on different approaches, 50-100 µg total protein was used for SDS-PAGE 
analysis. The specified amount of protein was prepared with 5x SDS-LB and then 
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boiled at 95°C for 5 min. The sample was cooled for 1 min at ice and spun down prior 
loading onto the protein gel. For determination of size of proteins, as marker was 
used “PageRuler Prestained Protein Ladder” of Fermentas (Cat.# SM0671). 
The electrophoresis was started at 100 V and subsequently elevated up to 140 V. 
Western Blotting 
The transfer of electrophoretically separated proteins to Immuno-blot PVDF 
membranes (Biorad, Cat.# 162-0239) was performed by Semidry-blotting a TE 70 
Semi-Dry Transfer Unit at 170 mA for 1 h  per membrane. 
The membrane was equilibrated for a few seconds in methanol (MeOH) prior use. 
For transfer the membrane and the gel were incubated and the filter papers soaked 
in 1x transfer buffer. After the transfer, the blots were blocked in blocking solution 
(TBS-T plus 5 % dried milk) for 1 h at RT and then incubated with the primary 
antibody diluted in blocking solution o/n at 4°C. The next day, the antibody dilution 
was discarded and the membrane was washed 3 x for 10 min with TBS-T. Then the 
membrane was incubated with the respective horse-radish-peroxidase-conjugated 
secondary antibody, diluted in blocking solution, for 1 h at RT. Afterwards the 
membrane was again washed 3 x for 10 min with TBS-T.  
Detection of bound antibodies was performed by chemiluminescence, using 
“Amersham ECL Western blotting detection reagents” from GE Healthcare (Cat.# 
RPN2106) and exposing the membrane to a light-sensitive film (“Amersham 
Hyperfilm MP” of GE Healthcare, Cat.# RPN1675K) for an appropriate time in an 
exposure-cassette. The film was developed using a Curix developer. 
Proteome Analyses with Proteome ProfilerTM (R&D Systems) 
MAPK-Array 
For analysing the phosphorylation status of all three major families of mitogen-
activated protein kinases (MAPKs), the extracellular signal-regulated kinases 
(ERK1/2), c-Jun N-terminal kinases (JNK1-3), different p38 isoforms (α/β/δ/γ), other 
intracellular kinases such as Akt, GSK-3 and p70 S6 kinases, the “Human Phospho-
MAPK Array Kit” from R&D Systems (Cat.# ARY002) was used. 
The principle of the assays is that capture and control antibodies have been spotted 
in duplicate on nitrocellulose membranes. Cell lysates are diluted and incubated with 
the Human Phospho-MAPK Array. After binding both, phosphorylated and non-
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phosphorylated kinases, unbound material is washed away. A cocktail of      
phospho-site-specific biotinylated antibodies is then used to detect phosphorylated 
kinases via Streptavidin-HRP and chemiluminescence.  
RTK-Array 
For analysing the relative levels of phosphorylation of 42 different receptor tyrosine 
kinases, the “Human Phospho-RTK Array Kit” from R&D Systems (Cat.# ARY001) 
was used. 
The principle of the assays is that capture and control antibodies have been spotted 
in duplicate on nitrocellulose membranes. Cell lysates are diluted and incubated with 
the Human Phospho-RTK Array. After binding the extracellular domain of both, 
phosphorylated and non-phosphorylated RTKs, unbound material is washed away. A 
pan anti-phospho-tyrosine-antibody conjugated to horseradish peroxidase (HRP) is 
then used to detect phosphorylated tyrosines on activated receptors by 
chemiluminescence. 
Immunohistochemistry 
An indirect immunoperoxidase assay was used to detect expression of CLCA2.         
5 µm thick sections were cut and mounted on poly-(L-lysine)-coated slides. After de-
paraffinisation and epitope retrieval with Proteinase K in TrisEDTA buffer pH 8.0 for 
15 min at 37°C, the sections were blocked with 10 % normal goat serum. The 
primary antibody was applied for 1 h at RT followed by incubation with goat anti-
rabbit horseradish peroxidase labelled polymer, Dako Envision System (Dako) for 30 
min at RT. The final reaction product was visualised with DAB (0.06 %                  
3,3’-diaminobenzidine in PBS, 0.003 % H2O2) for 2-5 min. Then the slides were 
dehydrated in alcohol and counterstained with hematoxylin. The specificity of the 
staining was confirmed by pre-incubating the primary anti-peptide-antibody with the 
corresponding synthetic peptide for 2 h at RT at the final concentration of 25 μg/ml of 
antibody which resulted in no staining of the tumour cells. 
Antibody Generation 
CLCA2 antibodies were generated by immunising rabbits with peptides 
corresponding to the amino acid sequence of CLCA2 (NH2-epitope-COOH).  
Three rabbits were immunised with the following peptides: Table 8 
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Rabbit No. 
 
Amino Acid Pos.  
in CLCA2 Protein Sequence 
Peptide Sequence 
 
1 K94 – N110 KANNNSKIKQESYEKAN 
  N179 – D199 NDKPFYINGQNQIKVTRCSSD 
2 E498 – T513 ESTGENVKPHHQLKNT 
  H690 – H708 HVNHSPSISTPAHSIPGSH 
3 T643 – L656 TVEPETGDPVTLRL 
 
Table 8. Peptides used for generation of antisera in rabbits 
 
The serum containing the anti-CLCA2-antibodies was affinity purified using the 
corresponding peptide coupled to a Sulfo-Link-Gel-column, using the SulfoLink Kit 
from Pierce (Cat.# 44895). The antiserum was eluted with 0.2 mol/l Glycine/HCl     
pH 2.7, 150 mmol/l NaCl. The fractions were tested in Western blotting analysis. 
 
In Silicio Analyses 
Statistical and Bioinformatic Analyses 
All mathematical calculations and graphics were performed with MS Excel and 
GraphPad Prism 4.0. 
Sequence Alignment 
Sequence data were edited and analysed with the VectorNTI Software of Invitrogen. 
Expression Profiling   
For expression analysis, box-and-whisker plots were generated as described 
[75;168]. The respective hybridisations were performed on Affymetrix Exon 
GeneChips. These microarrays are based on 25-mer oligonucleotides and allow the 
detection of more than 39,000 human transcripts, with probe sets of 11 
oligonucleotides used per transcript.  
Approximately 1 µg of total RNA was converted into DNA, which was fragmented and 
end-labeled. 5 µg of labelled target DNA was hybridised to the Affymetrix GeneChip-
Human Exon 1.0 Array at 45°C for 16 h as recommended by the manufacturer 
(http://www.affymetrix.com). After hybridisation arrays were washed and scanned on 
a GCS3000Scanner (Affymetrix, Santa Clara, CA). Chip data were normalised with 
the statistical algorithm implemented in the Microarray Suite version 5.0 (Affymetrix). 
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The raw expression intensity for a given chip experiment is multiplied by a global 
scaling factor to allow comparisons between chips. This factor is calculated by 
removing the highest 2 % and the lowest 2 % of the values of the non-normalised 
expression values, and calculating the mean for the remaining values, as trimmed 
mean. One hundred divided by the trimmed mean gives the scaling factor, where 100 
is the standard value used by GeneLogic. For oligonucleotide-specific background 
normalisation individual absent- and present-calls are calculated by comparing the 
absolute signal intensities for corresponding perfect-match and mismatch 
oligonucleotides. 
 
 
Media and Buffers (in alphabetical order) 
Molecularbiology 
1st Strand buffer, 5x: 250 mM Tris-HCl (pH 8.3) 
375 mM KCl  (Invitrogen; 
 Cat.# 18064-014) 15 mM MgCl2 
 
Ammonium acetate, 57.86 g NH4Ac 
7.5 M: add 100 ml H2O 
 
Ampicillin stock: 50 mg/ml Ampicillin in H2O 
 filter through 0.22 µm sterile 
 
Blocking solution: 1 x TBS-T buffer 
(for Western blot) 5 % dried milk 
 
Buffer EB: 10 mM Tris-HCl 
pH 8.5  (Qiagen; 
 Cat.# 27106 )  
 
 
Buffer P1: 50 mM Tris-HCl  (pH 8.0) 
10 mM EDTA  (Qiagen; 
 Cat.# 27106 ) 100 µg/ml RNAseA 
 
Buffer P2: 200 mM NaOH 
1 % SDS  (Qiagen; 
 Cat.# 27106 )  
 
Buffer P3: 2.55 M KAc  (pH 4.8) 
  (Qiagen; 
 Cat.# 27106 )  
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Buffer QBT: 750 mM NaCl 
50 mM MOPS  (pH 7.0)  (Qiagen; 
 Cat.# 12163 ) 15 % (v/v) Isopropanol 
 0.15 % (v/v) Triton X-100 
 
Buffer QC: 1 M NaCl 
50 mM MOPS  (pH 7.0)  (Qiagen; 
 Cat.# 12163 ) 15 % (v/v) Isopropanol 
 
Buffer QF: 1,25 M NaCl 
50 mM Tris-HCl  (pH 8.5)  (Qiagen; 
 Cat.# 12163 ) 15 % (v/v) Isopropanol 
 
DEPC-H2O: 0.1 % (v/v) DEPC in Millipore water; shake well 
 autoclave the next day 20 min at 1.5 bar 
 
DNA loading buffer 6x: 0.3 % Bromphenole Blue 
 0.3 % Xylene Cyanol 
 1 % SDS 
 30 % Glycerol 
 30 mM EDTA 
 
Klenow 10x buffer: 500 mM Tris-HCl  (pH 7.2)  
100 mM MgSO4 
 
(Promega; 
 Cat.# M195A) 1 mM DTT 
 
LB media: 10 g/l Tryptone 
(Lauria-Bertani Broth) 5 g/l Yeast extract 
10 g/l NaCl  (Biolab; 
 Cat.# LBB30500) pH 7.5 (approx.) 
 
LB-Amp media: 1000 ml LB media 
 1 ml 1000x Ampicillin Stock 
 
LB-Amp plates: 1000 ml LB media 
 15 g Bacto Agar (Difco) 
 autoclave 20 min at 1.5 bar 
 1 ml 1000x Ampicillin Stock 
(added at 55°C) 
 
 
Ligase buffer, 10x: 300 mM Tris-HCl  (pH 7.8) 
100 mM MgCl2 
 
(Promega; 
 Cat.# C126A, C126B ) 100 mM DTT 
 10 mM ATP 
 
PCR buffer, 10x: 100 mM Tris-HCl  (pH 8.3) 
500 mM KCl  (TaKaRa; 
 Cat.# R001A ) 15 mM MgCl2 
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PCR buffer, 10x: 100 mM Tris-HCl  (pH 8.3) 
Mg2+ free: 500 mM KCl 
  (TaKaRa; 
 Cat.# R001AM )  
 
SDS-loading buffer, 1x: 50 mM Tris-HCl  (pH 6.8) 
 100 mM DTT or β-Mercaptoethanol 
 2 % SDS 
 0.1 % Bromphenol Blue 
 10 % Glycerol 
 
SOC media: 2 % Tryptone 
0.5 % Yeast extract 
10 mM NaCl 
 
(Invitrogen; 
 Cat.# 15544-034) 
2.5 mM KCl 
 10 mM MgCl2 
 10 mM MgSO4 
 20 mM Glucose 
Sodium acetate, 3M: 40.8g NaAc.3H2O 
 80 ml H2O 
 adjust with Acetic acid to pH 5.2 
 add 100 ml H2O 
 
TBE buffer, 10x: 1 M Tris 
0.9 M Boric acid   (Invitrogen; 
 Cat.# 15581-044) 0.01 M EDTA 
 
TBS-T: 20 mM Tris-HCl 
(Tris buffered saline  150 mM NaCl 
with 0.05 % Tween 20) 0.05 % Tween 20 
 
TE: 10 mM Tris-HCl (pH 7.5 - 8) 
 1 mM EDTA 
 
Transfer buffer: 20 mM Tris-HCl 
 66.6 mM Glycine 
 20 % Methanol 
 
 
Cell Culture 
 
PBS, Dulbecco’s (1x): 0.2 g/l KCl 
0.2 g/l KH2PO4 
8 g/l NaCl 
 
(Gibco; 
 Cat.# 14190-094) 
1.15 g/l Na2HPO4 
 pH 7.2 
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Lysis buffer for protein 20 mM Hepes, pH 7.3 
lysates: 5 mM EDTA 
 2 nM EGTA 
 30 mM Sodiumfluoride 
 1 mM Sodiumorthovanadate (Na3VO4) 
 20mM Sodiumpyrophosphate 
 40 mM b Glycerophosphate 
 30 mM Sodiumfluoride 
 0.5 % Triton X-100 
 1 Tab. / 50 ml buffer Protease Inhibitor Cocktail, “complete, EDTA- 
           free”, Roche, Cat.# 04693132001 
 
Mammalian cell culture ~450 ml DMEM high glucose medium, with L-glutamine 
media for T47D Tet-on 
cell line: 
10 % Fetal bovine serum, Tet System approved 
(Clontech, Cat.# 631101) 
 5 ml 100x Hepes buffer 
 2 ml Geneticin (50mg/ml) 
 5 ml 100x Sodium pyruvate 
 0.5 ml Bovine Insuline  (10g/ml) 
 
Mammalian cell culture ~450 ml DMEM high glucose medium, with L-glutamine 
media for HN5 cell 10 % Fetal Bovine Serum 
line: 5 ml 100x Hepes buffer 
 5 ml 100x Sodium pyruvate 
 5 ml 100x NEAA Mixture 
 
Mammalian cell culture 450 ml DMEM high glucose medium, with L-glutamine 
media for MDA-MB-453 10 % Fetal Bovine Serum (GIBCOBRL) 
cell cine:  
 
Reagents for cell culture media:  (in alphabetical order) 
? Bovine Insuline,10 mg/ml insuline in 25 mM HEPES, pH 8.2, Sigma, Cat.# I0516 
? DMEM high glucose medium, with L-glutamine, Lonza Group, Cat.# BE12-604F 
? Doxycycline 5 g, Clontech, Cat.# 631311 
? D-PBS (1x), Invitrogen, Cat.# 14190-094 
? Fetal bovine serum, JRH Biosciences, Cat.# 12103-500M 
? Geneticin selective antibiotic, Invitrogen, 50 mg/ml Cat.# 10131-019 
? GlutaMAX-I supplement, 200 mM, Invitrogen, Cat.# 35050-038 
? Hepes buffer 1M, Cambrex, Cat.# BE17-737E 
? MEM medium, Invitrogen, Cat.# 21090-022 
? MEM non essential amino acids solution (100x), Invitrogen, Cat.# 11140-035 
? Puromycin, Sigma, Cat.# P9620 
? RPMI 1640 medium w/GlutaMAX, Invitrogen, Cat.# 61870-036 
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? Sodium Pyruvate MEM 100 mM, Invitrogen, Cat.# 11360-039 
? Tet system approved fetal bovine serum, Clontech, Cat.# 631101 
 
Primer 
All oligo-deoxynucleotides were ordered from metabion GmbH. The crystals were 
dissolved in elution buffer EB (10 mM Tris-HCl, pH 8.5) to a concentration of 
100 pmol/µl. Aliquotes of 5 pmol/µl were prepared. 
Cloning Primer 
Tm (in PCR buffer) = 22 + 1,46 (2*(G+C)+A+T) 
 
Name EBI-No. Sequenz (5' → 3') 
hCLCA2-EcoRI f 15911 ccggaattcatgacccaaaggagcattgc 
hCLCA2-XhoI r 15912 ccgctcgagttataataattttgttccattctctttc 
CLCA2-BamHI r 15957 cgggatcctaataattttgttccattctctttcttgt 
hCLCA2-NotI f 15958 ataagaatgcggccgcccaccatgacccaaaggagcattgc 
 
Table 9. Sequences of cloning primer 
 
Cloning Primer for In Vitro Site-Directed Mutagenesis of CLCA2 
Primers were designed according provider’s instructions, the melting temperature 
was calculated according provider’s Website: 
http://www.stratagene.com/QPCR/tmCalc.aspx 
 
Mutation Basepaire 
Change 
EBI-No. Sequence of Primer (5' → 3') 
C132A TGT → GCC 17201 (f) ccctacaatacagagggGCCggaaaagagggaaaatacattcatttcac 
    17202 (r) gtgaaatgaatgtattttccctcttttccGGCccctctgtattgtaggg 
C196A TGT → GCC - (f) caaattaaagtgacaaggGCCtcatctgacatcacaggc 
    - (r) gcctgtgatgtcagatgaGGCccttgtcactttaatttg 
C206A TGT → GCC - (f) cacaggcatttttgtgGCCgaaaaaggtccttgcc 
    - (r) ggcaaggacctttttcGGCcacaaaaatgcctgtg 
C211A TGC → GCC - (f) gtgtgtgaaaaaggtcctGCCccccaagaaaactg 
    - (r) cagttttcttggggGGCaggacctttttcacacac 
C216A TGT → GCC - (f) ggtccttgcccccaagaaaacGCCattattagtaagc 
    - (r) gcttactaataatGGCgttttcttgggggcaaggacc 
N150A AAC → GCC 16863 (f) cctaatttcctactgaatgatGCcttaacagctggctacggatcacg 
    16864 (r) cgtgatccgtagccagctgttaagGCatcattcagtaggaaattagg 
N522A AAC → GCC 16865 (f) ggataatactgtgggcGCcgacactatgtttctagttacgtggc 
    16866 (r) gccacgtaactagaaacatagtgtcGGcgcccacagtattatcc 
N822A AAT → GCC 16867 (f) gctattttagtaGCCacatcaaagcgaaatcctcagcaagctggcatcaggg 
    16868 (r) ccctgatgccagcttgctgaggatttcgctttgatgtGGCtactaaaatagc 
C132S TGT → TCC 17199 (f) ccctacaatacagagggtCCggaaaagagggaaaatacattcatttcac 
    17200 (r) gtgaaatgaatgtattttccctcttttccGGaccctctgtattgtaggg 
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H164C CAT → TGC 17207 (f) gaggccgagtgtttgtcTGCgaatgggcccacctc 
    17208 (r) gaggtgggcccattcGCAgacaaacactcggcctc 
H164N CAT → AAC 16968 (f) gaggccgagtgtttgtcAaCgaatgggcccacctc 
    16969 (r) gaggtgggcccattcGtAgacaaacactcggcctc 
H164Y CAT → TAC 16970 (f) gaggccgagtgtttgtcTaCgaatgggcccacctc 
    16971 (r) gaggtgggcccattcGtAgacaaacactcggcctc 
E165D GAA → GAC 17203 (f) cgagtgtttgtccatgaCtgggcccacctccgttg 
    17204 (r) caacggaggtgggcccaGtcatggacaaacactcg 
E165Q GAA → CAG 16966 (f) cgagtgtttgtccatCaGtgggcccacctccgttg 
    16967 (r) caacggaggtgggcccaCtGatggacaaacactcg 
H168C CAC → TGC 17209 (f) catgaatgggccTGcctccgttggggtgtg 
    17210 (r) cacaccccaacggaggCAggcccattcatg 
H168N CAC → AAC 16972 (f) catgaatgggccAacctccgttggggtgtg 
    16973 (r) cacaccccaacggaggtTggcccattcatg 
H168Y CAC → TAC 16974 (f) catgaatgggccTacctccgttggggtgtg 
    16975 (r) cacaccccaacggaggtaggcccattcatg 
N186A AAT → GCC 17205 (f) caatgacaaacctttctacataGCCgggcaaaatcaaattaaagtgacaaggtgttc
    17206 (r) gaacaccttgtcactttaatttgattttgcccGGCtatgtagaaaggtttgtcattg 
G670A GGA → GCC 17211 (f) gctgatgttataaaaaatgatgCCatttactcgaggtattttttctcctttgctgc 
    17212 (r) gcagcaaaggagaaaaaatacctcgagtaaatGGcatcattttttataacatcagc 
I671A ATT → GCC 17213 (f) gctgatgttataaaaaatgatggaGCCtactcgaggtattttttctcctttgctgc 
    17214 (r) gcagcaaaggagaaaaaatacctcgagtaGGCtccatcattttttataacatcagc 
I671L ATT → CTG 17386 (f) gctgatgttataaaaaatgatggaCtGtactcgaggtattttttctcctttgctgc 
    17387 (r) gcagcaaaggagaaaaaatacctcgagtaCaGtccatcattttttataacatcagc 
Y672A TAC → GCC 17215 (f) gctgatgttataaaaaatgatggaattGCctcgaggtattttttctcctttgctgc 
    17216 (r) gcagcaaaggagaaaaaatacctcgagGCaattccatcattttttataacatcagc 
Y672E TAC → GAG 17380 (f) gctgatgttataaaaaatgatggaattGaGtcgaggtattttttctcctttgctgc 
    17381 (r) gcagcaaaggagaaaaaatacctcgaCtCaattccatcattttttataacatcagc 
Y672F TAC → TTC 17384 (f) gctgatgttataaaaaatgatggaatttTctcgaggtattttttctcctttgctgc 
    17385 (r) gcagcaaaggagaaaaaatacctcgagAaaattccatcattttttataacatcagc 
Y672K TAC → AAG 17378 (f) gctgatgttataaaaaatgatggaattAaGtcgaggtattttttctcctttgctgc 
    17379 (r) gcagcaaaggagaaaaaatacctcgaCtTaattccatcattttttataacatcagc 
Y672Q TAC → CAG 17382 (f) gctgatgttataaaaaatgatggaattCaGtcgaggtattttttctcctttgctgc 
    17383 (r) gcagcaaaggagaaaaaatacctcgaCtGaattccatcattttttataacatcagc 
S673A TCG → GCC 17217 (f) gctgatgttataaaaaatgatggaatttacGcCaggtattttttctcctttgctgc 
    17218 (r) gcagcaaaggagaaaaaatacctGgCgtaaattccatcattttttataacatcagc 
R674A AGG → GCC 17219 (f) gatggaatttactcgGCCtattttttctcctttgctgcaaatggtagatatagc 
    17220 (r) gctatatctaccatttgcagcaaaggagaaaaaataGGCcgagtaaattccatc 
R674E AGG → GAG 17027 (f) gatggaatttactcgGAgtattttttctcctttgctgcaaatggtagatatagc 
    17023 (r) gctatatctaccatttgcagcaaaggagaaaaaatacTCcgagtaaattccatc 
R674F AGG → TTC 17029 (f) gatggaatttactcgTTCtattttttctcctttgctgcaaatggtagatatagcttg 
    17030 (r) caagctatatctaccatttgcagcaaaggagaaaaaataGAAcgagtaaattccatc
R674I AGG → ATC 17025 (f) gatggaatttactcgaTCtattttttctcctttgctgcaaatggtagatatagc 
    17026 (r) gctatatctaccatttgcagcaaaggagaaaaaataGAtcgagtaaattccatc 
R674K AGG → AAG 17362 (f) gatggaatttactcgaAgtattttttctcctttgctgcaaatggtagatatagc 
    17363 (r) gctatatctaccatttgcagcaaaggagaaaaaatacTtcgagtaaattccatc 
R674Q AGG → CAG 17366 (f) gatggaatttactcgCaGtattttttctcctttgctgcaaatggtagatatagc 
    17367 (r) gctatatctaccatttgcagcaaaggagaaaaaataCtGcgagtaaattccatc 
R674S AGG → TCC 16545 (f) gatggaatttactcgTCCtattttttctcctttgctgc 
    16546 (r) gcagcaaaggagaaaaaataggacgagtaaattccatc 
R674T AGG → ACC 17368 (f) gatggaatttactcgaCCtattttttctcctttgctgcaaatggtagatatagc 
    17369 (r) gctatatctaccatttgcagcaaaggagaaaaaataGGacgagtaaattccatc 
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R674Y AGG → TAC 17364 (f) gatggaatttactcgTaCtattttttctcctttgctgcaaatggtagatatagc 
    17365 (r) gctatatctaccatttgcagcaaaggagaaaaaataGtAcgagtaaattccatc 
Y675A TAT → GCC 17221 (f) gatggaatttactcgaggGCCtttttctcctttgctgcaaatggtagatatagc 
    17222 (r) gctatatctaccatttgcagcaaaggagaaaaaGGCcctcgagtaaattccatc 
Y675E TAT → GAG 17372 (f) gatggaatttactcgaggGaGtttttctcctttgctgcaaatggtagatatagc 
    17373 (r) gctatatctaccatttgcagcaaaggagaaaaaCtCcctcgagtaaattccatc 
Y675F TAT → TTC 17376 (f) gatggaatttactcgaggtTCtttttctcctttgctgcaaatggtagatatagc 
    17377 (r) gctatatctaccatttgcagcaaaggagaaaaaGAacctcgagtaaattccatc 
Y675K TAT → AAG 17370 (f) gatggaatttactcgaggAaGtttttctcctttgctgcaaatggtagatatagc 
    17371 (r) gctatatctaccatttgcagcaaaggagaaaaaCtTcctcgagtaaattccatc 
Y675Q TAT → CAG 17374 (f) gatggaatttactcgaggCaGtttttctcctttgctgcaaatggtagatatagc 
   17375 (r) gctatatctaccatttgcagcaaaggagaaaaaCtGcctcgagtaaattccatc 
F676A TTT → GCC 17223 (f) gatggaatttactcgaggtatGCCttctcctttgctgcaaatggtagatatagc 
    17224 (r) gctatatctaccatttgcagcaaaggagaaGGCatacctcgagtaaattccatc 
F676W TTT → TGG 17390 (f) gatggaatttactcgaggtattGGttctcctttgctgcaaatggtagatatagc 
    17391 (r) gctatatctaccatttgcagcaaaggagaaCCaatacctcgagtaaattccatc 
F676Y TTT → TAC 17388 (f) gatggaatttactcgaggtattACttctcctttgctgcaaatggtagatatagc 
    17389 (r) gctatatctaccatttgcagcaaaggagaaGTaatacctcgagtaaattccatc 
F677A TTC → GCC 17225 (f) gatggaatttactcgaggtattttGCctcctttgctgcaaatggtagatatagc 
    17226 (r) gctatatctaccatttgcagcaaaggagGCaaaatacctcgagtaaattccatc 
S678A TCC → GCC 17227 (f) gatggaatttactcgaggtattttttcGcctttgctgcaaatggtagatatagc 
    17228 (r) gctatatctaccatttgcagcaaaggCgaaaaaatacctcgagtaaattccatc 
 
Table 10. Sequences of mutagenesis primer 
 
Sequencing Primers 
Tm (in PCR buffer) = 22 + 1,46 (2*(G+C)+A+T) 
 
Name EBI-No. Sequenz (5' → 3') 
T7f 5567 taatacgactcactataggg 
pUC/M13r 6298 caggaaacagctatgac 
T3r 13174 attaaccctcactaaaggg 
pCMV-Tag1-T3 f 7148 aataaccctcactaaaggg 
pCMV-Tag1-T7 r 13432 gtaatacgactcactatagggc 
pCMV6-XL4 f (VP1.5) 15909 ggactttccaaaatgtcg 
pCMV6-XL4 r (XL39) 15910 attaggacaaggctggtggg 
pTRE2pur f - cgcctggagacgccatcc 
pTRE2pur r - cattctaaacaacaccctg 
CLCA2do3 - gcacatggagatgatccatacacccta 
CLCA2do4 - gcaagtacccacaaccaagaagcacca 
CLCA2do6 - ggaacagctaagcctgggcactggact 
CLCA2do7 15906 ggttacacagcaaacggtaatattcaga 
CLCA2do12 10071 gcacccaaaatgcaactgcatcaataatgt 
CLCA2do13 10072 gtgatgatattagtgaccagcggaga 
CLCA2up2 9626 cactttcgctcctcctcatttctgcct 
CLCA2up3 9657 cctgagctgactcggctaaagcccca 
CLCA2up10 9778 gacattttcacctgtactttcaagct 
CLCA2up12 9818 ggtgcttcttggttgtgggtacttgca 
CLCA2up13 9819 gattacatcccatgcacttctgaggct 
CLCA2up19 - gttatcattcagtaggaaattaggtgtga 
CLCA2up21 - gcacatggagatgatccatacacccta 
hClCa2-check-rev 15849 gggagatatttacgttctcacc 
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8F5-check-rev 15411 ggattcaatctcgtctcagc 
HA-check-rev 15842 gcgtaatctggaacatcgtatg 
c-myc-check-rev 15843 gtcctcctctgagatcagc 
lumio-check-rev 15844 caacagccaggacaacagg 
V5-check-rev 15845 ggagagggttagggatagg 
6x-His-check-rev 15846 agtgatggtgatggtgatgg 
 
Table 11. Sequences of sequencing primer 
 
Oligomers 
 
Name EBI-No. Sequenz (5' → 3') 
8F5-1 15829 gatccggcagggaagttaaagctgagacgagattgaatccttagtgacccggggatatca 
8F5-2 15830 agcttgatatccccgggtcactaaggattcaatctcgtctcagctttaacttccctgccg 
HA-1 15831 gatcctacccatacgatgttccagattacgcttagtgacccggggatatca 
HA-2 15832 agcttgatatccccgggtcactaagcgtaatctggaacatcgtatgggtag 
c-myc-1 15833 gatccgagcagaagctgatctcagaggaggacctgtagtgacccggggatatca 
c-myc-2 15834 agcttgatatccccgggtcactacaggtcctcctctgagatcagcttctgctcg 
V5-1 15837 gatccgggaagcctatccctaaccctctcctcggtctcgattctacgtagtgacccggggatatca 
V5-2 15838 agcttgatatccccgggtcactacgtagaatcgagaccgaggagagggttagggataggcttcccg 
6xHis-1 15839 gatcccatcaccatcaccatcactagtgacccggggatatca 
6xHis-2 15840 agcttgatatccccgggtcactagtgatggtgatggtgatgg 
 
Table 12. Sequences of oligomers 
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Plasmids 
pTRE2pur Expression Vector 
(“Tet-on Gene Expression System” of Clontech, Cat.# 630922)  
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pGEM-T Easy Vector  (Promega, Cat.# A1380 ) 
 
 
pCMV-Tag1 Expression Vector  (Stratagene, Cat.# 211170) 
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Human Full-Length cDNA Clone of CLCA2 in pCMV6-XL4 
(Origene, Cat.# TC116023,  Acc. NM_006536: Human calcium-activated chloride 
channel, family member 2 (CLCA2)) 
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Antibodies 
Target Protein Name Phospho-Site Company Cat. No. 
GAPDH (6C5) pan Abcam ab8245 
ß-Actin pan Sigma A5441 
HA-Tag (6E2) pan Cell Signaling 2367 
V5-Tag pan Invitrogen R960-25 
Integrin β4 (M126) pan Abcam ab29042 
PARP pan Cell Signalling 9542 
Akt S473 Cell Signaling #9271 
Akt S308 Cell Signaling #9275 
Akt Y326 Cell Signaling #2968 
Akt pan Cell Signaling #9272 
GSK-3beta S9 Cell Signaling #9336 
PTEN S380 Cell Signaling #9551 
PDK1 S241 Cell Signaling #3061 
PDK1 pan Cell Signaling #3062 
PI3K p85 Y458 / p55 Y199 Cell Signaling #4228 
FAK Y861 Biosource 44-626G 
iKKalpha/beta S176/180 Cell Signaling #2697S 
NF-KB p65 S536 Cell Signaling #3031 
NF-KB p65 pan Cell Signaling #3034 
MEK 1/2 S217/221 Cell Signaling #9121 
p44/42 MAP Kinase T202/Y204 Cell Signaling #9101 
p38 MAPK T180/Y182 Cell Signaling #9211 
p90RSK S380 Cell Signaling #9341  
RSK1 S221/S227 Biosource 44-924G 
RSK1 S363/S369 Biosource 44-926G 
Elk1 S383 Cell Signaling #9181 
Raf S259 Cell Signaling #9421 
c-Raf  S338 Biosource #9427 
ERK 1 & 2  T185/Y187 Biosource 44-680G 
Erk 1&2 pan Biosource 44-654G 
p70 S6 Kinase T389 Cell Signaling #9234S 
p70 S6 Kinase pan Cell Signaling #9202 
mTOR S2448 Cell Signaling #2971 
mTOR S2481 Cell Signaling #2974 
4E-BP1 T37/46 Cell Signaling #2855 
4E-BP1 T70 Cell Signaling #9455 
4E-BP1 S65 Cell Signaling #9451 
FoxO1 S319 Cell Signaling #2487 
FoxO3a S318/321 Cell Signaling #9465 
FoxO3a S253 Cell Signaling #9466 
Stat1 Y701 Cell Signaling #9171 
Stat2 Y690 Cell Signaling #4471 
Stat3 Y705 Cell Signaling #9131 
Stat3 S727 Cell Signaling #9134 
Stat3 Y705 Cell Signaling #9131 
Stat5 Y694 Cell Signaling #9351 
Stat6 Y641 Cell Signaling #9361 
NPM/B23 (Nucleophosmin 1) T234/T237 BioLegend #619101 
PKCe pan Biosource AHO0743 
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Target Protein Name Phospho-Site Company Cat. No. 
p27 pan novocastra NCL-p27 
Histon H3 S10 Upstate #06-570 
TSC2 T1462 Cell Signaling #3611 
TSC2 S1254 Cell Signaling #3616 
KI67 pan Dako Cytomation M7240 
rabbit IgG-HRP conj. pan Sigma Aldrich A8275 
mouse IgG-HRP conj. pan Sigma Aldrich A0168 
 
Table 13. Antibodies used for Western blots for this study 
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APPENDIX 
Sequence of CLCA2 
DNA Sequence 
Coding Sequence of human calcium-activated chloride channel, family member 2 
(CLCA2) mRNA. ACCESSION  NM_006536: 
 
atgacccaaa ggagcattgc aggtcctatt tgcaacctga agtttgtgac tctcctggtt     60 
 
gccttaagtt cagaactccc attcctggga gctggagtac agcttcaaga caatgggtat    120 
 
aatggattgc tcattgcaat taatcctcag gtacctgaga atcagaacct catctcaaac    180 
 
attaaggaaa tgataactga agcttcattt tacctattta atgctaccaa gagaagagta    240 
 
tttttcagaa atataaagat tttaatacct gccacatgga aagctaataa taacagcaaa    300 
 
ataaaacaag aatcatatga aaaggcaaat gtcatagtga ctgactggta tggggcacat    360 
 
ggagatgatc catacaccct acaatacaga gggtgtggaa aagagggaaa atacattcat    420 
 
ttcacaccta atttcctact gaatgataac ttaacagctg gctacggatc acgaggccga    480 
 
gtgtttgtcc atgaatgggc ccacctccgt tggggtgtgt tcgatgagta taacaatgac    540 
 
aaacctttct acataaatgg gcaaaatcaa attaaagtga caaggtgttc atctgacatc    600 
 
acaggcattt ttgtgtgtga aaaaggtcct tgcccccaag aaaactgtat tattagtaag    660 
 
ctttttaaag aaggatgcac ctttatctac aatagcaccc aaaatgcaac tgcatcaata    720 
 
atgttcatgc aaagtttatc ttctgtggtt gaattttgta atgcaagtac ccacaaccaa    780 
 
gaagcaccaa acctacagaa ccagatgtgc agcctcagaa gtgcatggga tgtaatcaca    840 
 
gactctgctg actttcacca cagctttccc atgaatggga ctgagcttcc acctcctccc    900 
 
acattctcgc ttgtacaggc tggtgacaaa gtggtctgtt tagtgctgga tgtgtccagc    960 
 
aagatggcag aggctgacag actccttcaa ctacaacaag ccgcagaatt ttatttgatg   1020 
 
cagattgttg aaattcatac cttcgtgggc attgccagtt tcgacagcaa aggagagatc   1080 
 
agagcccagc tacaccaaat taacagcaat gatgatcgaa agttgctggt ttcatatctg   1140 
 
cccaccactg tatcagctaa aacagacatc agcatttgtt cagggcttaa gaaaggattt   1200 
 
gaggtggttg aaaaactgaa tggaaaagct tatggctctg tgatgatatt agtgaccagc   1260 
 
ggagatgata agcttcttgg caattgctta cccactgtgc tcagcagtgg ttcaacaatt   1320 
 
cactccattg ccctgggttc atctgcagcc ccaaatctgg aggaattatc acgtcttaca   1380 
 
ggaggtttaa agttctttgt tccagatata tcaaactcca atagcatgat tgatgctttc   1440 
 
agtagaattt cctctggaac tggagacatt ttccagcaac atattcagct tgaaagtaca   1500 
 
ggtgaaaatg tcaaacctca ccatcaattg aaaaacacag tgactgtgga taatactgtg   1560 
 
ggcaacgaca ctatgtttct agttacgtgg caggccagtg gtcctcctga gattatatta   1620 
APPENDIX 
 
 184
 
tttgatcctg atggacgaaa atactacaca aataatttta tcaccaatct aacttttcgg   1680 
 
acagctagtc tttggattcc aggaacagct aagcctgggc actggactta caccctgaac   1740 
 
aatacccatc attctctgca agccctgaaa gtgacagtga cctctcgcgc ctccaactca   1800 
 
gctgtgcccc cagccactgt ggaagccttt gtggaaagag acagcctcca ttttcctcat   1860 
 
cctgtgatga tttatgccaa tgtgaaacag ggattttatc ccattcttaa tgccactgtc   1920 
 
actgccacag ttgagccaga gactggagat cctgttacgc tgagactcct tgatgatgga   1980 
 
gcaggtgctg atgttataaa aaatgatgga atttactcga ggtatttttt ctcctttgct   2040 
 
gcaaatggta gatatagctt gaaagtgcat gtcaatcact ctcccagcat aagcacccca   2100 
 
gcccactcta ttccagggag tcatgctatg tatgtaccag gttacacagc aaacggtaat   2160 
 
attcagatga atgctccaag gaaatcagta ggcagaaatg aggaggagcg aaagtggggc   2220 
 
tttagccgag tcagctcagg aggctccttt tcagtgctgg gagttccagc tggcccccac   2280 
 
cctgatgtgt ttccaccatg caaaattatt gacctggaag ctgtaaaagt agaagaggaa   2340 
 
ttgaccctat cttggacagc acctggagaa gactttgatc agggccaggc tacaagctat   2400 
 
gaaataagaa tgagtaaaag tctacagaat atccaagatg actttaacaa tgctatttta   2460 
 
gtaaatacat caaagcgaaa tcctcagcaa gctggcatca gggagatatt tacgttctca   2520 
 
ccccaaattt ccacgaatgg acctgaacat cagccaaatg gagaaacaca tgaaagccac   2580 
 
agaatttatg ttgcaatacg agcaatggat aggaactcct tacagtctgc tgtatctaac   2640 
 
attgcccagg cgcctctgtt tattcccccc aattctgatc ctgtacctgc cagagattat   2700 
 
cttatattga aaggagtttt aacagcaatg ggtttgatag gaatcatttg ccttattata   2760 
 
gttgtgacac atcatacttt aagcaggaaa aagagagcag acaagaaaga gaatggaaca   2820 
 
aaattattat aa                                                       2832 
 
Potein Sequence 
Translation of human calcium-activated chloride channel, family member 2 (CLCA2) 
mRNA, ACCESSION  NM_006536: 
 
Met Thr Gln Arg Ser Ile Ala Gly Pro Ile Cys Asn Leu Lys Phe Val  
1               5                   10                  15       
 
 
Thr Leu Leu Val Ala Leu Ser Ser Glu Leu Pro Phe Leu Gly Ala Gly  
            20                  25                  30           
 
 
Val Gln Leu Gln Asp Asn Gly Tyr Asn Gly Leu Leu Ile Ala Ile Asn  
        35                  40                  45               
 
 
Pro Gln Val Pro Glu Asn Gln Asn Leu Ile Ser Asn Ile Lys Glu Met  
    50                  55                  60                   
 
 
Ile Thr Glu Ala Ser Phe Tyr Leu Phe Asn Ala Thr Lys Arg Arg Val  
65                  70                  75                  80   
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Phe Phe Arg Asn Ile Lys Ile Leu Ile Pro Ala Thr Trp Lys Ala Asn  
                85                  90                  95       
 
 
Asn Asn Ser Lys Ile Lys Gln Glu Ser Tyr Glu Lys Ala Asn Val Ile  
            100                 105                 110          
 
 
Val Thr Asp Trp Tyr Gly Ala His Gly Asp Asp Pro Tyr Thr Leu Gln  
        115                 120                 125              
 
 
Tyr Arg Gly Cys Gly Lys Glu Gly Lys Tyr Ile His Phe Thr Pro Asn  
    130                 135                 140                  
 
 
Phe Leu Leu Asn Asp Asn Leu Thr Ala Gly Tyr Gly Ser Arg Gly Arg  
145                 150                 155                 160  
 
 
Val Phe Val His Glu Trp Ala His Leu Arg Trp Gly Val Phe Asp Glu  
                165                 170                 175      
 
 
Tyr Asn Asn Asp Lys Pro Phe Tyr Ile Asn Gly Gln Asn Gln Ile Lys  
            180                 185                 190          
 
 
Val Thr Arg Cys Ser Ser Asp Ile Thr Gly Ile Phe Val Cys Glu Lys  
        195                 200                 205              
 
 
Gly Pro Cys Pro Gln Glu Asn Cys Ile Ile Ser Lys Leu Phe Lys Glu  
    210                 215                 220                  
 
 
Gly Cys Thr Phe Ile Tyr Asn Ser Thr Gln Asn Ala Thr Ala Ser Ile  
225                 230                 235                 240  
 
 
Met Phe Met Gln Ser Leu Ser Ser Val Val Glu Phe Cys Asn Ala Ser  
                245                 250                 255      
 
 
Thr His Asn Gln Glu Ala Pro Asn Leu Gln Asn Gln Met Cys Ser Leu  
            260                 265                 270          
 
 
Arg Ser Ala Trp Asp Val Ile Thr Asp Ser Ala Asp Phe His His Ser  
        275                 280                 285              
 
 
Phe Pro Met Asn Gly Thr Glu Leu Pro Pro Pro Pro Thr Phe Ser Leu  
    290                 295                 300                  
 
 
Val Gln Ala Gly Asp Lys Val Val Cys Leu Val Leu Asp Val Ser Ser  
305                 310                 315                 320  
 
 
Lys Met Ala Glu Ala Asp Arg Leu Leu Gln Leu Gln Gln Ala Ala Glu  
                325                 330                 335      
 
 
Phe Tyr Leu Met Gln Ile Val Glu Ile His Thr Phe Val Gly Ile Ala  
            340                 345                 350          
 
 
Ser Phe Asp Ser Lys Gly Glu Ile Arg Ala Gln Leu His Gln Ile Asn  
        355                 360                 365              
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Ser Asn Asp Asp Arg Lys Leu Leu Val Ser Tyr Leu Pro Thr Thr Val  
    370                 375                 380                  
 
 
Ser Ala Lys Thr Asp Ile Ser Ile Cys Ser Gly Leu Lys Lys Gly Phe  
385                 390                 395                 400  
 
 
Glu Val Val Glu Lys Leu Asn Gly Lys Ala Tyr Gly Ser Val Met Ile  
                405                 410                 415      
 
 
Leu Val Thr Ser Gly Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr  
            420                 425                 430          
 
 
Val Leu Ser Ser Gly Ser Thr Ile His Ser Ile Ala Leu Gly Ser Ser  
        435                 440                 445              
 
 
Ala Ala Pro Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys  
    450                 455                 460                  
 
 
Phe Phe Val Pro Asp Ile Ser Asn Ser Asn Ser Met Ile Asp Ala Phe  
465                 470                 475                 480  
 
 
Ser Arg Ile Ser Ser Gly Thr Gly Asp Ile Phe Gln Gln His Ile Gln  
                485                 490                 495      
 
 
Leu Glu Ser Thr Gly Glu Asn Val Lys Pro His His Gln Leu Lys Asn  
            500                 505                 510          
 
 
Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Met Phe Leu Val  
        515                 520                 525              
 
 
Thr Trp Gln Ala Ser Gly Pro Pro Glu Ile Ile Leu Phe Asp Pro Asp  
    530                 535                 540                  
 
 
Gly Arg Lys Tyr Tyr Thr Asn Asn Phe Ile Thr Asn Leu Thr Phe Arg  
545                 550                 555                 560  
 
 
Thr Ala Ser Leu Trp Ile Pro Gly Thr Ala Lys Pro Gly His Trp Thr  
                565                 570                 575      
 
 
Tyr Thr Leu Asn Asn Thr His His Ser Leu Gln Ala Leu Lys Val Thr  
            580                 585                 590          
 
 
Val Thr Ser Arg Ala Ser Asn Ser Ala Val Pro Pro Ala Thr Val Glu  
        595                 600                 605              
 
 
Ala Phe Val Glu Arg Asp Ser Leu His Phe Pro His Pro Val Met Ile  
    610                 615                 620                  
 
 
Tyr Ala Asn Val Lys Gln Gly Phe Tyr Pro Ile Leu Asn Ala Thr Val  
625                 630                 635                 640  
 
 
Thr Ala Thr Val Glu Pro Glu Thr Gly Asp Pro Val Thr Leu Arg Leu  
                645                 650                 655      
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Leu Asp Asp Gly Ala Gly Ala Asp Val Ile Lys Asn Asp Gly Ile Tyr  
            660                 665                 670          
 
 
Ser Arg Tyr Phe Phe Ser Phe Ala Ala Asn Gly Arg Tyr Ser Leu Lys  
        675                 680                 685              
 
 
Val His Val Asn His Ser Pro Ser Ile Ser Thr Pro Ala His Ser Ile  
    690                 695                 700                  
 
 
Pro Gly Ser His Ala Met Tyr Val Pro Gly Tyr Thr Ala Asn Gly Asn  
705                 710                 715                 720  
 
 
Ile Gln Met Asn Ala Pro Arg Lys Ser Val Gly Arg Asn Glu Glu Glu  
                725                 730                 735      
 
 
Arg Lys Trp Gly Phe Ser Arg Val Ser Ser Gly Gly Ser Phe Ser Val  
            740                 745                 750          
 
 
Leu Gly Val Pro Ala Gly Pro His Pro Asp Val Phe Pro Pro Cys Lys  
        755                 760                 765              
 
 
Ile Ile Asp Leu Glu Ala Val Lys Val Glu Glu Glu Leu Thr Leu Ser  
    770                 775                 780                  
 
 
Trp Thr Ala Pro Gly Glu Asp Phe Asp Gln Gly Gln Ala Thr Ser Tyr  
785                 790                 795                 800  
 
 
Glu Ile Arg Met Ser Lys Ser Leu Gln Asn Ile Gln Asp Asp Phe Asn  
                805                 810                 815      
 
 
Asn Ala Ile Leu Val Asn Thr Ser Lys Arg Asn Pro Gln Gln Ala Gly  
            820                 825                 830          
 
 
Ile Arg Glu Ile Phe Thr Phe Ser Pro Gln Ile Ser Thr Asn Gly Pro  
        835                 840                 845              
 
 
Glu His Gln Pro Asn Gly Glu Thr His Glu Ser His Arg Ile Tyr Val  
    850                 855                 860                  
 
 
Ala Ile Arg Ala Met Asp Arg Asn Ser Leu Gln Ser Ala Val Ser Asn  
865                 870                 875                 880  
 
 
Ile Ala Gln Ala Pro Leu Phe Ile Pro Pro Asn Ser Asp Pro Val Pro  
                885                 890                 895      
 
 
Ala Arg Asp Tyr Leu Ile Leu Lys Gly Val Leu Thr Ala Met Gly Leu  
            900                 905                 910          
 
 
Ile Gly Ile Ile Cys Leu Ile Ile Val Val Thr His His Thr Leu Ser  
        915                 920                 925              
 
 
Arg Lys Lys Arg Ala Asp Lys Lys Glu Asn Gly Thr Lys Leu Leu  
    930                 935                 940              
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Abbreviations 
 
°C degree Celsius 
µg microgram 
µl microliter 
µmol micromole 
14-3-3 sigma/ SDN stratifin  
2D 2 dimensional 
3D 3 dimensional 
4E-BP1  4E binding protein 1 
AA amino acid 
AC adenocarcinoma 
Acc. accession number 
AFF4 (MCEF) AF4/MR2 family member 4 
Ala Alanine 
All acute lymphocytic leukaemia 
amp Ampicillin 
ASPM Asp (abnormal spindle)-like, microcephaly associated (drosophila)  
ATP adenosine 5'-triphosphate 
bp base pair 
BSA bovine serum albumin 
C10orf118 chromosome 10 open reading frame 118  
Ca carcinoma 
Ca2+  calcium ion 
CAM's cell-cell adhesion molecules 
cap methyl-7-G(5')pppN - structure 
CD8  cluster of differentiation 
CDIPT  CDP-diacylglycerol-inositol 3-phosphatidyltransferase  
(phosphatidyinositol synthase)  
CDK cyclin-dependent kinase 
cDNA complementary DNA 
cfu colony forming unit 
CHD6 chromodomain helicase DNA binding protein 6  
chr1 Chromosome 1 
CLCA calcium-activated chloride channel 
CMTX Charcot-Marie-Tooth disease 
CMV cytomegalo virus 
CN copy number 
ColonMucinCa mucinous colon carcinoma 
COPD obstructive pulmonary disease 
cpm counts per minute 
CTCL cutaneous T cell lymphoma  
Cys Cysteine 
DEPC diethyl pyrocarbonate 
DEPC-H2O di-ethyl-propyl carbonate-treated H2O 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotides 
Doxy Doxycycline 
DSC3 desmocollin 3 
dsDNA double strand DNA 
DSG3 desmoglein 3 
DTT dithiothreitol  
DTX2 deltex homolog 2 (drosophila)  
E. coli Escherichia coli 
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ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor  
EGFR epidermal growth factor receptor 
eIF eukaryotic initiation factor 
EMCV encephalomyocraditis virus 
EMT epithilial mesenchymal transition 
EP300 E1A binding protein p300 
ERBB2 erythroblastic leukemia viral oncogene homolog 2 
ERK extracellular signal-regulated kinase 
EtBr ethidiumbromide 
FGF fibroblast growth factor 
g gram 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GDP guanosine 5'-diphosphate 
GlioblastMultiform glioblastoma multiforme 
GPCR G protein-coupled receptor 
GTP guanosine 5'-triphosphate 
HA hemagglutinin 
HAV hepatitis A virus 
HCC hepatocellular carcinoma 
HCS high-content screening  
Her2 epidermal growth factor receptor 2 
His Histidine 
HNF4A hepatocyte nuclear factor 4 alpha 
HNSCC head and neck squamous cell carcinoma 
HRV2  human rhinovirus type 2 
IC50 half maximal inhibitory concentration  
IGF-I R  insulin-like growth factor 1 receptor 
IHC  immunohistochemistry 
IL10  Interleukin 10 
IL2 Interleukin 2 
InfDuc infiltrating ductal 
InfLob infiltrating lobular 
IPA Ingenuity Pathways Analysis 
IQR interquartile range 
JNK N-terminal kinase 
K+ potassium ion 
KAc potassium acetate 
kD kilo Dalton 
KPNA2  karyopherin alpha 2 
KRT5 keratin 5  
l liter 
LAD1/CD18 ladinin 1  
LB Lauria Bertani 
LCC large cell carcinomas 
LCM laser-capture-microdissected  
LN lymphnode 
LNSCCMet lymph node metastases of SCCs 
LTBP1 latent transforming growth factor beta binding protein 1  
Lys Lysine 
M molar 
MACF1 microtuble-actin crosslinking factor 1  
Malig malignant 
MAPK  mitogen-activated protein kinase 
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Mel melanoma 
MEM minimal essential medium 
Met metastasis 
min minute 
ml milliliter 
MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 
mM millimolare 
MM multiple myeloma 
MOPS 4-morpholinepropanesulfonic acid 
MRE11  meiotic recombination 11, S. cerevisiae, homolog of a MRE11A 
mRNA messenger RNA 
myc refers to the myc gene 
Myc refers to the Myc protein 
NaAc sodium acetate 
NBS1 p95 protein of the MRE11/RAD50 complex 
NEAA non essential aminoacids 
NED no evidence of disease 
ng nanogram 
NH4Ac ammonium acetate 
NPM nucleophosmin 
NSCLC non-small cell lung cancer 
nt nucleotide 
OD optical density 
ORF open reading frame 
P4HA2 prolyl-4 hydroxylase-2  
p53 protein 53 
PapillFollic papillary and follicular 
PARP poly ADP-ribose polymerase 
PBS phosphate-buffered saline  
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PDK1 phosphoinositide dependent kinase 1 
PERP TP53 apoptosis effector  
Phe Phenylalanine 
PI3K phosphoinositide-3-kinase 
PKP plakophilin 
pmol picomole 
POS positive 
PV verified by pathologist 
RAB38 member RAS oncogene family 
RAD50 RAD50 homolog (S. cerevisiae) 
Rb retinoblastoma 
RCC renal cell carcinoma 
RE restriction enzyme 
RNA ribonucleic acid 
RNAse ribonuclease 
rpm rotations per minute 
RT  room temperature 
RTK  receptor tyrosine kinase 
RT-qPCR quantative real-time PCR 
RUTBC3 RUN and TBC1 domain containing 3  
SATB1 special AT-rich sequence binding protein 1  
SCC squamous cell carcinoma 
SCLC small cell lang cancer 
SDS sodium dodecyl sulfate 
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sec second 
SFI1 spindle assembly associated (yeast) 
siCTRL non-targeting siRNA CONTROL#1 of Dharmacon 
siRNA small interfering RNA (also short interfering RNA or silencing RNA) 
SMAD3 mothers against decapentaplegic homolog 3 
SNP  single nucleotide polymorphism 
Squam squamous 
ssDNA single strand cDNA 
STAT signal transducer and activator of transcription 
T reg regulatory T cells  
TCC transitional cell carcinoma 
Tet Tetracycline 
TGF tumour growth factor 
Tiss tissue 
Tm melting temperature 
TNF tumour necrosis factor 
TP53  tumour protein p53 
TP53BP1 tumour protein p53 binding protein 1 
TRIM29 tripartite motif-containing 29  
TSC1 tuberous sclerosis complex 1  
Tyr Tyrosine 
U Unit 
UNC84A unc-84 homolog A (C. elegans)  
UV ultraviolet 
VEGF vascular endothelial growth factor 
VP2  adeno-associated virus 2 
vWA von Willebrand factor type A 
WHO  World Health Organization 
wt wild type 
Zn2+  zinc ion 
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